

# **Translational Aspects of Behçet's Disease**

Genetics, cytokines and new treatment modalities

Jasper Kappen

Onderzoek beschreven in dit proefschrift werd mede mogelijk gemaakt door:

- Stichting Janivo
- Stichting Mitalto
- Dr. N. Nobel
- Actelion Pharmaceuticals Ltd
- De Landelijke Stichting voor Blinden en Slechtzienden
- Vereniging Trustfonds Erasmus Universiteit Rotterdam

De uitgave van dit proefschrift werd mede mogelijk gemaakt door:

- Vasculitis Stichting
- Janssen-Cilag B.V.
- Abbvie B.V.

Cover: Joris en Rosa samen met oma Liesbeth

ISBN: 978-94-6169-642-7

Layout and printing: Optima Grafische Communicatie, Rotterdam, The Netherlands

# **Translational Aspects of Behçet's Disease**

Genetics, cytokines and new treatment modalities

## **Translationele aspecten van de ziekte van Behçet**

Genetica, cytokines en nieuwe behandel mogelijkheden

### **Proefschrift**

Ter verkrijging van de graad van doctor aan de  
Erasmus Universiteit Rotterdam  
op gezag van de  
rector magnificus  
Prof.dr. H.A.P. Pols  
en volgens besluit van het College voor Promoties.  
De openbare verdediging zal plaatsvinden op  
dinsdag 19 mei 2015 om 15:30 uur

door

**Jasper Henk Kappen**

geboren te Eindhoven

**Promotor:** Prof.dr. P.M. van Hagen

**Overige leden:** Prof.dr. E.P. Prens  
Prof.dr. D.L.P. Baeten  
Dr. G.R. Wallace

**Copromotor:** Dr. J.A.M. van Laar

## TABLE OF CONTENTS

### 1. Introduction:

Behçet's Disease	9
Outline of the thesis	25

### 2. Epidemiology

Behçet's disease, prevalence and symptoms in the Rotterdam area	31
---	----

### 3. Genetics:

Low prevalence of NOD2 SNPs in Behçet's disease suggests protective association in Western Caucasians	45
Genome-wide association study in an admixed case series reveals IL12A as a new candidate in Behçet disease	55
Whole genome sequence in Behçet disease patients	73

### 4. Cytokines in Behçet's disease

Cytokine profiles in tissue	83
Detection of intestinal Behçet's disease by double balloon enteroscopy combined to serum cytokine profiles; improved diagnostic yield?	91

### 5. Novel treatment modalities

Mycophenolate sodium: effective treatment for therapy refractory intestinal Behçet's disease, evaluated with enteroscopy	105
Successful long-term triple disease control by ustekinumab in a patient with Behçet's disease, psoriasis, and hidradenitis suppurativa	113
Adalimumab treatment in refractory mucocutaneous Behçet's Disease: An observational case series	119

### 6. Discussion



133

**7. Appendix:**

a. Summaries	
i. English summary	155
ii. Nederlandse samenvatting	158
b. Dankwoord	161
c. Biografie	163
d. List of publications	165
e. PhD portfolio	167

# 1

## Introduction







# Behçet's disease

*Based on:*

**Managing Behçet's Disease: an update on current and emerging treatment options**

P.L.A. van Daele, MD, PhD, J.H. Kappen, MSc, P.M. van Hagen, MD, PhD, J.A.M. van Laar, MD, PhD

*Ther Clin Risk Manag. 2009 Apr;5(2):385-90*

**"Nieuwe ontwikkelingen in de Medische Immunologie 2010"** Chapter 16 "Ziekte van Behçet"

ISBN 978-90-73436-91-6

Jan AM van Laar, P. Martin van Hagen, Jasper H Kappen.



## INTRODUCTION

Behçet's disease (BD) is an multifactorial auto-inflammatory vasculitis characterized by recurrent oral -and genital ulcers, uveitis, and skin lesions [1, 2]. The first series of patients with BD was already published in 1937 as a triad of these symptoms [3]. Less frequently, involvement of the gastrointestinal tract, central nervous system and large vessels may occur. As in other immune mediated disorders BD is characterised by attacks rather than by a persistent inflammatory disease [4].

Cases of Behçet's disease cluster along the ancient Silk Road, which extends from eastern Asia to the Mediterranean basin. The reported prevalence in Turkey varies between 70 and 420 per 100.000 [5]. In Northern European countries however the prevalence is probably less than 1 per 100.000 in Caucasians. It is believed that both genetic and environmental factors contribute to the development of the disease [6, 7]. Men might be more frequently and severely affected than women


Susceptibility to BD is strongly associated with the presence of the HLA-B51 allele and its presence is also strongly associated with a more aggressive course [8]. The cause of BD, however, is still unknown. Triggers such as infections, both viral and bacterial, trauma, and other stress factors may play a role.

Although the exact cause of BD remains to be elucidated, it is clear that neutrophils interacting with T-cells play an important role in the pathophysiology. The activated T-cells produce TNF- $\alpha$ , which in turn leads to production of other proinflammatory cytokines like interleukin 1 and interleukin 6 by other immune cells. These proinflammatory cytokines stimulate migration and activation of leucocytes, thereby causing a local inflammatory response [2]. Additionally, a disturbed function of regulatory T-cell may also play a role. Eventually vessel -and subsequently tissue damage occurs, as can be seen in biopsies taken from BD lesions from various sites involved [4].

## IMMUNE SYSTEM EN CYTOKINES

The inflammation in BD is characterized by a Th-1 and probably also Th-17 mediated immune response (figure 1) [2, 9]. In the early phase of inflammation granulocytes and gamma-delta T-cells ( $\gamma\delta$ ) are identified in the affected tissues. These are believed to be activated by environmental "triggers" [10]. A lymphohistiocytic infiltrate is found in a later phase.

The assumption that granulocytes play an important role in BD is fed by a number of observations: increased prevalence of HLA-B51 in 13-80% of the patients [4], associated with over-activated neutrophils. increased toll like receptor expressions on granulocytes



**Figure 1;** Immunopathophysiology of Behçet's disease. It is assumed that stimulation by pathogens of granulocytes, T $\gamma\delta$  and DCs, in a genetically predisposed host a cascade of inflammatory cytokines eventually lead to vascular damage and vasculitis.

Abbreviations: IL; interleukin, TNF; tumor necrosis factor, T $\gamma\delta$ ; T $\gamma\delta$  subset T cells, Th; CD4 + cells Thelper, DC; dendritic cells

of BD patients, frequently occurring hyperactive granulocytes, and observations of hyperactive response of granulocytes to "heat shock proteins" and fragments of the bacterial cell wall [11]. The inflammatory effect of these observations seems that these hypersensitive granulocytes, but also T $\gamma\delta$  cells through antigen presenting dendritic cells start a cascade of pro-inflammatory cytokines. Several cytokines are involved in the pathophysiological mechanisms. IL6, produced by antigen presenting cells, which promotes the differentiation towards Th1 cells and IL23, produced by T $\gamma\delta$  cells that promotes the Th17 differentiation P40 [12, 13]. The central cytokine in this inflammatory process is tumor necrosis factor (TNF) - $\alpha$ , which is produced by virtually all the cells involved. TNF- $\alpha$  subsequently activates the production of other cytokines such as interleukin (IL) -1 $\beta$ , IL-6, IL-8, IL-10 and IL-17 (Figure 1). Other inflammatory cells are attracted to the inflammation site and contribute to an inflammatory infiltrate. Increased tissue (pro) inflammatory cytokines and serum concentrations in various affected tissues from patients with BD are described [14-16]. A disturbed, hyperactive local immune response seems responsible for the initial inflammatory symptoms that are seen in BD.

Also regulatory T cells (Treg) are of interest in autoimmune diseases. These cells seem essential for the immunological homeostasis in which the T-cell-effector response is inhibited. The involvement of Treg in BD is debated. In summary, in BD tissue damage together with a local hyper-inflammation appears to play an important role.

## GENETICS

In patients of Turkish origin there is positive family history in 12% of the cases with a sibling risk ratio between 11–52 [2, 17]. The heritability of BD has been estimated to range between 20 to 60%, with the strongest genetic association embracing variants in HLA-B51, explaining about 20% of the disease heritability [2, 17]. The combination of epidemiological and genetic data suggest causal involvement of both genetic and environmental factors [6].

Over the years numerous single nucleotide polymorphisms (SNPs) have been found associated with BD [7, 18–20]. In 2010 the first genome-wide association study (GWAS) in BD cohorts of Turkish and Japanese origin demonstrated association of various variants in the known HLA-B51 domain, and two new association signals, mapping to the interleukin-10 (*IL10*), and the IL-23 receptor–IL-12 receptor Beta2 (*IL23R–IL12RB2*) locus [21, 22]. These associations later have been confirmed in an Iranian cohort [23]. Yet another study in Algerian individuals only replicated the associations from the *IL10* variants [24]. GWAS in Chinese and Korean individuals reported associations of SNPs mapping to two other loci, with regions containing the signal transducer and activator of transcription 4 (*STAT4*) and GTPase of immune associated protein *GIMAP* genes, respectively. Polymorphisms in *IL10* and *IL23R–IL12RB2* were not found to be significantly associated with BD in either of those studies [14, 15]. Most recently associations with *CCR1*, *STAT4* and *KLRC4* were identified by imputation analysis [25]. This study also identified the *IL12A* region as suggestively associated with BD, but genome wide significance was not reached. Discrepancies in association results, as have been shown for the *GIMAP* variants might be explained by the different ethnic origin of the cohorts studied [26, 27].

## CLINICAL PICTURE

### Diagnosis:

Currently the diagnosis of BD is based on the criteria as proposed by the International Study Group for BD in 1990 [28]. To fulfil these criteria recurrent oral ulcers must be present together with two or more of the following; recurrent genital ulceration, eye lesions, skin lesions or a positive pathergy test (table 1). This test consists of pricking a sterile

**Table 1:** International Study Group criteria for Behçet's disease

Finding	Definition
Recurrent oral ulceration	Minor aphthous, major aphthous, or herpetiform ulcers observed by the physician or patient, which have recurred at least three times over a 12 month period
Recurrent genital ulceration	Aphthous ulceration or scarring observed by the physician or patient
Eye lesions	Anterior uveitis, posterior uveitis, or cells in the vitreous on slit-lamp examination; or retinal vasculitis detected by an ophthalmologist
Skin lesions	Erythema nodosum observed by the physician or patient, pseudofolliculitis, or papulopustular lesions; or acneiform nodules observed by the physician in a post-adolescent patient who is not receiving corticosteroids
Positive pathergy test	Test interpreted as positive by the physician at 24 to 48 hours

20G needle into the skin of a patient's forearm. The results are judged to be positive when the puncture causes an aseptic erythematous nodule or pustule that is more than 2 mm in diameter at 24 to 48 hours. At the reaction site there is initially an accumulation of neutrophils, followed by the accumulation of mononuclear cells [29]. The pathergy test is sometimes considered pathognomonic for the disease but can also be positive in other diseases like pyoderma gangrenosum [30].

### **Clinical manifestations [2, 4] (Chapter 2):**

#### *Oral aphthous ulcers:*

Often the oral ulcers are the first and sometimes the only symptom of the disease. An inverse relationship with cigarette smoking exists, in which a worsening of the disease is seen when stopping. The localization to the often very painful and persistent ulcers importantly affect the daily lives of patients, it can even lead to severe emaciation. Various forms of ulcers are described; minor, major and herpetiform. The ulcers are aphtous in nature and can be up to 2 cm in diameter. They occur throughout the intestinal area and tend to form in places where a trauma, such as, for example, occurred after a dental procedure.

#### *Genital ulcers:*

Painful genital ulcers are described throughout the urogenital area. Such an ulcer is often mistaken for a sexually transmitted disease (STD). An STD must therefore be excluded before proceeding to treatment. The ulcers are characterized by poor wound healing, in more than 75 percent scar formation occurs.

*Skin disorders:*

Skin disorders are seen in 75 percent of the BD patients and again described in various forms. The most common skin lesions are sterile papulo-pustular lesions that may be found spread over the whole body. Erythema nodosum is not uncommon, often present in female patients and usually seen on the lower extremities. Other common skin conditions are thrombophlebitis, pyoderma- or acnei-form abnormalities. Folliculitis and pustules often occur in places where skin shaved or minor skin damage can occur. 'Nail-fold lesions' and dermatography are less frequently seen.

*Pathergy skin test:*

The pathergy skin test is a local inflammatory response to a sterile puncture and has a specificity of almost one hundred percent for BD. The sensitivity of the test varies considerably and is between five and eighty percent. When using sterile needles the frequency of positive pathergy tests seem to be decreased.

*Eye involvement:*

Untreated eye symptoms can quickly lead to blindness. In non-Western countries twenty percent of the BD patients is blind. Each segment of the eye may be affected. Usually it involves inflammation in the anterior chamber (anterior uveitis). More seriously is posterior uveitis in which the optic nerve may be involved. Scleritis and conjunctivitis have been reported in BD patients, but are not seen often [2].

*Intestinal BD:*

Because BD can also manifest in the small intestine and colon in the form of aphthous ulcers, intestinal scarring, fistula or perianal lesions, the possibility of confusion with Crohn's disease of is present. Microscopic, however, in BD granulomas are not often encountered. Granulomas are quite often are present in the Crohn's disease.

*Joint involvement:*

Non-erosive oligoarticular joint manifestation is often present. It usually remains restricted to the large joints such as the knee, ankle and wrist. Erosive defects are rarely seen.

*Vasculitis:*

Vasculitis plays a central role in the pathophysiological disease process and causes the involvement of various organs. Both veins and arteries can get involved at all levels, microvascular arterial vasculitis is seen the most. In addition, a wide variety of clinical syndromes, such as deep vein thrombosis, (pulmonary arterial) aneurysms, intra-cerebral arterial occlusions, Budd-Chiari syndrome, and thrombophlebitis are described in BD-patients. All these disorders are caused by a local inflammation of the vascular

wall and therefore is treated as such with immunosuppressive medications. Pulmonary aneurysms caused by vasculitis may lead to life-threatening arteriobronchiale fistulas and and present late with hemoptysis.

*Neurological manifestations:*

Localization in the central nervous system is seen in 5 to 10 per cent of the cases and causes a high mortality rate. The brainstem is the most frequently affected, however also aseptic meningitis and arterial vasculitis is seen. The most common symptoms include cranial nerve dysfunction, ataxia, and bilateral pyramidal symptoms such as hemiparesis, areflexia or bladder dysfunction. Neuropsychiatric manifestations may manifest as behavioural changes, dementia and other psychiatric disorders. Polyneuropathy is not a symptom that is seen in BD. Diagnostics in neuro-BD is often very difficult because of the lack of hard diagnostic criteria. Examination of the CSF the total protein, neutrophil granulocytes and CSF pressure sometimes is slightly increased. However, a normal CSF examination does not rule out a cerebral BD. Various deviations can be seen radiological. High intensive-enhancing parenchymal lesions are often only found using a T1-weighted MRI, whereas CT shows no abnormalities. A (MR) angiography may in some cases be used to demonstrate a cerebral vasculitis or vasculopathy. Cerebral vasculitis can be a rapidly progressive disease. A tight control is desired when a BD patient has striking migraine symptoms and loss of function.

## **CURRENT TREATMENT OPTIONS**

First of all we must state that unfortunately most of the treatment regimens in BD the level of evidence is limited since there are few randomized controlled trials.

Treatment of patients with BD is directed by the presence of organ involvement, or vision –or life-threatening situations (table 2). Topical steroids are usually effective for mucocutaneous involvement. Some patients however respond insufficiently and in these cases additional treatment may be necessary. Colchicine is the mainstay of BD therapy, effective for refractory mucocutaneous disease, although a double blinded study conducted already in 1980 did not show a statistically significant reduction in the recurrence of both oral and genital ulcers as compared to placebo [31, 32]. Thalidomide has also been shown to be effective in patients with mucocutaneous lesions refractory to treatment with colchicine. Thalidomide exerts considerable side effects (neuropathy, constipation) and for obvious reasons should be avoided in women with childbearing potential unless they adhere to stringent anti-conceptive regime. Pentoxifylline, which reduces the production of inflammatory cytokines like TNF- $\alpha$ , was effective in reduc-



**Table 2:** Current treatment used for Behçet's disease

Medication	Dose	Main indications
Prednisonev	Local	Uveitis
	Systemic: 0.5 – 1 mg/kg	Mucocutaneous involvement Induction treatment uveitis Neurological involvement Refractory arthritis Gastro-intestinal ulceration
Colchicine	0.5 - 1.5 mg / day	Skin involvement Arthritis
Dapsone	100 - 200 mg / day	Mucocutaneous involvement Arthritis
Azathioprine	2 - 3 mg / kg / day	Uveitis
Pentoxifylline	1200 mg /day	Mucocutaneous involvement
Sulfasalazine	1- 3 g / day	Mucocutaneous involvement arthritis
Thalidomide	50 - 200 mg / day	Refractory mucocutaneous involvement
Cyclosporine	2 dd 3 - 5 mg/kg / day	Uveitis Mucocutaneous involvement
Methotrexate	7.5 - 15 mg / week	Arthritis Uveitis (rarely)
Cyclophosphamide	750 mg / m <sup>2</sup> /mo IV	Life threatening involvement (vasculitis, neurological)
IFN- $\alpha$ -2a	9 million units 3 /week for 3 months followed by a low maintenance dose of 3 million units 3 /week)	Uveitis
TNF- $\alpha$ blockers	Various doses	Uveitis Arthritis Gastro-intestinal ulceration

ing the frequency and severity of oral an vaginal ulcers [33]. Alternative treatment for mucocutaneous involvement are dapsone [34] and cyclosporine. Cyclosporine is used infrequently for this indication for fear of side effects [35]. However, being a potent immunosuppressive agent, cyclosporine resulted in significantly more alleviation of oral aphthous ulcers versus colchicine in a study by *Masuda et al.* [36] Sulfasalazine is mainly effective in arthritis and gastrointestinal involvement [4, 37].

Involvement of internal organs, sight-threatening uveitis, or severe CNS involvement may require much more aggressive treatment consisting of systemic corticosteroids of > 1mg/kg/day combined to DMARDs such azathioprine or cyclosporine. These immunosuppressives are considered effective treatment for patients with BD, especially those with uveitis. One of the newer immunosuppressive drugs, mycophenolic acid derivates, although not effective in mucocutaneous lesions [38] can be effective in therapy refractory gastro-intestinal involvement [39].

Especially (large vessel) vasculitis involving the pulmonary arteries and neurological disease, both notoriously life-threatening call for intensive measures. In these cases the use of cyclophosphamide alone or in combination with prednisone is warranted [40, 41].

Interestingly, although the cause of BD is unknown, treatment with high dose penicillin either alone or in combination with colchicine was effective in reducing symptoms (mucocutaneous and joint manifestations) in several studies. A possible role for streptococcal infection has been proposed [42-44].

In some patients the aforementioned therapies are either ineffective or associated with intolerable adverse effects necessitating alternative treatment strategies. In the slipstream of the success of new developments in the management of immune mediated diseases such as rheumatoid arthritis and IBD, promising designed novel agents targeting key-immunological factors of these immunopathological compatible diseases, have been tried in BD patients with sometimes astonishing results.

## **EMERGING TREATMENT OPTIONS**

As mentioned above, T-cells and cytokines are believed to play an important role in the pathogenesis of BD. Emerging therapies aim at influencing T-cell function or cytokines.

### **Interferon alpha**

Interferon- $\alpha$  (IFN- $\alpha$ ) maybe no longer deserves to be called an emerging therapy as it is used for therapy refractory BD for over twenty years [45]. IFN- $\alpha$  has been reported to restore the low natural killer cell activity in patients with BD to a near normal level. A double-blind study assigned 50 patients to receive either IFN- $\alpha$ 2a (6 million units 3 times weekly) or placebo for 3 months [46]. Significant decreases in pain and duration of oral ulcers, frequency of genital lesions, and number of pustular papules were noted in patients receiving IFN- $\alpha$ 2a. The frequency and duration of erythema nodosum-like lesions and thrombophlebitis were also decreased in the same group. In a systematic review of 32 studies and 4 published abstracts published before 2002, a total of 338 patients received either IFN- $\alpha$ 2a or 2b of various doses [47]. Within a few months of therapy, eighty-six percent of the patients with mucocutaneous symptoms, 96% with arthritis, and 94% with uveitis exhibited a partial or complete response. Significant improvements were also found in erythema nodosum-like lesions, skin ulcerations, and superficial thrombophlebitis. Interferon- $\alpha$ -2a seems to be more efficacious than IFN- $\alpha$ -2b. Compared with low-dose regimens, high-dose regimens were more effective and achieved more remissions. However, disease activity generally returned to baseline level either immediately after or up to 7 months after therapy was discontinued. Side effects of IFN- $\alpha$  include mild alopecia, mild leukopenia (generally reversible with discontinuing

interferon), influenza-like symptoms, and depression or psychosis. The recommended regimen is a high dose of IFN- $\alpha$ -2a (9 million units divided in 3 doses per week) for 3 months followed by a low maintenance dose (3 million units divided in 3 doses per week). Since the successful advance of TNF blockers, IFN- $\alpha$  are seldomly used in the daily practice of most clinics, especially in the ErasmusMC.

### **TNF- $\alpha$ blockers**

It is believed that TNF- $\alpha$  plays a central role in the inflammatory process of BD. Th-1 proinflammatory cytokines such as IL-1- $\beta$ , IFN- $\gamma$  and IL-12, but most of all, TNF- $\alpha$  are involved in the inflammatory response that is held responsible for disease related symptoms. TNF blockers represent a novel regimen in the treatment of BD. The most often representative of this group is the chimeric TNF- $\alpha$  antibody infliximab. Its use has been reported effective in more than 10 smaller studies including a total of more than 120 patients and 115 other single BD cases of refractory mucocutaneous lesions, severe gastrointestinal -or neurological involvement, and ocular disease [48-53]. Evidence. One of the most significant studies was published in 2004 by Sfikakis et al. [54] In this study 25 patients with ocular disease were treated with a single infusion of 5mg/kg infliximab. In all but one patient ocular inflammation was controlled within one day. In general, remarkable and swift improvement or complete resolution of the oro-genital ulcers, gastrointestinal ulcerations, and other BD related symptoms can be achieved shortly after one or two infusions of infliximab at various doses ranging from 3 -10 mg/kg. A dose of 300 – 500 mg is generally accepted effective, but the time of interval and duration of therapy remain undetermined. In patients with acute, unilateral, posterior uveitis and significant reduction of visual acuity (<0.2), as well as in those cases with inflammation of the macular area, a single infusion of infliximab, or intravitreal steroids, may be superior to other immunosuppressive drugs. In cases of bilateral posterior eye segment inflammation, a single infusion of infliximab could be used as a first-line agent to achieve a fast-onset response, along with the initiation of other immunosuppressive drugs. However, if the ocular disease remains uncontrolled a combination of immunosuppressive regimens with repetitive infusions of infliximab 5 mg/kg every 6–8 weeks for up to 2 years can be initiated.

Another TNF- $\alpha$  blocker used in BD is the fusion protein etanercept. One double-blind, placebo-controlled study has been conducted by Melikoglu et al. [55] This study involved 40 male patients with mainly mucocutaneous disease randomly given either 4 weeks of 25 mg etanercept (subcutaneously twice a week) or placebo. Significant improvements of oral ulcers, nodular and papulopustular lesions were observed in the etanercept group. Within four weeks 45% of the etanercept group remained free of oral ulcers compared with only 5% in the placebo group. No significant improvement in genital ulcers or pathergy positivity was observed. Eighty-five percent of the patients

receiving etanercept were free of nodular lesions compared with 25% of those in the placebo group. Most patients experienced recurrent disease 3 months after etanercept was stopped. Other case reports include in total less than 10 BD patients mainly successful treated with etanercept.

In 2006 two groups reported treatment with adalimumab, a human TNF- $\alpha$  antibody, in 9 refractory BD patients. In both retrospective studies all patients various symptoms resolved swiftly and persistently [56, 57]. Adalimumab could be given for at least 3 years without serious adverse effects. In Chapter 4 we present new data on the use of adalimumab in BD patients.

The role of TNF blockers in patients with uveitis is currently accepted for selected cases. Although reportedly very effective in BD, the place of TNF- $\alpha$  blockers in the therapeutic strategy, its long-term effects and the timing of intervals still has not been determined yet.

### **Anti IL-1 and anti IL-6**

The role of other cytokines like IL-1 and IL-6 in the pathogenesis of BD is becoming more eminent. Blocking the involved pathways can lead to new treatment options in BD. A case report of 2008 already describes a patient with refractory BD responding rapidly to treatment with daily anti IL-1. Lowering the dose to alternate day injections led to an increase in disease activity, again responding to an increase in the dose [58]. A recent overview of biological treatment in BD shows positive effects with no new safety issues [59]. Also inhibition of IL-6 signalling could be promising [59, 60]. Tocilizumab is a humanized monoclonal antibody that binds both to soluble and to membrane-bound IL-6 receptor and has been shown to be effective in rheumatoid arthritis. It goes without saying that more data, on efficacy and indication with regard to these novel treatment modalities is needed.

## REFERENCES

1. Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behcet's Disease. *Semin Arthritis Rheum*. 1998;27(4): 197-217.
2. Yazici H, Fresko I, Yurdakul S. Behcet's syndrome: disease manifestations, management, and advances in treatment. *Nat Clin Pract Rheumatol*. 2007;3(3):148-55.
3. Dilsen N. History and development of Behcet's disease. *Rev Rhum Engl Ed*. 1996;63(7-8):512-9.
4. Sakane T, Takeno M, Suzuki N, Inaba G. Behcet's disease. *N Engl J Med*. 1999;341(17):1284-91.
5. Idil A, Gurler A, Boyvat A, Caliskan D, Ozdemir O, Isik A, et al. The prevalence of Behcet's disease above the age of 10 years. The results of a pilot study conducted at the Park Primary Health Care Center in Ankara, Turkey. *Ophthalmic Epidemiol*. 2002;9(5):325-31.
6. Gul A, Inanc M, Ocal L, Aral O, Konice M. Familial aggregation of Behcet's disease in Turkey. *Ann Rheum Dis*. 2000;59(8):622-5.
7. Baranathan V, Stanford MR, Vaughan RW, Kondeatis E, Graham E, Fortune F, et al. The association of the PTPN22 620W polymorphism with Behcet's disease. *Ann Rheum Dis*. 2007;66(11):1531-3.
8. Takeno M, Kariyone A, Yamashita N, Takiguchi M, Mizushima Y, Kaneoka H, et al. Excessive function of peripheral blood neutrophils from patients with Behcet's disease and from HLA-B51 transgenic mice. *Arthritis Rheum*. 1995;38(3):426-33.
9. Hamzaoui K. Th17 cells in Behcet's disease: a new immunoregulatory axis. *Clin Exp Rheumatol*. 2011;29(4 Suppl 67):S71-6.
10. Verjans GM, van Hagen PM, van der Kooi A, Osterhaus AD, Baarsma GS. Vgamma9Vdelta2 T cells recovered from eyes of patients with Behcet's disease recognize non-peptide prenyl pyrophosphate antigens. *J Neuroimmunol*. 2002;130(1-2):46-54.
11. Pineton de Chambrun M, Wechsler B, Geri G, Cacoub P, Saadoun D. New insights into the pathogenesis of Behcet's disease. *Autoimmun Rev*. 2012;11(10):687-98.
12. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. *Immunity*. 2003;19(5):641-4.
13. Watford WT, Hissong BD, Bream JH, Kanno Y, Muul L, O'Shea JJ. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. *Immunol Rev*. 2004;202:139-56.
14. Direskeneli H. Autoimmunity vs autoinflammation in Behcet's disease: do we oversimplify a complex disorder? *Rheumatology (Oxford)*. 2006;45(12):1461-5.
15. van Laar JA, Kappen JH, van Daele PL, van Hagen PM. Do synovial biopsies help to support evidence for involvement of innate immunity in the immunopathology of Behcet's disease? *Arthritis Res Ther*. 2009;11(2):109.
16. Kappen JH, Dik WA, Dingjan GM, van Daele PL, Hooijkaas H, van Hagen PM, et al. Cytokines in the colon of a patient with Behcet's disease. *Arthritis Res Ther*. 2009;11(4):412.
17. Altenburg A, Mahr A, Maldini C, Kneifel CE, Krause L, Kotter I, et al. [Epidemiology and clinical aspects of Adamantiades-Behcet disease in Gemany. Current data]. *Ophthalmologe*. 2012;109(6): 531-41.
18. Kappen JH, Wallace GR, Stolk L, Rivadeneira F, Uitterlinden AG, van Daele PL, et al. Low prevalence of NOD2 SNPs in Behcet's disease suggests protective association in Caucasians. *Rheumatology (Oxford)*. 2009;48(11):1375-7.
19. Touma Z, Farra C, Hamdan A, Shamseddeen W, Uthman I, Hourani H, et al. TNF polymorphisms in patients with Behcet disease: a meta-analysis. *Arch Med Res*. 2010;41(2):142-6.
20. Hu K, Yang P, Jiang Z, Hou S, Du L, Li F. STAT4 polymorphism in a Chinese Han population with Vogt-Koyanagi-Harada syndrome and Behcet's disease. *Hum Immunol*. 2010;71(7):723-6.

21. Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet's disease. *Nat Genet.* 2010;42(8):698-702.
22. Mizuki N, Meguro A, Ota M, Ohno S, Shiota T, Kawagoe T, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet's disease susceptibility loci. *Nat Genet.* 2010;42(8):703-6.
23. Xavier JM, Shahram F, Davatchi F, Rosa A, Crespo J, Abdollahi BS, et al. Association study of IL10 and IL23R-IL12RB2 in Iranian patients with Behcet's disease. *Arthritis Rheum.* 2012;64(8):2761-72.
24. Khaib Dit Naib O, Aribi M, Idder A, Chiali A, Sairi H, Toutou I, et al. Association Analysis of IL10, TNF-alpha, and IL23R-IL12RB2 SNPs with Behcet's Disease Risk in Western Algeria. *Front Immunol.* 2013;4:342.
25. Kirino Y, Bertsias G, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E, et al. Genome-wide association analysis identifies new susceptibility loci for Behcet's disease and epistasis between HLA-B\*51 and ERAP1. *Nat Genet.* 2013;45(2):202-7.
26. Lee YJ, Horie Y, Wallace GR, Choi YS, Park JA, Choi JY, et al. Genome-wide association study identifies GIMAP as a novel susceptibility locus for Behcet's disease. *Ann Rheum Dis.* 2013;72(9):1510-6.
27. Ortiz-Fernandez L, Conde-Jaldon M, Garcia-Lozano JR, Montes-Cano MA, Ortego-Centeno N, Castillo-Palma MJ, et al. GIMAP and Behcet disease: no association in the European population. *Ann Rheum Dis.* 2014.
28. Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. *Lancet.* 1990;335(8697):1078-80.
29. Chang HK, Cheon KS. The clinical significance of a pathergy reaction in patients with Behcet's disease. *J Korean Med Sci.* 2002;17(3):371-4.
30. Akay N, Boyvat A, Heper AO, Soykan I, Arica IE, Bektas M, et al. Behcet's disease-like presentation of bullous pyoderma gangrenosum associated with Crohn's disease. *Clin Exp Dermatol.* 2006;31(3):384-6.
31. Graham-Brown RA, Sarkany I. Failure of colchicine and fibrinolytic therapy in Behcet's disease. *Clin Exp Dermatol.* 1980;5(1):87-92.
32. Aktulga E, Altac M, Muftuoglu A, Ozyazgan Y, Pazarli H, Tuzun Y, et al. A double blind study of colchicine in Behcet's disease. *Haematologica.* 1980;65(3):399-402.
33. Yasui K, Ohta K, Kobayashi M, Aizawa T, Komiyama A. Successful treatment of Behcet disease with pentoxifylline. *Ann Intern Med.* 1996;124(10):891-3.
34. Convit J, Gohman-Yahr M, Rondon-Lugo AJ. Effectiveness of dapsone in Behcet's disease. *Br J Dermatol.* 1984;111(5):629-30.
35. Lin P, Liang G. Behcet disease: recommendation for clinical management of mucocutaneous lesions. *J Clin Rheumatol.* 2006;12(6):282-6.
36. Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. *Lancet.* 1989;1(8647):1093-6.
37. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. EULAR recommendations for the management of Behcet disease. *Ann Rheum Dis.* 2008;67(12):1656-62.
38. Adler YD, Mansmann U, Zouboulis CC. Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Behcet's disease. *Dermatology.* 2001;203(4):322-4.
39. Kappen JH, Mensink PB, Lesterhuis W, Lachman S, van Daele PL, van Hagen PM, et al. Mycophenolate sodium: effective treatment for therapy-refractory intestinal Behcet's disease, evaluated with enteroscopy. *Am J Gastroenterol.* 2008;103(12):3213-4.

40. Melillo N, Sangle S, Stanford MR, Andrews TC, D'Cruz DP. Low-dose intra-venous cyclophosphamide therapy in a patient with neurological complications of Behcet's disease. *Clin Rheumatol*. 2007;26(8):1365-7.
41. Aktogu S, Erer OF, Urpek G, Soy O, Tibet G. Multiple pulmonary arterial aneurysms in Behcet's disease: clinical and radiologic remission after cyclophosphamide and corticosteroid therapy. *Respiration*. 2002;69(2):178-81.
42. Calguneri M, Ertenli I, Kiraz S, Erman M, Celik I. Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behcet's disease. *Dermatology*. 1996;192(2):125-8.
43. Calguneri M, Kiraz S, Ertenli I, Benekli M, Karaarslan Y, Celik I. The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behcet's disease. A randomized clinical trial. *Arthritis Rheum*. 1996;39(12):2062-5.
44. Al-Waiz MM, Sharquie KE, MH AQ, Hayani RK. Colchicine and benzathine penicillin in the treatment of Behcet disease: a case comparative study. *Dermatol Online J*. 2005;11(3):3.
45. Feron EJ, Rothova A, van Hagen PM, Baarsma GS, Suttorp-Schulten MS. Interferon-alpha 2b for refractory ocular Behcet's disease. *Lancet*. 1994;343(8910):1428.
46. Alpsyoy E, Durusoy C, Yilmaz E, Ozgurel Y, Ermis O, Yazar S, et al. Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. *Arch Dermatol*. 2002;138(4):467-71.
47. Kotter I, Gunaydin I, Zierhut M, Stubiger N. The use of interferon alpha in Behcet disease: review of the literature. *Semin Arthritis Rheum*. 2004;33(5):320-35.
48. Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behcet's syndrome with chimeric tumour necrosis factor alpha antibody. *Gut*. 2001;49(5):725-8.
49. Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: a case report. *Gastroenterology*. 2001;120(4):995-9.
50. Sfikakis PP, Theodossiadi PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. *Lancet*. 2001;358(9278):295-6.
51. Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behcet's disease: analysis of published data on 369 patients. *Semin Arthritis Rheum*. 2011;41(1):61-70.
52. Calvo Catala J, Campos Fernandez C, Rueda Cid A, Gonzalez-Cruz Cervellera MI, Baixauli Rubio A, Pastor Cubillo MD. [Efficacy of adalimumab in Behcet's disease. Description of 6 cases] Eficacia del adalimumab en la enfermedad de Behcet: descripcion de 6 casos. *Reumatol Clin*. 2011;7(4):258-61.
53. Perra D, Alba MA, Callejas JL, Mesquida M, Rios-Fernandez R, Adan A, et al. Adalimumab for the treatment of Behcet's disease: experience in 19 patients. *Rheumatology (Oxford)*. 2012;51(10):1825-31.
54. Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadi PG, Papaefthimiou S, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. *Ann Intern Med*. 2004;140(5):404-6.
55. Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S, et al. Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study. *J Rheumatol*. 2005;32(1):98-105.
56. van Laar JA, Missotten T, van Daele PL, Jamnitski A, Baarsma GS, van Hagen PM. Adalimumab: a new modality for Behcet's disease? *Ann Rheum Dis*. 2007;66(4):565-6.
57. Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sight-threatening uveitis in Behcet's disease. *Eye*. 2007;21(6):824-5.
58. Botsios C, Sfriso P, Furlan A, Punzi L, Dinarello CA. Resistant Behcet disease responsive to anakinra. *Ann Intern Med*. 2008;149(4):284-6.

59. Arida A, Sfikakis PP. Anti-cytokine biologic treatment beyond anti-TNF in Behcet's disease. *Clin Exp Rheumatol*. 2014;32(4 Suppl 84):S149-55.
60. Borhani Haghighi A, Safari A. Tocilizumab may be a potential addition to our weapons against neuro-Behcet's disease. *Med Hypotheses*. 2008;71(1):156-7.



## Outline of the thesis



“Although the etiology of Behçet’s disease (BD) still needs to be unravelled, it is widely considered an excessive T-cell mediated inflammatory response in a genetically susceptible host.” This sentence is often the introduction in research articles on BD. It summarises not only the reason for this thesis but also covers the outline.

The chapters in this thesis travel from the demography towards morbidity towards immunopathology and etiology ending with (molecular designed) therapy in BD.

Chapter 2 will focus on the epidemiology of BD in the Rotterdam area. Apart from an overview of patients characteristics and with prevalence data of the different ethnicities, we take place in the camp that challenges, the assumption that the prevalence of BD declines after immigration. In Chapter 3 genetic aspects of BD are presented, starting with a targeted gene approach, the prevalence of NOD variants that are related to Crohn’s disease, a disorder with many similarities to BD. Subsequently a non-targeted approaches by use of a Genome wide associations study as well as a whole genome sequence is presented. Chapter 4 cytokines addresses the subject of involved, cytokines and where to measure these, in tissue or in serum? As a result of the immunopathological studies, novel treatment modalities are shown in Chapter 5, with emphasis on the use of biologicals such as the major cytokine (TNF) blocking agents . Finally the results are summarized and discussed in chapter 6.



# 2

## Epidemiology





# Behçet's disease, prevalence and manifestations in the Rotterdam area

Kappen J.H., van Dijk E.H.C., Baak-Dijkstra M., van Daele P.L.A., Lam-Tse W.K.,  
van Hagen P.M., van Laar J.A.M.

*Submitted*

## ABSTRACT

*Introduction:* Behçet's disease (BD) is most prevalent in countries along the former Silk Road. Prevalence varies from 70-420 per 100,000 in Turkey, and 13.5-20 and 1-2 per 100,000 in Asia and Western Europe, respectively. Additionally, disease severity and morbidity might be correlated with ethnicity. We studied demography and morbidity in the Dutch BD cohort and compared those with known figures.

*Patients and Methods:* The prevalence of BD patients in the Rotterdam area was determined by comparing the total amount of patients within the ethnic population with the amount of patients diagnosed with BD. Patient files of the Erasmus University Medical Centre (Erasmus MC) were reviewed for morbidity figures and compared with existing data.

*Results:* In total 84 BD patients of Dutch, Turkish or Moroccan descent were identified in the Rotterdam area. Prevalences of BD differed per ethnicity; 1, 71 and 39 per 100.000 for Dutch-Caucasians, Turks, and Moroccans, respectively. These figures are comparable with the occurrence of BD in West Turkey and Morocco. Within the studied Erasmus MC cohort no significant differences in morbidity appeared between the ethnic groups. However, uveitis and pustules were significantly more present in the Erasmus MC cohort as compared to UK, German, Turkish and Moroccan cohorts.

*Discussion and Conclusions:* We present the first epidemiologic study of BD in the Netherlands. The prevalence of BD in the studied Dutch region and in countries of ancestry is similar. Morbidity is equally spread, compared to other countries, but uveitis and pustules seem to be more present in the Netherlands.



## INTRODUCTION

Behçet's disease (BD), first described by Hulusi Behçet in 1937, is an idiopathic systemic vasculitis with variable clinical manifestations [1]. The diagnosis BD is based on clinical criteria with the presence of recurrent oral ulceration together with genital ulcers, ocular inflammation and skin lesions [2]. Less often arthritis, central nervous system (CNS) -and gastrointestinal tract inflammation is present [3-5]. The etiology still needs to be unravelled. The inflammatory symptoms are considered to be caused by an excessive T-cell mediated inflammatory response, triggered by an environmental antigen in a genetically susceptible host [3, 6, 7]. Over the years several genetic associations with BD are identified [8-14]. Furthermore, a positive family history can be found in 12% of non-Caucasoid patients and a sibling risk ratio of 11–52 in Turkish patients.

BD typically occurs in countries along the former Silk Road, an ancient route of commerce between the Mediterranean (Spain and Portugal) and the Far East (China). The highest prevalences of BD are seen in Turkey (20-420 per 100,000, with about 70 per 100,000 in its European region). In Asian countries, such as Japan, Korea, China, Iran, and Saudi Arabia, prevalence varies from 13.5 to 20 cases per 100,000. In Western countries prevalences of approximately 1 per 100,000 are reported [5] [15, 16]. Morbidity is reported to be lower in Western populations, in comparison with Eastern Mediterranean and Middle and Far Eastern countries [3, 15, 16]. BD can develop at any age, but the disease appears most frequently between the second and fourth decade of life [17]. In countries along the former Silk Road, BD is more frequent among men, whereas in Western countries it is more prevalent in women [17-22]. Demographic and morbidity data of BD in Northern Europe and the Netherlands are sparse. Demographic data from other Northern European countries are restricted to two German and British cohorts [23, 24]. It has been suggested that life-style or environmental factors could be influential on the immuno-etiology of BD hence influencing the prevalence in patients migrating to other countries [20, 25]. In this light countries, such as the Netherlands, to where patients from high incidence countries migrate to can be helpful to address this issue.

Therefore we initiated a demographic study in Dutch BD patients to elucidate variability of prevalence and morbidity amongst different ethnic groups and changing figures upon migration.

## MATERIALS AND METHODS

All patients included in our study fulfilled the diagnosis BD by the criteria of the International Study Group for BD [2]. For prevalence analyses the numbers of BD patients were collected from hospital records in the Rotterdam area (Erasmus University Medical

Center (Erasmus MC), Vlietland Hospital, Maasstad Hospital, Sint Franciscus Gasthuis). Only Dutch, Turkish and Moroccan ethnicities were included in this analyses since the occurrence of BD in other ethnic backgrounds in the Netherlands are known to be too low to reach significant power. Public information on populations and ethnicities of inhabitants of the postal area Rotterdam is freely accessible from the governmental institute for statistical data (Centraal Bureau voor de Statistiek).

The morbidity analyses were performed by reviewing files on the presence of disease symptoms from all Erasmus MC visiting BD patients (also from outside the Rotterdam postal area) up to January 2012. To compare our data to other cohorts we performed a PubMed survey on epidemiological data and BD. Statistical analyses were performed with SPSS 17.0 version (Chicago Illinois). Chi-square test method was used, a p-value < 0.05 was considered to be statistically significant.

## RESULTS

### Prevalence

In total 84 BD patients of Dutch, Turkish or Moroccan descent were identified in the area with the postal code 2900 - 3319 (table 1). The other 16 patients were from different origin. The prevalence of BD in the Rotterdam area differed per ethnicity, 1 per 100,000 for Dutch, 71 per 100,000 for Turkish and 39 per 100,000 for Moroccans. We identified 11 Turkish and 3 Moroccan BD patients that were born in the Netherlands.

**Table 1;** Prevalence of BD in the Rotterdam area.

Rotterdam area (postal code 2900 - 3319)	Inhabitants	BD patients	per 100,000	Born in the Netherlands
Total	1,319,680	100	8	
Dutch-Caucasian	874,162	12	1	
Turkish	73,028	52	71	11
Moroccan	51,218	20	39	3

### Disease features

The Erasmus MC cohort of 110 BD patients was distributed in three subpopulations of Dutch-Caucasian, Turkish and Moroccan patients. The remainders constituted a mix of various ethnicities. Patient characteristics are presented in table 2a. The average age of the patients was 44 years (Table 2a). The male female ratio was 1 for the entire group; 0.64 for the Dutch patients, 1.31 for the Turkish, and 1.66 for the Moroccan patients, respectively. Oral and genital ulcers and skin involvement were most prevalent. No sig-

**Table 2a;** Ethnic comparison of Dutch BD patients for diagnostic criteria in BD.

n=110	All	The Netherlands	Turkey	Morocco	Others
	100% (110)	37.3% (41)	34.5% (38)	14.5% (16)	13.7% (15)
Average age	44.2	43.0	44.3	46.5	
♂:♀ ratio	1	0.64	1.31	1.66	
Oral ulcers	100% (110)	100% (41)	100% (38)	100% (16)	100% (15)
Genital ulcers	79.1% (87)	85.4% (35)	84.2% (32)	62.5% (10)	66.7% (10)
Erythema nodosum	31.8% (35)	24.4% (10)	36.8% (14)	37.5% (6)	33.3% (5)
Pustules	80.9% (89)	73.2% (30)	81.6% (31)	93.8% (15)	86.6% (13)
Uveitis*	61.8% (68)	51.2% (21)	60.5% (23)	68.8% (11)	86.6% (13)
Positive pathology Test	57.1% (32/56)	66.7% (16/24)	38.1% (8/21)	40% (2/5)	100% (6/6)

\* No distinction was made between anterior, intermediate or posterior uveitis.

**Table 2b;** Ethnic comparison of Dutch BD patients for other features present during the disease course.

n=110	All	The Netherlands	Turkey	Morocco	Others
	100% (110)	37.3% (41)	34.5% (38)	14.5% (16)	13.7% (15)
Fatigue	68.2% (75)	61.0% (25)	76.3% (29)	68.8% (11)	66.7% (10)
Headache	60.0% (66)	48.8% (20)	57.9% (22)	75.0% (12)	80% (12)
<i>Arthralgia</i>	67.3% (74)	<u>51.2% (21)</u>	<u>73.7% (28)</u>	<u>81.3% (13)</u>	80% (12)
<i>Arthritis</i>	30.9% (34)	<u>22.0% (9)</u>	34.2% (13)	<u>50.0% (8)</u>	26.7% (4)
Gastro-intestinal complaints	44.5% (49)	36.6% (15)	42.1% (16)	62.5% (10)	53.3% (8)
Diarrhea	22.7% (25)	24.4% (10)	18.4% (7)	31.3% (5)	20.0% (3)
Neurological involvement	12.7% (14)	12.2% (5)	5.3% (2)	12.5% (2)	33.3% (5)
HLA-B51 positivity	43.3% (13/30)	40.0% (6/15)	44.4% (4/9)	33.3% (1/3)	66.7% (2/3)

*Italic/ underlined = statistically significant*

nificant differences were observed between the ethnic groups in any of the symptoms of the diagnostic criteria (supplementary table 1).

Other clinical symptoms were again split up, per ethnicity (table 2b). Fatigue, headache and arthralgia were often present. Of all symptoms significant differences between the ethnic cohorts were only demonstrated for the prevalence of arthritis and arthralgia between Dutch and Moroccan patients ( $p < 0.038$ ) and arthralgia between Dutch and Turkish patients ( $p < 0.04$ ); a preference for the Turkish and Moroccan patients was seen (supplementary table 1). There was no significant difference between morbidity in male and female patients (data not shown).

### Comparison to other cohorts

We compared our data with Turkish, Moroccan, German and British cohorts (table 3a en 3b [23, 24, 26, 27]). The German cohort consisted of two main ethnicities: German

**Table 3a;** International comparison between the EMC and 4 other cohorts for diagnostic criteria for BD.

	The Netherlands	Germany (23)	UK (24)	Turkey (26)	Morocco (27)
n	110	590	419	2,147	1,034
♂/♀ ratio	1	1.4	0.5	1.03	2
Oral ulcers	100%	98%	100%	100%	100%
<i>Genital ulcers</i>	<u>79.1%</u>	<u>64%</u>	<u>89%</u>	<u>88%</u>	<u>86%</u>
<i>Erythema* nodosum</i>	<u>31.8%</u>	<u>42%</u>	-	-	<u>16%</u>
<i>Pustules*</i>	<u>80.9%</u>	<u>62%</u>	-	-	<u>64%</u>
<i>Uveitis</i>	<u>61.8%</u>	53%	68%	<u>29%</u>	<u>44%</u>
<i>Positive pathergy test</i>	<u>57.1%**</u>	<u>34%</u>	<u>32%</u>	56%	53%

*Italic/ underlined = statistically significant*

\* 86% of UK BD patients had skin manifestations; this was not specified in the original study.

\*\* Not all Dutch BD patients underwent a pathergy test; therefore this figure was based on all positive tests in 56 patients who underwent this test.

In the other cohorts, data on other disease features related to BD were limited (table 3b). We did find a significant difference between prevalence of arthralgia (common in the UK), arthritis and neurological involvement. (supplementary table 2).

**Table 3b;** International comparison between the EMC and 4 other cohorts for other features in the course of BD.

	The Netherlands	Germany (23)	UK (24)	Turkey (26)	Morocco (27)
n	110	590	419	2,147	1,034
<i>Arthralgia</i>	<u>67.3%</u>	-	<u>93%</u>	-	<u>32%</u>
<i>Arthritis</i>	<u>30.9%</u>	-	-	-	<u>45%</u>
Gastro-intestinal complaints*	48.2%	-	-	-	-
Gastro-intestinal involvement **	-	12%	7%	2.8%	11%
<i>Neurological involvement</i>	<u>12.7%</u>	11%	<u>31%</u>	<u>2.2%</u>	17%

*Italic/ underlined = statistically significant*

\* Gastro-intestinal involvement included one of the following; nausea, vomiting, abdominal pain, diarrhea. Ulceration of the gastro-intestinal was not necessarily found.

\*\* Ulceration of the gastro-intestinal tract was objectivated.

(38.5%) and Turkish (45.3%). For all empty cells in the table no data were available in the original articles. The male female ratio was 0.5 in the UK cohort and 1 or higher in the other cohorts. Oral and genital ulcers and skin involvement were most prevalent. In contradiction to observations in our own cohort, disease manifestations differed between the different populations (table 3a and supplementary table 2). Pustules appeared to be more prevalent in the Erasmus MC cohort as compared to Germany and Morocco. Furthermore, uveitis was more prevalent in Western cohorts as compared to Turkish and Moroccan.

## DISCUSSION

We present the first epidemiological and morbidity data of BD patients living in the Netherlands. In this population the majority of patients are Dutch-Caucasian, Turkish or Moroccan. The prevalence of BD in the Rotterdam area amongst these groups reflects epidemiological studies in comparable populations and does not appear to shift after migration.

Comparable data from Germany showed that the prevalence of BD in the Turkish population was similar to our findings, and equals the reported prevalence in the European part of Turkey [22]. Thus, our observation of next generation immigrants with BD and the fact that BD can also develop in non-Turkish (or Asian) patients can get BD contradicts with the suggestion that BD does not develop after migration. This suggestion of causative land-based disease was based on the observation that BD did not occur in Japanese immigrants on Hawaii [25] and on the presence of a decreasing BD prevalence after migration from Turkey to Germany [20]. However, the latter could not be confirmed in a second study by the same group in 2012 [22].

We therefore would like to stress that the pathogenesis of BD does not appear to be decisively determined by the country of residence. Whether the disease severity is influenced could not be studied, since no validated BD severity scoring system exists.

The average age of the BD patients in the Erasmus MC cohort was similar amongst various ethnicities [17] [28]. The Dutch-Caucasian male/ female ratio tended to be lower as compared with Moroccans and Turks. Apparently a female prevalence occurs in Western and Asian countries as observed in other cohorts (table 2a) [24, 27]. Saylan et al reported female predominance in the United States, the United Kingdom, Korea, and China, whereas a male predominance was found for almost all Middle Eastern countries [29]. A low male/ female ratio is often seen in auto-immune diseases. However, BD is generally not associated with auto-immunity, rather with auto-inflammation [30]. The latter is not associated with female predominance, leading to uncertainty about the significance of the mentioned observations [31].

Prevalence of many symptoms was significantly different in our EMC cohort as compared to other cohorts, differences in data collection can be of influence. Clinically considered relevant differences in morbidity merely consist of skin lesions and uveitis. In Dutch patients a significantly higher percentage of pustules as compared to Germany and Morocco was seen. Prevalence of erythema nodosum also was statistically significant higher in the Erasmus MC cohort and in the German study, as compared to Moroccan figures. It is widely thought that environmental components are essential in BD patho-

physiology. Therefore it was expected that skin involvement would have been higher in countries with high disease prevalence. Other factors, such as genetic susceptibility could account for our observation.

A significantly higher prevalence of uveitis was seen in Western cohorts compared to Turkish and Moroccan population. Since BD is rare in the Netherlands it is possible that a general physician could miss the diagnosis BD in a patient that presents with oral ulcers [28]. A relative underdiagnoses of the less severe cases of BD might lead to relatively higher prevalence of severe case with uveitis. A second additive reason for the high percentage of uveitis found in the Erasmus MC cohort is the close cooperation between our hospital and the Rotterdam Eye Hospital in respect of referral of patients .

In conclusion, the prevalence of BD in different ethnic groups in the Rotterdam area is similar to those in the countries of origin of these patients. It does not appear to shift after migration. However, a substantial amount of patient data is necessary to elucidate migrational effects on the occurrence and morbidity of BD more robustly. This warrants international cooperation between BD treating physicians.

## REFERENCES

1. Behçet H. Über rezidivierende, aphthöse, durch ein Virus verursachte Geschwüre am Munde, am Auge und an den Genitalien. *Dermatologische Wochenschrift*. 1937;36:1152–7.
2. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. *Lancet*. 1990 May 5;335(8697):1078–80.
3. Yurdakul S YH. Behçet's syndrome. *Best Pract Res Clin Rheumatol*. 2008 Oct;22(5):793–809.
4. Ideguchi H SA, Takeno M, Ueda A, Ohno S, Ishigatsubo Y. Behçet disease: evolution of clinical manifestations. *Medicine (Baltimore)*. 2011 Mar;90(2):125–32.
5. Kastner DL. *Intermittent and periodic arthritic syndromes*. 13 ed. Baltimore: Williams & Wilkins; 1997.
6. Sakane T TM, Suzuki N, Inaba G. Behçet's disease. *N Engl J Med*. 1999 Oct 21;341(17):1284–91.
7. Gul A, Inanc M, Ocal L, Aral O, Konice M. Familial aggregation of Behçet's disease in Turkey. *Ann Rheum Dis*. 2000;59(8):622–5.
8. Baranathan V, Stanford MR, Vaughan RW, Kondeatis E, Graham E, Fortune F, et al. The association of the PTPN22 620W polymorphism with Behçet's disease. *Ann Rheum Dis*. 2007;66(11):1531–3.
9. Kappen JH, Wallace GR, Stolk L, Rivadeneira F, Uitterlinden AG, van Daele PL, et al. Low prevalence of NOD2 SNPs in Behçet's disease suggests protective association in Caucasians. *Rheumatology (Oxford)*. 2009;48(11):1375–7.
10. Touma Z, Farra C, Hamdan A, Shamseddeen W, Uthman I, Hourani H, et al. TNF polymorphisms in patients with Behçet disease: a meta-analysis. *Arch Med Res*. 2010;41(2):142–6.
11. Hu K, Yang P, Jiang Z, Hou S, Du L, Li F. STAT4 polymorphism in a Chinese Han population with Vogt-Koyanagi-Harada syndrome and Behçet's disease. *Hum Immunol*. 2010;71(7):723–6.
12. Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. *Nat Genet*. 2010;42(8):698–702.
13. Mizuki N, Meguro A, Ota M, Ohno S, Shiota T, Kawagoe T, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci. *Nat Genet*. 2010;42(8):703–6.
14. Price AL, Zaitlen NA, Reich D, Patterson N. New approaches to population stratification in genome-wide association studies. *Nat Rev Genet*. 2010;11(7):459–63.
15. Kaklamani VG VG, Kaklamani PG. Behçet's disease. *Semin Arthritis Rheum*. 1998;27:197–217.
16. Nakae K MF, Hashimoto T, Inaba G, Mochizuki M, Sakane T. *Recent epidemiological features of Behçet's disease in Japan*. Amsterdam: Excerpta Medica; 1993.
17. Önder M GM. The multiple faces of Behçet's disease and its aetiological factors. *J Eur Acad Dermatol Venereol*. 2000;15:126–36.
18. Ghate JV JJ. Behçet's disease and complex aphthosis. *J Am Acad Dermatol*. 1999;40:1–18.
19. Tugal-Tutkun I ÖS, Altan Yaycioglu R. Uveitis in Behçet's disease: an analysis of 880 patients. *Am J Ophthalmol*. 2004;138:373–80.
20. Zouboulis CC, Kotter I, Djawari D, Kirch W, Kohl PK, Ochsendorf FR, et al. Epidemiological features of Adamantiades-Behçet's disease in Germany and in Europe. *Yonsei Med J*. 1997;38(6):411–22.
21. Yazici H, Fresko I, Yurdakul S. Behçet's syndrome: disease manifestations, management, and advances in treatment. *Nat Clin Pract Rheumatol*. 2007;3(3):148–55.
22. Altenburg A, Mahr A, Maldini C, Kneifel CE, Krause L, Kotter I, et al. [Epidemiology and clinical aspects of Adamantiades-Behçet disease in Germany. Current data]. *Ophthalmologie*. 2012;109(6):531–41.

23. Altenburg A PN, Orawa H. Epidemiologie und Klinik des Morbus Adamantiades-Behçet in Deutschland—Aktuelle pathogenetische Konzepte und therapeutische Möglichkeiten. *J Dtsch Dermatol Ges.* 2006;4:49-66.
24. Seaman G PR. Behçet's Disease manifestation in a population drawn from the UK Behçet's Syndrome Society. Hamza M (ed) *Behçet's Disease.* 1997:196–9.
25. Hirohata T, Kuratsune M, Nomura A, Jimi S. Prevalence of Behçet's syndrome in Hawaii. With particular reference to the comparison of the Japanese in Hawaii and Japan. *Hawaii Med J.* 1975; 34(7):244-6.
26. Gurler A BA, Tursen U. Clinical manifestations of Behçet's Disease: an analysis of 2147 patients. *Yonsei Med J.* 1997;38:423–7.
27. Benamour S NT, Echchilali K. Study of 1034 cases of Behçet's Disease. *Clin Exp Rheumatol.* 2006; 24:513.
28. Fauci/Braunwald/Kasper/Hauser. *Harrison's Internal Medicine.* 17 ed: McGraw-Hill Education - Europe; 2008.
29. Saylan T MC, Fresko I, Melikoglu M. Behçet's Disease in the Middle East. *Clin in Dermatol.* 1999;17: 209-23.
30. Gul A. Behçet's disease as an autoinflammatory disorder. *Curr Drug Targets Inflamm Allergy.* 2005; 4(1):81-3.
31. Geraint James D. Silk Route disease. *Postgraduate Medical Journal.* 1986;62:151-3.



## SUPPLEMENTARY DATA

**Supplementary table 1;** P-values for ethnic comparison of Dutch BD patients for diagnostic criteria and other features in BD.

<i>Parameter</i>	<i>Compared for ethnicity</i>	<i>p-value*</i>	<i>Table</i>
♂:♀ ratio	Dutch - Turks	0.093	2a
	Dutch - Moroccans	0.110	
	Turks - Moroccans	0.753	
<i>HLA-B51 positivity</i>	Dutch - Turks	0.831	2a
	Dutch - Moroccans	0.829	
	Turks - Moroccans	0.735	
<i>Genital ulcers</i>	Dutch - Turks	0.886	2a
	Dutch - Moroccans	0.057	
	Turks - Moroccans	0.080	
<i>Erythema nodosum</i>	Dutch - Turks	0.229	2a
	Dutch - Moroccans	0.332	
	Turks - Moroccans	0.964	
<i>Pustules</i>	Dutch - Turks	0.373	2a
	Dutch - Moroccans	0.087	
	Turks - Moroccans	0.250	
<i>Uveitis</i>	Dutch - Turks	0.405	2a
	Dutch - Moroccans	0.231	
	Turks - Moroccans	0.568	
<i>Pathergy test positivity</i>	Dutch - Turks	0.055	2a
	Dutch - Moroccans	0.264	
	Turks - Moroccans	0.937	
<i>Fatigue</i>	Dutch - Turks	0.143	2b
	Dutch - Moroccans	0.585	
	Turks - Moroccans	0.562	
<i>Headache</i>	Dutch - Turks	0.417	2b
	Dutch - Moroccans	0.073	
	Turks - Moroccans	0.235	
<i>Arthralgia</i>	Dutch - Turks	<b>0.040**</b>	2b
	Dutch - Moroccans	<b>0.038**</b>	
	Turks - Moroccans	0.553	
<i>Arthritis</i>	Dutch - Turks	0.225	2b
	Dutch - Moroccans	<b>0.038**</b>	
	Turks - Moroccans	0.277	
<i>Gastro-intestinal complaints</i>	Dutch - Turks	0.616	2b
	Dutch - Moroccans	0.076	
	Turks - Moroccans	0.171	
<i>Diarrhea</i>	Dutch - Turks	0.519	2b
	Dutch - Moroccans	0.597	
	Turks - Moroccans	0.300	
<i>Neurological involvement</i>	Dutch - Turks	0.279	2b
	Dutch - Moroccans	0.975	
	Turks - Moroccans	0.354	

\* All p-values were calculated using a Chi-square test method in SPSS.

\*\* All p-values  $\leq 0.05$  were considered to be significant and were therefore made **bold**.

**Supplementary table 2;** P-values for international comparison between the EMC and 4 other cohorts for diagnostic criteria for BD and other features in the course of BD.

<i>Parameter</i>	<i>Compared for ethnicity</i>	<i>p-value*</i>	<i>Table</i>
<i>Genital ulcers</i>	Dutch - German	<b>0.002**</b>	3a
	Dutch - British	<b>0.006**</b>	
	Dutch - Turkish	<b>0.006**</b>	
	Dutch - Moroccan	0.052	
<i>Erythema nodosum</i>	Dutch - German	<b>0.045**</b>	3a
	Dutch - British	***	
	Dutch - Turkish	***	
	Dutch - Moroccan	<b>10<sup>-19**</sup></b>	
<i>Pustulas</i>	Dutch - German	<b>10<sup>-19**</sup></b>	3a
	Dutch - British	***	
	Dutch - Turkish	***	
	Dutch - Moroccan	<b>10<sup>-19**</sup></b>	
<i>Uveitis</i>	Dutch - German	0.090	3a
	Dutch - British	0.219	
	Dutch - Turkish	<b>10<sup>-19**</sup></b>	
	Dutch - Moroccan	<b>10<sup>-19**</sup></b>	
<i>Pathergy test positivity</i>	Dutch - German	<b>0.001**</b>	3a
	Dutch - British	<b>10<sup>-19**</sup></b>	
	Dutch - Turkish	0.863	
	Dutch - Moroccan	0.545	
<i>Arthralgia</i>	Dutch - German	***	3b
	Dutch - British	<b>10<sup>-19**</sup></b>	
	Dutch - Turkish	***	
	Dutch - Moroccan	<b>10<sup>-19**</sup></b>	
<i>Arthritis</i>	Dutch - German	***	3b
	Dutch - British	***	
	Dutch - Turkish	***	
	Dutch - Moroccan	<b>0.005**</b>	
<i>Neurological involvement</i>	Dutch - German	0.603	3b
	Dutch - British	<b>10<sup>-19**</sup></b>	
	Dutch - Turkish	<b>10<sup>-19**</sup></b>	
	Dutch - Moroccan	0.250	
<i>Major vessel involvement</i>	Dutch - German	0.536	3b
	Dutch - British	<b>10<sup>-19**</sup></b>	
	Dutch - Turkish	0.095	
	Dutch - Moroccan	<b>0.021**</b>	

\* All p-values were calculated using a Chi-square test method in SPSS.

\*\* All p-values  $\leq 0.05$  were considered to be significant and were therefore made **bold**.

\*\*\* These fields were left blank, because of lack of data in the original study. Therefore no p-value could be determined.

# 3

## Genetics





# Low prevalence of NOD2 SNPs in Behçet's disease suggests protective association in Western Caucasians

Kappen J.H., Wallace G.R., Stolk L., Rivadeniera F., Uitterlinden A.G., van Daele P.L.A., Laman J.D., Kuijpers, R.W.A.M., Baarsma, G.S., Stanford M.R., Fortune F., Madanat W., van Hagen P.M., van Laar J.A.M.

*Rheumatology (Oxford)*. 2009 Nov;48(11):1375-7

**ABSTRACT**

*Objectives:* It has been shown previously that three NOD2 variants (Arg702Trp, Gly908Arg and Leu1007fs) are associated with Crohn's disease (CD), a disorder clinically resembling Behçet's disease (BD). We studied the frequency of these variants in BD patients.

*Methods:* DNA samples of 200 BD patients (59 Western Caucasian, 139 Middle Eastern of Arab descent (ME) and 2 Asian) and 520 healthy controls (444 Western Caucasian and 76 ME) were genotyped using a Taqman assay.

*Results:* Both the Arg702Trp and Leu1007fs (=frameshift) variants were significantly less frequently present amongst BD patients compared to healthy controls (0.5% versus 5.8%,  $p < 1.10 \cdot 10^{-5}$  and 0.0% versus 1.8%,  $p < 0.007$ , respectively). In the Western Caucasian subpopulation Arg702Trp was significantly less frequent in the BD group as compared to the controls ( $p = 0.04$ ). In the ME subpopulation a trend was observed ( $p < 0.06$ ).

*Conclusion:* Of the three CD associated SNPs one of the variant NOD2 alleles was significantly less present in Western Caucasian BD patients.

## INTRODUCTION

BD is an idiopathic systemic vasculitis characterized by recurrent oral and genital aphthous ulcers, skin lesions, ocular inflammation and more seldomly, arthritis, CNS - and gastrointestinal tract inflammation [1, 2].

Prevalence varies from 110 to 420 per 100.000 in Turkey to about 2 per 100.000 in western countries [2]. A strong association with HLA-B51, a positive family history in 12% of non-Caucasoid patients and a sibling risk ratio of 11-52 suggest causal involvement of both genetic and environmental factors [3].

The etiology of BD is still to be unravelled but it is widely considered an excessive inflammatory response, possibly triggered by an (infectious) antigen in a genetically susceptible host. The abundance of neutrophils in early lesions and the association of HLA-B51 with neutrophil activation indicate involvement of innate immunity in BD [1-2, 4].

Similar symptoms such as uveitis, arthritis, erythema nodosum and colitis with ileocaecal mucosal inflammation and punched-out fissuring ulcers suggest a genetic overlap between BD and CD [5, 6]. Recently, the latter has been linked with genetic alterations in innate immunity. Increased susceptibility to CD is associated with two SNPs (Arg702Trp, Gly908Arg) and a frameshift mutation (Leu1007fs) in the CARD15 gene [7, 8]. This gene encodes for the nucleotide-binding oligomerization domain containing 2 (NOD2) protein. In short, NOD2 acts by recognition of muramyl dipeptide (MDP) derived from peptidoglycan, present in the cell wall of all bacteria. NOD2 engagement activates nuclear factor-kappaB (NF- $\kappa$ B), a transcription factor with a central role in both innate and adaptive immunity. This transcription factor is also considered to play a key role in many inflammatory diseases including BD and CD [7,9,10].

Since BD and CD share many clinical features and for both diseases innate immune mechanisms appear crucial, we addressed the hypothesis that NOD2 variants are mechanistically operational in both diseases. We therefore determined the occurrence of the aforementioned NOD2 SNPs in two large and independent BD cohorts

## MATERIALS AND METHODS

### Study population

Two cohorts of in total 200 unrelated BD patients (52 from the Erasmus MC at Rotterdam, 109 from The Jordan Hospital, Amman, Jordan and St John's Ophthalmic Hospital, East Jerusalem, Israel and 39 from St. Thomas' Hospital, London, UK). Of those, 59 were Western Caucasian, 2 of Asian and 139 from ME origin of Arab descent. All patients fulfilled the International Study Group criteria for the diagnosis of BD [5]. In total 520

healthy controls were recruited (444 Caucasian and 77 ME). Dutch controls were healthy Caucasian blood donors, the UK controls were Caucasian transplant donors from which Afro-Caribbean and Far Eastern individuals were removed. Given the high prevalence of BD in the ME, local controls were either hospital staff or otherwise healthy cataract patients matched to the same population as BD patients from each country. ME controls were over 50 years of age as new presentation with BD after this age is extremely unusual in this population. The ethical committees of all centers approved genetic evaluations after written informed consent by the patients.

### Genotyping

Genomic DNA was extracted from 5 mL samples of peripheral venous blood using the magnetic bead separation technique from AGOWA (Berlin, Germany) on a Microlab STAR pipetting robot (Hamilton Robotics, Reno, Nevada, USA). 1–2 ng genomic DNA was dispensed into 384-well plates using a Caliper Sciclone ALH3000 pipetting robot (Caliper LS, Mountain View, Ca, USA). Genotypes were determined using a Taqman allelic discrimination assay. The Assay-on-Demand service ([www.appliedbiosystems.com](http://www.appliedbiosystems.com)) was used for the polymorphisms Arg702Trp and Gly908Arg. For Leu1007fs the Primers and probes for Leu1007fs were designed as described by Inhora *et al.*[8] (Isogen, IJsselstein, The Netherlands).

The PCR reaction mixture for the assay-on-demand assays included 1–2 ng of genomic DNA in a 2  $\mu$ L volume and the following reagents: FAM and VIC probes (200 nM), primers (0.9  $\mu$ M), and 2x Taqman PCR master mix (ABgene, Epsom, UK). For Leu1007fs the PCR reaction mixture included 2 ng of DNA in a 2  $\mu$ L volume and the following reagents: FAM probes (250 nM), TET probe (500 nM), primers (300 nM) and 2x Taqman PCR master mix (Applied Biosystems Inc, Foster City, Ca, USA). PCR cycling reaction was performed in 384-well PCR plates in an ABI 9700 PCR system (Applied Biosystems Inc) and consisted of initial denaturation for 15 min at 95  $^{\circ}$ C, and 40 cycles with denaturation of 15 s at 95  $^{\circ}$ C and annealing and extension for 60 s at 60  $^{\circ}$ C. Results were analyzed by the ABI Taqman 7900HT using the sequence detection system 2.22 software (Applied Biosystems Inc).

### Statistics

All data were submitted for Hardy Weinberg Equilibrium (HWE) calculations before inclusion in the analyses. Subjects were grouped according to genotype for the polymorphisms of interest. Per subject the allele information of both alleles was added. To detect allele frequency differences between cases and controls Pearson's chi-square test was used. The analyses were performed in Haploview 4.0. A p-value of < 0.05 was considered significant.



## RESULTS

Of all alleles less than 2.5% were excluded for further data processing because genotyping failed. In the 200 patients (400 alleles) and 520 controls (1040 alleles) no homozygous variants were present.

Both the Arg702Trp and Leu1007fs variants were significantly less frequently present among BD patients compared to healthy controls. The largest difference was found in the Arg702Trp variant: 0.5% versus 5.8%. For the Leu1007fs variant a difference of 0.0% versus 1.8% was observed. The frequency of the NOD2 Gly908Arg variant was not significantly different between the BD patients and the controls (Table 1).

Differences in frequencies of NOD2 polymorphisms may vary with geographical location [11]. We thus separately re-assessed the SNPs of the Western Caucasian and Middle Eastern subpopulations. Though not powered for this analysis, the Arg702Trp variant remained significantly reduced in the Western Caucasian subpopulation ( $p=0.042$ ). In the ME group a trend ( $p=0.058$ ) was seen for a reduced occurrence of Arg702Trp. The Leu1007fs variant was not significantly different in the sub-cohorts (Table 1).

## DISCUSSION

In this genetic study consisting of 200 BD patients, three NOD2 variants were genotyped to test the assumption that these variants have a similar distribution as in CD patients. Contrary to this initial hypothesis, we observed a significantly lower frequency of two of the three variant alleles in the BD group as compared to healthy controls.

In the subgroup analysis, a statistically significant difference was obtained for the Arg702Trp variant allele of the Caucasian subpopulation. Our study was appropriately powered to identify frequencies of NOD2 variants in the same magnitude as described for CD. In contrast to this we observed a lower proportion of variant alleles in our BD population. Apparently the other subgroups in our study were too low in number to reach significance.

In our study we focused on individual SNP frequencies in an ethnically mixed cohort and extracted subpopulations. Ahmad *et al.* described haplotypes of three NOD2 variants in combination with other SNPs in 374 patients and 500 controls and could not find an association with BD[11]. Details on the individual variants, however, were not presented. Uyar *et al* used an entirely Turkish cohort (existing of 85 BD patients and 100 healthy controls) and could not demonstrate a significant difference[12]. It has been shown in other studies as well as in our present study that the NOD2 variants are observed at a lower frequency in ME cohorts[11, 12, 13]. Therefore, the size of the Turkish cohort might

**Table 1:** The frequency of three variant alleles in total cohort of 200 BD patients and 520 healthy controls (left column) and in sub-cohorts of Caucasian and Middle Eastern individuals (right column). Significantly less Arg702Trp and Leu1007fs variants are seen in the BD cohort compared to the healthy controls.

SNP	Allele	Total	Caucasian			Middle East			P-value
			BD (frequency)	Control (frequency)	P-value	BD (frequency)	Control (frequency)	P-value	
Arg702Trp	Arg	388 (0.995)	961 (0.942)	811 (0.934)	0.0421	272 (1.000)	150 (0.987)	0.0579	
	Trp	2 (0.005)	59 (0.058)	57 (0.066)		0 (0.000)	2 (0.013)		
Gly908Arg	Gly	387 (0.982)	1011 (0.980)	864 (0.982)	0.1432	267 (0.974)	147 (0.967)	0.6606	
	Arg	7 (0.018)	21 (0.020)	16 (0.018)		7 (0.026)	5 (0.033)		
Leu1007fs		392 (1.000)	1017 (0.982)	866 (0.980)	0.1209	272 (1.000)	151 (0.993)	0.1805	
	fs	0 (0.000)	19 (0.018)	18 (0.020)		0 (0.000)	1 (0.007)		

be too small to detect the observations made in our larger study. A relation of NOD2 variants and HLA-B51 has not been shown in the past and therefore not expected to be of value in the present study since these genes are located on different chromosomes (16 and 6, respectively) [11, 12].

Assuming that the findings in the current study can be confirmed by future studies, it is of interest to speculate how the low frequency of NOD2 variants in BD might contribute to the understanding of the underlying mechanism of the disease. It is clear that variation in many genes will contribute to BD susceptibility and disease progression. Candidates are the PTPN22 620W, IL-10 and TNF- $\alpha$  genes that support an increased inflammatory responses and a failure of regulation[14]. Similar mechanisms in CD are postulated to explain the involvement of NOD2 variants leading to decreased NF- $\kappa$ B activation (loss of function) and thus reduced defensin production resulting in an increased bacterial load in the gut of CD patients[9, 15, 16]. Moreover, NOD2 activation inhibits stimulation of Toll-like receptors by pathogen products, and as NOD2 function is impaired, TLR signalling is enhanced and generates an exaggerated inflammatory response inducing tissue damage[9, 15].

In a second model transgenic expression of the Leu1007fs variant show a gain of function, with a direct increase in NF- $\kappa$ B, proinflammatory cytokines and tissue damage[9]. A potential connection between these paradoxical results is the kinetics of the NOD2 response. Acute stimulation of human blood-derived macrophages with the NOD2 agonist, muramyl dipeptide (MDP) induces a proinflammatory cytokine response. By comparison, persistent treatment of cells with MDP prior to activation through TLR2 or TLR4 ligands decreases cytokine responses, possibly through induction of IRAK-M, in support of control of TLR signalling. However, this tolerance is lost in cells from Leu1007fs homozygous patients[17]. As gut epithelial cells, dendritic cells and macrophages are in constant contact with bacterial products of the normal gut flora it is proposed that such tolerance is a protective mechanism[18]. Failure to control responses would lead to tissue damage as seen in CD.

Our findings suggest that NOD2 variants react in some cases with a decreased production of inflammatory cytokines to an exogenous stimulus. This is supported by the observation that NOD2 gene-deficient mice show reduced joint inflammation and are protected against early cartilage damage after intraarticular injection of *Streptococcus pyogenes* cell wall fragments[19]. In addition to this, human peripheral blood mononuclear cells of Leu1007fs variant donors exposed to cell wall fragments, produce less TNF- $\alpha$  and IL-1 $\beta$  than healthy controls[19]. However, this is contradictory to macrophage data discussed above, and may be due to the in vivo nature of these experiments, route of challenge, or the type of antigen used. The complex role of NOD2 in response to bacterial challenge in different cell types should be addressed in BD and other conditions.

In conclusion, our observations indicate that at least Western Caucasian carriers of the NOD2 variant allele have a reduced risk of developing BD. Our study contributes to the general assumption that genetic factors are involved in BD. It will therefore be of considerable interest to investigate other variants in BD patients in order to gain more insight into the pathophysiology and potentially identify new leads for treatment options.

## **ACKNOWLEDGEMENTS**

This work was partly supported by the “vereniging trusfonds Erasmus universiteit Rotterdam”.

Prof dr J Laman’s research is partly supported by the Dutch MS Research Foundation.

## REFERENCES

- 1 Evereklioglu C, Current concepts in the etiology and treatment of Behçet disease. *Surv Ophthalmol* 2005; 50:297-350.
- 2 Yazici H, Fresko I, Yurdakul S. Behçet's syndrome: disease manifestations, management, and advances in treatment. *Nat Clin Pract Rheumatol* 2007; 3:148-55.
- 3 Gül A, Inanç M, Ocal L, Aral O, Koniçe M. Familial aggregation of Behçet's disease in Turkey. *Ann Rheum Dis* 2000; 59:622-5.
- 4 Takeno M, Kariyone A, Yamashita N, *et al.* Excessive function of peripheral blood neutrophils from patients with Behçet's disease and from HLA-B51 transgenic mice. *Arthritis Rheum* 1995; 38: 426-33.
- 5 Marshall SE, Behcet's disease. *Best Pract Res Clin Rheumatol* 2004; 8:291-311.
- 6 Sakane T, Takeno M, Suzuki N, Inaba G. Behcet's disease. *N Engl J Med* 1999; 341:1284-91.
- 7 Girardin SE, Boneca IG, Viala J, *et al.* Nod2 is a general sensor of peptidoglycan through Muramyl Dipeptide (MDP) detection. *J Biol Chem* 2003; 278:8869-8872.
- 8 Inohara N, Ogura Y, Fontalba A, *et al.* Host recognition of bacterial Muramyl Dipeptide Mediated through NOD2. Implications for Crohn's disease. *J Biol Chem* 2003; 278:5509-5512.
- 9 Strober W, Murray PJ, Kitani A, Watanabe T. Signalling pathways and molecular interactions of NOD1 and NOD2. *Nat Rev Immunol* 2006; 6:9-20.
- 10 Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. *J Clin Invest* 2001; 107:7-11.
- 11 Ahmad T, Zhang L, Gogus F, *et al.* CARD15 polymorphisms in Behçet's disease. *Scand J Rheumatol* 2005; 34:233-237.
- 12 Uyar FA, Saruhan-Direskeneli G, Gul A. Common Crohn's disease-predisposing variants of the CARD15/NOD2 gene are not associated with Behcet's disease in Turkey. *Clin Exp Rheumatol* 2004; 22(Suppl 34):50-52.
- 13 Uyar FA, Over-Hamzaoğlu H, Türe F, *et al.* Distribution of common CARD15 variants in patients with sporadic Crohn's disease: cases from Turkey. *Dig Dis Sci* 2006; 51:706-710.
- 14 Baranathan V, Stanford MR, Vaughan RW, *et al.* The association of the PTPN22 620W polymorphism with Behcet's disease. *Ann Rheum Dis* 2007; 66:1531-3.
- 15 Chamaillard M, Philpott D, Girardin SE, *et al.* Gene-environment interaction modulated by allelic heterogeneity in inflammatory diseases. *Proc Natl Acad Sci U S A* 2003; 100:3455-60.
- 16 Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nuñez G, Flavell RA. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. *Science* 2005; 307: 731-4.
- 17 Hedl M, Li J, Cho JH, Abraham C. Chronic stimulation of Nod2 mediates tolerance to bacterial products. *Proc Natl Acad Sci U S A* 2007; 104:19440-5
- 18 Abreu MT, Fukata M, Arditi M. TLR signaling in the gut in health and disease. *J Immunol* 2005; 174: 4453-60.
- 19 Joosten LA, Heinhuis B, Abdollahi-Roodsaz S, *et al.* Differential function of the NACHT-LRR (NLR) members Nod1 and Nod2 in arthritis. *Proc Natl Acad Sci U S A* 2008; 105:9017-22.



# Genome-wide association study in an admixed case series reveals *IL12A* as a new candidate in Behçet disease

Kappen JH, Medina-Gomez C, van Hagen PM, Stolk L, Estrada K, Rivadeneira F, Uitterlinden AG, Stanford MR, Ben-Chetrit E, Wallace GR, Soylu M, van Laar JAM

*PLoS One.* 2015 Mar 23;10(3):e0119085

## ABSTRACT

*Introduction:* The etiology of Behçet's disease (BD) is unknown, but widely considered an excessive T-cell mediated inflammatory response in a genetically susceptible host. Recent genome-wide association studies (GWAS) have shown limited number of novel loci-associations. The rarity and unequal distribution of the disease prevalence amongst different ethnic backgrounds have hampered the use of GWAS in cohorts of mixed ethnicity and sufficient sample size. However, novel statistical approaches have now enabled GWAS in admixed cohorts.

*Methods:* We ran a GWAS on 336 BD cases and 5,843 controls. The cases consisted of Western Europeans, Middle Eastern and Turkish individuals. Participants from the Generation R study, a multiethnic birth cohort in Rotterdam, The Netherlands were used as controls. All samples were genotyped and data was combined. Linear regression models were corrected for population stratification using Genomic Principal Components and Linear Mixed Modelling. Meta-analysis was performed on selected results previously published.

*Results:* We identified SNPs associated at genome-wide significant level mapping to the 6p21.33 (HLA) region. In addition to this known signal two potential novel associations on chromosomes 6 and 18 were identified, yet with low minor allele frequencies. Extended meta-analysis reveal a GWS association with the *IL2A* variant rs17810546 on chromosome 3.

*Discussion:* We demonstrate that new statistical techniques enable GWAS analyses in a limited sized cohort of mixed ethnicity. After implementation, we confirmed the central role of the HLA region in the disease and identified new regions of interest. Moreover, we validated the association of a variant in the *IL2A* gene by meta-analysis with previous work. These findings enhance our knowledge of genetic associations and BD, and provide further justification for pursuing collective initiatives in genetic studies given the low prevalence of this and other rare diseases.



## INTRODUCTION

Behçet's disease (BD) is a systemic auto-inflammatory occlusive vasculitis presenting with oral and genital aphthous ulcers, skin lesions, ocular inflammation and a pathognomonic pathergy test [1-3]. Although the etiology of the disease is largely unknown, it is considered to be an excessive inflammatory response possibly triggered by an infectious antigen in a genetically susceptible host. Prevalence varies from 110–420 per 100,000 in the Middle East (Turkey) to about 2 per 100,000 in Western countries [3, 4]. In patients of Turkish origin there is a positive family history in 12% of the cases with a sibling risk ratio between 11–52 [3, 4]. The heritability of BD has been estimated to range between 20 to 60%, with the strongest genetic association embracing variants in HLA-B51, explaining about 20% of the disease heritability [3, 4]. The combination of epidemiological and genetic data suggest causal involvement of both genetic and environmental factors [5].

Over the years, numerous single nucleotide polymorphisms (SNPs) have been found associated with BD [6-9]. In 2010 the first genome-wide association study (GWAS) in BD cohorts of Turkish and Japanese origin demonstrated association of various variants in the known HLA-B51 domain, and two new association signals, mapping to the interleukin-10 (*IL10*), and the IL-23 receptor–IL-12 receptor Beta2 (*IL23R–IL12RB2*) locus [10, 11]. These associations later have been confirmed in an Iranian cohort [12]. Yet another study in Algerian individuals only replicated the associations from the *IL10* variants [13]. GWAS in Chinese and Korean individuals reported associations of SNPs mapping to two other loci, with regions containing the signal transducer and activator of transcription 4 (*STAT4*) and GTPase of immune associated protein *GIMAP* genes, respectively. Polymorphisms in *IL10* and *IL23R–IL12RB2* were not found to be significantly associated with BD in neither of those studies [14,15]. More recently, associations with *CCR1*, *STAT4* and *KLRC4* were identified by means of imputation and GWAS meta-analysis [14]. This study also identified the *IL12A* region as suggestively associated with BD, but genome wide significance (GWS) was not reached. Discrepant association results, as those observed for variants mapping to the *GIMAP* locus, might be explained by the different ethnic origin of the cohorts studied [15, 16]. Therefore, studying cohorts of diverse ethnic background may be useful to understand the origin of these differences. Moreover, the inclusion of multiple ethnicities results in larger datasets (representing higher power) crucial for these analyses given the typically small effects of common genetic variants discovered by the GWAS approach [17]. Nonetheless, GWAS results can be confounded by ancestry differences between cases and controls, potentially leading to spurious associations. This challenge in multi-ethnic studies has so far been approached by methods that take into account confounding by genetic ancestry, such as correction for Genomic Principal Components (GPC) [18]. More recently, linear mixed models (LMM) have been introduced as a reliable method to correct not only for ancestry differences, but also for family structure and/or cryptic relationships [19].

We have therefore set up a multi-center GWAS including BD patients of both Middle Eastern and Western background. We demonstrate that by means of novel statistic approaches it is feasible to run a GWAS in a small multiethnic cohort and use these results for meta-analysis.

## MATERIALS AND METHODS

### Study populations

A total of 369 unrelated BD patients from 18 different geographic origins were included in our study (Table 1).

The age range was 18 to 73 years (mean 47 years). All patients fulfilled the International Study Group (ISG) criteria of BD diagnoses [20]. No exclusion criteria were applied.

**Table 1. Cases before and after QC.** Collection at [1] Erasmus MC at Rotterdam, The Netherlands, [2] University Hospital of Cukurova, Turkey, [3] St John's Ophthalmic Hospital, Jerusalem, Israel, [4] St Thomas' Hospital, London, UK, [5] University Hospital, Damascus, Syria, Ethnicity of cases after QC.

Ethnicity	Number of patients	Collection	Number of patients after QC
Afghanistan	1	[1]	1
Iranian	4	[1]	4
Lebanese	1	[1]	1
Cape Verde	2	[1]	2
Curacao	1	[1]	1
Dominican Republic	1	[1]	1
Dutch caucasian	24	[1]	20
Greece	1	[1]	1
Israel	1	[1]	1
Jordan	1	[1]	1
Morocco	16	[1]	12
Surinam	2	[1]	1
Thailand	1	[1]	1
China	1	[1]	1
Turkey	35	[1]	32
Turkey	91	[2]	87
Arab Jerusalem ancestry	110	[3]	98
UK caucasian	38	[4]	33
Syrian	38	[5]	38
<b>Total</b>	<b>369</b>		<b>336</b>

As controls, 87 Syrian healthy volunteers (22-73 years, mean 51 years) and 5,756 participants from the Generation R study, a multi-ethnic birth cohort in Rotterdam (4-9 years, mean 6 years), The Netherlands, were used [21].

Replication was pursued in a cohort of 82 BD patients who met the ISG criteria, and 98 ethnically matched controls in Western European, collected from Birmingham and Midland Eye Centre, Birmingham, UK.

The ethics committees of the involved centers (Erasmus MC (METC), Ethical Committee at Çukurova University and Sandwell and West Birmingham Hospitals Trust Ethics Committee) approved the study, and written informed consent was obtained from all participants.

### **Genome wide genotyping**

Genotyping of cases and controls (including the Generation R Study) was performed using the Illumina HumanHap 610K and/or 660 K arrays, following manufacturers protocols. Quality Control (QC) was performed individually for each set following a standard protocol to exclude samples and SNPs with low quality genotyping. Markers with minor allele frequency (MAF)  $\leq 1\%$ , missing genotypes  $\geq 5\%$  or which failed an exact test of Hardy-Weinberg equilibrium proportions in the controls ( $P < 1 \times 10^{-7}$ ) were excluded from the datasets. Samples with gender discrepancy, excess of heterozygosity, duplicates or samples with relatedness or other inconsistencies were also removed. In a subsequent stage, we extracted SNPs common to both platforms which passed individual QC and then applied the QC protocol for the combined dataset.

### **Phenotype-Genotype Analyses**

#### *Heritability*

To characterize the extent to which common genetic variants play a role in BD susceptibility, we applied a recently proposed approach for estimating heritability based on genome-wide sharing between distantly related individuals, as implemented in the GCTA software in combination with the determination of ancestry-aware kinship coefficients by REAP software [22, 23]. No pairs exceeded the standard cutoff coefficient of 0.025 for genetic relatedness, confirming that no two individuals in the analysis were closer than third degree cousins. Relatedness coefficients calculated from REAP were used in the relatedness matrix before implementing GCTA. A disease prevalence of 0.42% was used in the modelling [3, 4].

#### *Genome-wide association analysis*

Association between BD susceptibility and 553,224 genome-wide SNPs was carried out using a regression framework adjusting for population stratification. GWS threshold for

the association was established at  $p < 5 \times 10^{-8}$ . Two different strategies were followed to adjust for population sub-structure in the data.

#### *Genomic Principal Components*

In the first approach, 20 GPC were obtained for all pairs of individuals in the combined dataset based on the similarities of individual genotypic profiles for 37,060 independent autosomal SNPs contained in the HapMap Phase II release 22 build 36 [24] using Multi-Dimensional Scaling (MDS) as implemented in PLINK (<http://pngu.mgh.harvard.edu/purcell/plink/>). Afterwards, we performed logistic regression adjusting for those 20 GPC.

#### *Linear Mixed models*

In the second approach we used LMM in order to account for possible population structure in the association analysis. This methodology estimates the level of relatedness even between independent individuals using the genotyped markers. By modeling the dissimilarity between genotypes of the subjects, it is able to correct the association results for stratification. This approach is implemented in the publicly available EMMA eXpedited (EMMAX) software [25]. Since the effect sizes reported by EMMAX are based on Mantel–Haenszel statistics, the odd ratios for associations of the significant SNPs were estimated from the regular logistic regression models performed in PLINK.

#### *Meta-analysis*

Meta-analysis of our own study results with published results for the BD suggestive associated SNP rs17810546 [14] was performed using an inverse variance fixed-effects approach in METAL [26]

### **Replication analysis**

Four SNPs: rs8187722, rs439033, rs11969661 and rs17087141 were genotyped using TaqMan assays designed by Applied Biosystems, Warrington, UK in 82 BD patients and 98 control samples. In short, PCR was performed in 384-well plates with a 10  $\mu$ l total reaction volume containing 20 pg/ml DNA (samples) or water (controls) and 2x LC-480 probe master (Roche, West Sussex UK) followed by endpoint genotyping analysis using the LC-480 system (Roche, West Sussex UK). Genotypes were determined as either homozygous (e.g. AA or GG) or heterozygous (e.g. AG) according to the presence or absence of fluorescence for each genotype.

## RESULTS

An overview of the ethnicity of the included BD cases is presented in Table 1; all controls were collected in St John's Ophthalmic Hospital, Jerusalem and had Arab ancestry. In order to gain power and match all remaining ethnicities, this dataset was combined with the genotyped samples from the multiethnic Generation R Study.

### Genome wide Genotyping

Genotyping was performed in 456 samples (369 cases and 87 controls) collected from the different participating hospitals (Erasmus MC at Rotterdam, The Netherlands, University Hospital of Cukurova, Turkey, St John's Ophthalmic Hospital, Jerusalem, Israel and by St Thomas' Hospital, London, UK). After quality control, 553,224 genotyped SNPs in 423 of these samples remained. We excluded 33 patients (including 1 control) because of low Illumina call rate ( $< 97.5\%$ ) and one more individual was excluded for gender mismatch. After QC of this combined dataset, 336 cases and 5843 controls were available for analysis.

### Phenotype Genotype Analyses

#### *Heritability*


The heritability estimate, based on the 505,454 genotyped SNPs and 4,855 unrelated individuals (296 cases) was 32.0% (95%CI 21.0-44.0%; $P= 5.5E-17$ ). Thus a considerable percent of the BD risk is explained by the additive effect of the common SNPs analyzed.

#### *Genomic Principal Components*


The representation of the first GPC for the combined dataset projected together with the three reference panels of the International HapMap Project Phase II known as YRI, CEU and CHB/JPT representing populations of African, European and Asian background respectively [27] is shown in Figure 1. As shown by the overlapping distribution across the four first GPC, BD cases (represented in black) are well matched by genetic ancestry to controls (represented in yellow Syrian volunteers and grey for Generation R participants).

#### *Genome wide association analysis*

Association analyses were performed for 505,454 SNPs. As expected in such structured population, results from analysis without any type of stratification adjustment, showed association through the whole genome and a Genomic Inflation Factor ( $\lambda$ ) of 5.25 (Supplementary Figure 1). After GPC correction, the association analysis showed minimal inflation of the test statistics with a  $\lambda$  of 1.035 (Figure 2).



**Figure 1. Genetic substructure of the Combined GWAS dataset.** Two-dimensional scatterplots from multidimensional scaling analyses of the Generation R Study and Behçet collected data together with the three initial Panels from the HapMap Project. Each dot represents an individual in the dataset. Color codes: Grey=Generation R, Black= Behçet Cases, Yellow = Jordan controls. Blue= CEU, Red=YRB, Green= JPT.



**Figure 2. Behçet GWAS results using Genomic Principal Components (GPC) adjustment.** Each dot represents an SNP in the dataset. **a. QQ-plot.** Associated SNPs deviating from the null hypothesis of no association (identity line). **b. Manhattan plot.** SNPs showing association with the disease map to chromosome 6 and a singleton in chromosome 18.

The top associated SNPs mapped to the HLA region on chromosome 6 with rs7770216 being the most significant (Table 2). Yet, another GWS signal in chromosome 18 driven by rs17087141 mapped to a region containing the uncharacterized miscRNA LOC400655.

Additional association analyses using different strategies including reduction of number of matching controls (to different case/control ratios) and incorporating different number of genomic principal components in the models yielded similar results for effect coefficients and genomic inflation factors (data not shown).


**Table 2. GWS SNPs associated with Behçet's disease susceptibility using GPC and EMMAX approaches.** Results for the association analysis when correcting for 20 PCs to adjust for stratification. In italic font the SNPs which show association only by one of the two approaches

CHR	SNP	BP	A1	A2	MAF	N	20PCs		EMMAX*
							OR	P	P
6	rs9380215	31157634	A	G	0.09	6178	2.132	1.32E-10	3.15E-15
6	rs4947296	31166157	C	T	0.09	6178	2.131	1.38E-10	4.98E-15
6	rs9263509	31174398	T	C	0.16	6179	1.82	6.62E-09	2.69E-10
6	rs2233984	31187243	A	G	0.09	6179	2.064	3.35E-10	1.08E-15
6	rs4495304	31188697	C	T	0.09	6028	2.069	7.92E-10	3.84E-14
6	rs4959053	31207556	A	G	0.09	6175	2.348	1.20E-12	3.90E-17
6	<i>rs2523589</i>	<i>31435313</i>	<i>C</i>	<i>A</i>	<i>0.43</i>	<i>6177</i>	<i>0.5466</i>	<i>2.92E-09</i>	<i>5.83E-08</i>
6	rs2844575	31442924	G	A	0.48	6173	1.81	5.62E-10	5.92E-08
6	rs9266409	31444547	C	T	0.25	6178	2.183	3.66E-16	2.62E-18
6	rs2253907	31444849	A	G	0.48	6175	1.797	4.41E-10	1.46E-09
6	rs7770216	31448590	T	G	0.26	6072	2.198	9.75E-17	2.25E-18
6	rs6933050	31451611	C	T	0.25	6178	2.183	3.69E-16	2.59E-18
6	rs1131896	31487094	A	G	0.31	6141	1.647	6.86E-08	2.66E-09
6	rs2256028	31487177	T	G	0.21	6177	1.784	1.72E-09	7.49E-12
6	rs2848713	31492458	A	G	0.1	6173	2.118	3.03E-12	7.08E-22
6	<i>rs11969661</i>	<i>160626409</i>	<i>T</i>	<i>C</i>	<i>0.02</i>	<i>6179</i>	<i>2.696</i>	<i>1.30E-03</i>	<i>5.15E-09</i>
6	<i>rs439033</i>	<i>160739406</i>	<i>C</i>	<i>T</i>	<i>0.02</i>	<i>6163</i>	<i>2.016</i>	<i>2.30E-03</i>	<i>1.14E-08</i>
6	<i>rs8187722</i>	<i>160784748</i>	<i>G</i>	<i>A</i>	<i>0.01</i>	<i>6179</i>	<i>1.696</i>	<i>1.00E-04</i>	<i>2.87E-15</i>
18	rs17087141	69036707	C	T	0.03	6167	4.925	1.08E-13	2.81E-18


\* Odd ratios cannot be calculated by EMMAX approach

Results from the GWAS analysis using EMMAX yielded three independent GWS signals (Table 2). In addition to those mapping to the two previously described BD loci from chromosomes 6 and 18, an additional signal was found on chromosome 6q25.3 in the solute carrier family 22 member 3 (*SLC22A3*) gene region. The three most significant markers underlying this GWAS signal included rs11969661, rs439033 and rs8187722 (Table 2). Using EMMAX resulted in adequate adjustment for population stratification as corroborated by  $\lambda=1.0$  (Table 2) and the absence of early deviation from the identity line in the QQplot (Figure 3).

The most significant SNP identified by the EMMAX approach maps also to the HLA region in chromosome 6. The regional association plot of this HLA-B region is shown in Supplementary Figure 2. This HLA-B region has been associated with BD susceptibility in previous GWAS analyses [10, 22]. Figures 4 and 5 show the association plots for the




**Figure 3. Behcet GWAS results using Linear Mixed Models Genomic approach.** Each dot represents an SNP in the dataset. **a. QQ-plot.** Associated SNPs deviating from the null hypothesis of no association (identity line). **b. Manhattan plot.** SNPs showing association with the disease map to two different signals in chromosome 6 and a singleton in chromosome 18.



**Figure 4. SNP association plot for Behcet's susceptibility-associated region of chromosome 6q25.3.** Dots represent GWAS P-values (EMMAX approach) and positions of SNPs found within the 6q25.3 locus. The top SNP, i.e. rs8187722, is denoted by a diamond. Different colours indicate varying degrees of pair-wise linkage disequilibrium (1000 Genomes Nov 2010 CEU) between the top SNP and all other genotyped SNPs. Genetic coordinates are per 1000 Genomes Nov 2010-CEU. Bottom, LD heat map based on  $D'$  values from the combined population under study including all SNPs in the 500Kb region.





**Figure 5. SNP association plot for Behçet's susceptibility-associated region of Chromosome 18q22.3.** Dots represent GWAS P-values (EMMAX approach) and positions of SNPs found within the 18q22.3 locus. The top SNP, i.e. rs17087141, is denoted by a diamond. Different colours indicate varying degrees of pairwise linkage disequilibrium (1000Genomes CEU) between the top SNP and all other genotyped SNPs. Genetic coordinates are per 1000 Genomes Nov 2010-CEU. . Bottom, LD heat map based on  $D'$  values from the combined population under study including all SNPs in the 500Kb region.

other two GWS signals in 6q25.3 (*SCLA22A3* locus) and 18q22.3, which have not been previously reported as associated with BD.

### Meta-analyses

By scanning published BD GWAS, we identified a variant suggestive of association ( $P=6.01 \times 10^{-7}$ ) [14], showing strong evidence for association with BD in our study, although not at GWS level. After meta-analysis of our results with those published by Kirino et al. in two Turkish cohorts the leading SNP (rs17810546) in *IL12A* reached GWS. The G-allele conferred a 1.7 increased risk for BD (OR= 1.66; 95%CI [1.42,1.93];  $P= 1.12 \times 10^{-10}$  (Table 3.)).

**Table 3. Meta-analysis of leading SNP in IL12A.** Association results for rs17810456 (G-allele) in two Turkish cohorts (14) and the current study.

Study	N	N cases	OR	CI 95%	P value
Turkish replication*	2487	1209	1.64	[1.31 - 2.04]	1.20E-05
Turkish discovery*	1447	821	1.41	[1.06 - 1.89]	2.00E-02
Current study	6179	336	2.06	[1.49 - 2.84]	9.31E-06
Combined	10113	2366	1.66	[1.42 - 1.93]	1.12E-10

\* From Table 1 Kirino et al. 2013

## Replication

No significant evidence for replication of the leading SNPs from the GWAS signals of chromosome 6 and 18 was found, while the MAF of the genotyped markers were very similar to those reported in healthy individuals.

## DISCUSSION

Enabled by innovative novel methodology we could run a GWAS in a rare condition like BD within a unique case collection of multiethnic background. We identified variants associated with BD mapping to the well-established MICA-HLA-B locus and to two regions on chromosome 6 in the *SLC22A* gene region and on chromosome 18 in an uncharacterized region. Moreover, meta-analysis with previous published results enabled the identification of a GWS association with variants in the *IL12A* region. All together, these common variants across this four loci explained up to 32% of the variance in BD risk.

Methods for the calculation of heritability estimates from SNP microarray data of population-base studies have recently emerged [22, 23]. We could determine that the narrow sense heritability of BD explained by common variants in our study was 32%, estimate in line with those obtained by previous reports based on family data [3, 4, 28], albeit smaller. This could be explained by the overestimation of heritability estimates in family-based design, as a result of biases due to epistatic interactions or shared environment. In addition, GCTA estimates should be interpreted as the lower bound of the true additive genomic influence on heritability, since the genetic variance is limited to the common SNPs present in the arrays(29). Therefore variance explained by rarer variants (MAF<0.01) and/or causal variants that were not genotyped or are not tagged by the SNPs on the genotyping array will be missed. As GCTA is intended for studies on homogeneous populations it is necessary to use appropriate methods to calculate the relatedness matrix in studies with admixed individuals to avoid overestimation of the heritability. Therefore, to obtain unbiased estimates we used REAP for the estimation of the kinship coefficient [30].

Methods based on LMM enabled the analysis of GWAS data in a cohort of mixed ethnicity of relative small sample size, maximizing power. The fact that our GWAS identified well-established variants in the HLA-B locus, provides certainty that the methodological approach was sound and in fact applicable to other rare diseases. Expanding the current case collection or performing meta-analysis with other collections is warranted. Efforts including datasets of different ancestries, should be analyzed with methodologies which take into account different genomic architecture based on ethnic background. Such methods can also be applied at the meta-analysis level as implemented in MANTRA [31].

In addition to the signal in the well-known HLA locus on chromosome 6, we also identified two genomic regions of interest. Nevertheless, all variants had relatively low MAF (2-3%) and thus their significance should be interpreted with caution. We could not find evidence for replication of the associations in an independent yet underpowered case/control set. Considering the low MAF and the very limited power of the replication further scrutiny in an expanded dataset is required to confirm these variants as real or spurious associations.

Yet another GWS association with rs17810546 in the *IL12A* locus was identified by meta-analyses of our results with those reported previously in the literature. These results support the role of this locus in the susceptibility of BD. Kirino et al., described this locus as suggestive for association with BD. In that study the variants did not reach GWS in the combined analysis likely due to the variant being monomorphic in the samples of Japanese origin included in the study. Variants in *CCR1-CCR3*, *STAT4* and *KLRC4* which were polymorphic in both Turkish and Japanese populations surpassed GWS thresholds, suggesting that the lower power likely contributed to the non-significant findings in the *IL12A* locus.

BD is a rare disease, even in countries with the highest prevalence. Collecting the patient material for large multi-ethnic genetic studies proved to be challenging. Not surprisingly, the first two GWAS studies reported in BD were in two separate cohorts with a single ethnicity, a Turkish and a Japanese cohort [10, 11]. After meta-analyses of the data of both studies, polymorphisms in *IL10* and *IL23R-IL12RB2* proved to be associated at GWS level. In our study, these two polymorphisms were not associated with BD, nor in two other recent studies in Chinese and Korean individuals [32, 33]. Moreover, the *GIMAP* variants presented in the Chinese and a Korean cohort were not identified in the other studies. Recently, Ortiz-Fernandez et al., reported no association of *GIMAP* variants in a Spanish study but also acknowledged lack of power as a likely cause for this negative results [16]. Considering that most of our cases are of admixed ethnicity differences in ethnic background, specific pathology or clinical features of the cases are a more plausible explanation for the lack of replication of those variants in our study on top of limited power [32, 33].

In conclusion we have shown that appropriate methodological approaches enable performing GWAS in cohorts of admixed ethnicity, combining cases of different ethnic origin as is often required in rare conditions like BD. As such, previously reported SNPs in the MICA-HLA-B locus reached GWS in the current approach. Additionally, we have shown that results of a mixed cohort can successfully be used in meta-analysis, by which we could establish the involvement of previously putative variant in the *IL12A* locus in the susceptibility of the disease.

Our results emphasize the need of collaborative efforts intending to enlarge the collection of BD cases, which can enable a well-powered setting for detection of genetic associations with the disease, especially when interrogating low-frequency variants.

Potentially novel loci need to be further explored in additional studies, and ultimately coupled with functional studies, allowing a better understanding of the pathophysiology and the genetic architecture underlying the risk for BD.

## **COMPETING FINANCIAL INTERESTS**

The authors declare no competing financial interests.

## **ACKNOWLEDGEMENTS**

No acknowledgements.

## **FUNDING**

Financial support by; Vereniging Trustfonds Erasmus Universiteit Rotterdam , De Landelijke Stichting voor Blinden en Slechtzienden, Stichting Janivo, Stichting Mitalto, dr N. Nobel and Actelion made this study possible.


## **DATA AVAILABILITY**

Due to restrictions based on privacy regulations and informed consent of participants, phenotype and genotype data cannot be made freely available in a public repository. Data of the Generation R Study can be obtained upon request. Requests should be directed towards Prof.dr. V. Jaddoe (v.jaddoe@erasmusmc.nl). As for the data collected exclusively for this effort, requests should be directed towards the corresponding author.


## REFERENCES

1. Sakane T, Takeno M, Suzuki N, Inaba G. Behcet's disease. *The New England journal of medicine*. 1999;341(17):1284-91.
2. Gul A. Behcet's disease: an update on the pathogenesis. *Clinical and experimental rheumatology*. 2001;19(5 Suppl 24):S6-12.
3. Yazici H, Fresko I, Yurdakul S. Behcet's syndrome: disease manifestations, management, and advances in treatment. *Nature clinical practice Rheumatology*. 2007;3(3):148-55.
4. Altenburg A, Mahr A, Maldini C, Kneifel CE, Krause L, *et al*. [Epidemiology and clinical aspects of Adamantiades-Behcet disease in Gemany. Current data]. *Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft*. 2012;109(6):531-41. Epub 2012/06/16. Epidemiologie und Klinik des Morbus Adamantiades-Behcet in Deutschland. Aktuelle Daten.
5. Gul A, Inanc M, Ocal L, Aral O, Konice M. Familial aggregation of Behcet's disease in Turkey. *Annals of the rheumatic diseases*. 2000;59(8):622-5.
6. Baranathan V, Stanford MR, Vaughan RW, Kondeatis E, Graham E, *et al*. The association of the PTPN22 620W polymorphism with Behcet's disease. *Annals of the rheumatic diseases*. 2007;66(11):1531-3.
7. Kappen JH, Wallace GR, Stolk L, Rivadeneira F, Uitterlinden AG, *et al*. Low prevalence of NOD2 SNPs in Behcet's disease suggests protective association in Caucasians. *Rheumatology (Oxford)*. 2009;48(11):1375-7.
8. Touma Z, Farra C, Hamdan A, Shamseddeen W, Uthman I, *et al*. TNF polymorphisms in patients with Behcet disease: a meta-analysis. *Archives of medical research*. 2010;41(2):142-6. Epub 2010/05/18.
9. Hu K, Yang P, Jiang Z, Hou S, Du L, Li F. STAT4 polymorphism in a Chinese Han population with Vogt-Koyanagi-Harada syndrome and Behcet's disease. *Human immunology*. 2010;71(7):723-6.
10. Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, *et al*. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet's disease. *Nature genetics*. 2010;42(8):698-702. Epub 2010/07/14.
11. Mizuki N, Meguro A, Ota M, Ohno S, Shiota T, *et al*. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet's disease susceptibility loci. *Nature genetics*. 2010;42(8):703-6. Epub 2010/07/14.
12. Xavier JM, Shahram F, Davatchi F, Rosa A, Crespo J, *et al*. Association study of IL10 and IL23R-IL12RB2 in Iranian patients with Behcet's disease. *Arthritis and rheumatism*. 2012;64(8):2761-72.
13. Khaib Dit Naib O, Aribi M, Idder A, Chiali A, Sairi H, Touitou I, *et al*. Association Analysis of IL10, TNF-alpha, and IL23R-IL12RB2 SNPs with Behcet's Disease Risk in Western Algeria. *Frontiers in immunology*. 2013;4:342. Epub 2013/10/24.
14. Kirino Y, Bertsias G, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, *et al*. Genome-wide association analysis identifies new susceptibility loci for Behcet's disease and epistasis between HLA-B\*51 and ERAP1. *Nature genetics*. 2013;45(2):202-7.
15. Lee YJ, Horie Y, Wallace GR, Choi YS, Park JA, *et al*. Genome-wide association study identifies GIMAP as a novel susceptibility locus for Behcet's disease. *Annals of the rheumatic diseases*. 2013;72(9):1510-6.
16. Ortiz-Fernandez L, Conde-Jaldon M, Garcia-Lozano JR, Montes-Cano MA, Ortego-Centeno N, *et al*. GIMAP and Behcet disease: no association in the European population. *Annals of the rheumatic diseases*. 2014.

17. McCarthy MI, Hirschhorn JN. Genome-wide association studies: potential next steps on a genetic journey. *Human molecular genetics*. 2008;17(R2):R156-65.
18. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, *et al*. Principal components analysis corrects for stratification in genome-wide association studies. *Nature genetics*. 2006;38(8):904-9.
19. Price AL, Zaitlen NA, Reich D, Patterson N. New approaches to population stratification in genome-wide association studies. *Nature reviews Genetics*. 2010;11(7):459-63.
21. Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. *Lancet*. 1990;335(8697):1078-80.
21. Jaddoe VW, van Duijn CM, Franco OH, van der Heijden AJ, van Iizendoorn MH *et al*. The Generation R Study: design and cohort update 2012. *European journal of epidemiology*. 2012;27(9):739-56.
22. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex trait analysis. *American journal of human genetics*. 2011;88(1):76-82.
23. Thornton T, Tang H, Hoffmann TJ, Ochs-Balcom HM, Caan BJ, *et al*. Estimating kinship in admixed populations. *American journal of human genetics*. 2012;91(1):122-38.
24. International HapMap C. The International HapMap Project. *Nature*. 2003;426(6968):789-96.
25. Kang HM, Sul JH, Service SK, Zaitlen NA, Kong SY, *et al*. Variance component model to account for sample structure in genome-wide association studies. *Nature genetics*. 2010;42(4):348-54.
26. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics*. 2010;26(17):2190-1.
27. A haplotype map of the human genome. *Nature*. 2005;437(7063):1299-320.
28. Zaitlen N, Kraft P, Patterson N, Pasaniuc B, Bhatia G, *et al*. Using extended genealogy to estimate components of heritability for 23 quantitative and dichotomous traits. *PLoS genetics*. 2013;9(5):e1003520.
29. Plomin R, Deary IJ. Genetics and intelligence differences: five special findings. *Molecular psychiatry*. 2014.
30. Coram MA, Duan Q, Hoffmann TJ, Thornton T, Knowles JW, *et al*. Genome-wide characterization of shared and distinct genetic components that influence blood lipid levels in ethnically diverse human populations. *American journal of human genetics*. 2013;92(6):904-16.
31. Morris AP. Transethnic meta-analysis of genomewide association studies. *Genetic epidemiology*. 2011;35(8):809-22.
32. Hou S, Yang Z, Du L, Jiang Z, Shu Q, *et al*. Identification of a susceptibility locus in STAT4 for Behcet's disease in Han Chinese in a genome-wide association study. *Arthritis and rheumatism*. 2012;64(12):4104-13.
33. Lee YJ, Horie Y, Wallace GR, Choi YS, Park JA, *et al*. Genome-wide association study identifies GIMAP as a novel susceptibility locus for Behcet's disease. *Annals of the rheumatic diseases*. 2013 Sep 1;72(9):1510-6



**Supplementary Figure 1. Behçet GWAS results using not adjustment for population stratification.** Each dot represents a SNP in the dataset. **a. QQ-plot.** Associated SNPs deviating from the null hypothesis of no association (identity line) evidence high inflation. **b. Manhattan plot.** SNPs though all chromosomes show association with the disease.



**Supplementary Figure 2 HLA Regional Association Plot. GWAS results for Behçet susceptibility using Linear Mixed Models approach.** Top SNP rs2848713 EMMAX approach (MAF=0.10, A-risk allele) is denoted by a diamond. Marker rs7770216 is the top SNP for the Genomic Principal Components adjustment approach (MAF=0.25, T-risk allele). Marker rs4495304 is the top SNP in the association reported by Mizuki et al. (MAF=0.09, A-risk allele) for the GWAS of Behçet susceptibility without an. . Bottom, LD heat map based on  $D'$  values from the combined population under study including all SNPs in the 500Kb region.





# Whole genome sequence in Behçet disease patients

Kappen JH, van Hagen PM, Swagemakers SMA, van der Spek PJ, van Laar JAM

*Unpublished data*



## INTRODUCTION

Behçet's disease (BD) a systemic auto-inflammatory occlusive vasculitis, is characterized by oral and genital aphthous ulcers, skin lesions, ocular inflammation and the pathognomonic pathergy test(1-3). The etiology of the disease is largely unraveled. It is, considered to be an excessive inflammatory response triggered by an (infectious) antigen in a genetically susceptible host. Prevalences vary from 70–420 per 100 000 in the Middle East (Turkey) to about 1-7 per 100 000 in Western countries. In patients of Turkish origin there is positive family history in 12% of the cases with a sibling risk ratio between 11–52 [3, 4]. The heritability of BD has been estimated to range between 20 to 60%. The strongest genetic association is with HLA-B51, it explains about 20% of the disease heritability [3, 4]. The combination of epidemiological and genetic data suggest causal involvement of both genetic and environmental factors(5).

Over the years numerous single nucleotide polymorphisms (SNP) have been found associated with BD(6-9). In 2010 the first genome-wide association study (GWAS) in BD cohorts of Turkish and Japanese origin demonstrated a range of variants in the HLA-B51 domain, but also two new association signals, the interleukin-10 (*IL10*), and the IL-23 receptor–IL-12 receptor Beta2 (*IL23R–IL12RB2*) locus(10, 11). These associations have been confirmed in an Iranian cohort(12). Another study in Algerian individuals only replicated the associations from the IL10 variants(13). GWAS in Chinese and Korean individuals reported associations of SNPs mapping to two other loci, with regions containing the transduction and activator of transcription-4 (*STAT4*) and GTPase of immune associated protein GIMAP genes, respectively. Polymorphisms in *IL10* and *IL23R–IL12RB2* were not found significantly associated in either of those studies(14,15). Most recently associations with *CCR1*, *STAT4* and *KLRC4* were identified by imputation analysis [14]. Kirino et al in this study identified the *IL12a* region as an area of interest but genome wide significance was not reached.

In GWAS a limited number of polymorphisms is examined, from 200.000 up to 600.000 in BD studies. The number can be increased by imputation studies. However the largest part of the genome is neglected. Whole genome sequencing now enables to look at the complete genomic code. Performing such study in a family with multiple individuals afflicted by the disease simplifies the data analyses in order to identify genetic variants so far unknown.


We therefore performed a whole genome sequence study in five family members with 3 BD patients and 2 healthy individuals.

## MATERIALS AND METHODS

### Study population

Five family members were included in our study (figure 1). The father and two sons were BD patients, one son and one daughter are healthy individuals.

All patients fulfilled the International Study Group (ISG) criteria of BD diagnoses(15). No exclusion criteria were applied. All subjects gave their written informed consent.



**Figure 1.** Family with three BD patients (black boxes) and 2 healthy individuals (white boxes)

### Whole genome sequencing

Sequencing-by-ligation method from Complete Genomics (software version 2.5.0.33, format version 2.5) as described by Drmanac et al. (2010) was used. The human genome sequencing procedures include DNA library construction, DNA Nano-Ball (DNB) generation, DNB array self-assembling, cPAL-based sequencing, imaging, image data analyses including base calling, DNB mapping, and sequence assembly. Reads were mapped to the National Center for Biotechnology Information (NCBI) reference genome, build 37. Variants were annotated using NCBI build 37 and dbSNP build 137. Data were provided as lists of sequence variants (SNPs and short indels) relative to the reference genome. Analysis of the whole genome sequencing data was performed using Complete Genomics analysis tools (cga tools version 1.8.0; <http://www.completegenomics.com/sequence-data/cgatools/>) and TIBCO Spotfire version 6.0.0 (build version 6.0.0.40) (<http://spotfire.tibco.com/>).

### Data analyses

Data were analyzed using a python (2.7) script for multiple genome analysis, cga tools version 1.8.0 and Spotfire

6.0.0.40 (Tibco). Sequenced exome fraction (where  $\text{weightSumSequenceCoverage} \geq 40x$ ) were 0.985 (Imm4) and 0.986 (Imm5).

## RESULTS

DNA isolation failed in three cases, therefore genome sequencing was performed on DNA of the affected father and of a non-affected son.

IBS (identity by sequence) analysis showed that both samples share one allele over 99% of the genome, confirming the father and son relation.

In total 5,817,040 variants were detected in one or both family members, including single nucleotide variants (4,4681,960 and small insertions (713,715), deletions (429,173) and substitutions (205,956) (up to about 50 bp).

Of these, 410,868 variants were not present at all in any of the control samples (597 welllderly samples, healthy individuals of over 85 years).

Regarding the inheritance pattern, we searched for dominant variants in the father that were not present in the non-affected son and in the healthy controls. (Genotypes: Imm4:00|0; Imm5:01|11|1 and allowing 2 No-calls)

165,768 variants were found, of which 75,162 variants were found in genes. 821 of these variants were protein affecting variants (PAV) in 732 different genes. 346 protein affecting variants (in 322 genes) had a high (H) varScore. The top 40 list is presented in table 1.

**Table 1.** Top 40 list of protein affecting variants identified by whole genome sequencing.

Chromosome	Gene Variant	Chromosome	Gene Variant
chr10	DMBT1	chr9	ALDH1B1
chr1	RPTN	chr5	TTC37
chr18	DLGAP1-AS3	chr12	KCNH3
chr1	C8A	chr15	DIS3L
chr3	PFKFB4	chr11	LOC338667
chr13	FREM2	chr12	C12orf42
chr6	RNF146	chr17	FN3KRP
chr21	DNMT3L	chr5	CARD6
chr1	ITGA10	chr2	NABP1
chr22	ISX	chr22	PRR14L
chr6	PGC	chr22	CLTCL1
chr9	KIAA0020	chr3	AMIGO3
chr10	NSMCE4A	chr19	ZNF160
chr12	GLI1	chr5	PCDHGA10
chr1	MTMR11	chr1	VWA5B1
chr12	WSCD2	chr17	KIF19
chr5	CARD6	chr15	FMN1
chr19	ILVBL	chr1	SLAMF9
chr12	PLBD1	chr10	LCOR
chr2	HIBCH	chr13	NEK5

These 346 PAV could be subdivided in: 269 missense; 37 frameshift; 18 insert; 13 deletion; 6 nonsense; 2 disrupt and 1 nonsense variants.

## DISCUSSION

Over the years genetic associations have been identified by a candidate gene approach as well as GWAS approach. numerous single nucleotide polymorphisms (SNP) have been found associated with BD(6-13)(14,15). In order to identify new genetic variants we performed a whole genome sequence study in a family of BD patients. An exome sequence study in a different family identified *TNFRSF9*, *MGEA5* and *TNFAIP3* genes is possible candidates(16).

Due to a low yield in DNA we only analyzed the data of the father (case) and son (healthy). This led to a total of 346 PAV, a number too high for further analyzations. It identified interesting candidate variants that could be involved in BD, however it is not possible to focus on such number of genes. Variants identified earlier are not found in in our dataset. Therefore new patient material is collected en sequence analyses will be re-done using all five family members of this unique family with such high incidence of BD.

## REFERENCES

1. Sakane T, Takeno M, Suzuki N, Inaba G. Behcet's disease. *The New England journal of medicine*. 1999;341(17):1284-91. Epub 1999/10/21.
2. Gul A. Behcet's disease: an update on the pathogenesis. *Clinical and experimental rheumatology*. 2001;19(5 Suppl 24):S6-12. Epub 2002/01/05.
3. Yazici H, Fresko I, Yurdakul S. Behcet's syndrome: disease manifestations, management, and advances in treatment. *Nature clinical practice Rheumatology*. 2007;3(3):148-55. Epub 2007/03/06.
4. Altenburg A, Mahr A, Maldini C, Kneifel CE, Krause L, Kotter I, et al. [Epidemiology and clinical aspects of Adamantiades-Behcet disease in Gemany. Current data]. *Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft*. 2012;109(6):531-41. Epub 2012/06/16. *Epidemiologie und Klinik des Morbus Adamantiades-Behcet in Deutschland. Aktuelle Daten*.
5. Gul A, Inanc M, Ocal L, Aral O, Konice M. Familial aggregation of Behcet's disease in Turkey. *Annals of the rheumatic diseases*. 2000;59(8):622-5. Epub 2000/07/27.
6. Baranathan V, Stanford MR, Vaughan RW, Kondeatis E, Graham E, Fortune F, et al. The association of the PTPN22 620W polymorphism with Behcet's disease. *Annals of the rheumatic diseases*. 2007;66(11):1531-3. Epub 2007/07/31.
7. Kappen JH, Wallace GR, Stolk L, Rivadeneira F, Uitterlinden AG, van Daele PL, et al. Low prevalence of NOD2 SNPs in Behcet's disease suggests protective association in Caucasians. *Rheumatology (Oxford)*. 2009;48(11):1375-7. Epub 2009/09/15.
8. Touma Z, Farra C, Hamdan A, Shamseddeen W, Uthman I, Hourani H, et al. TNF polymorphisms in patients with Behcet disease: a meta-analysis. *Archives of medical research*. 2010;41(2):142-6. Epub 2010/05/18.
9. Hu K, Yang P, Jiang Z, Hou S, Du L, Li F. STAT4 polymorphism in a Chinese Han population with Vogt-Koyanagi-Harada syndrome and Behcet's disease. *Human immunology*. 2010;71(7):723-6. Epub 2010/05/05.
10. Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet's disease. *Nature genetics*. 2010;42(8):698-702. Epub 2010/07/14.
11. Mizuki N, Meguro A, Ota M, Ohno S, Shiota T, Kawagoe T, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet's disease susceptibility loci. *Nature genetics*. 2010;42(8):703-6. Epub 2010/07/14.
12. Xavier JM, Shahram F, Davatchi F, Rosa A, Crespo J, Abdollahi BS, et al. Association study of IL10 and IL23R-IL12RB2 in Iranian patients with Behcet's disease. *Arthritis and rheumatism*. 2012;64(8):2761-72. Epub 2012/03/02.
13. Khaib Dit Naib O, Aribi M, Idder A, Chiali A, Sairi H, Touitou I, et al. Association Analysis of IL10, TNF-alpha, and IL23R-IL12RB2 SNPs with Behcet's Disease Risk in Western Algeria. *Frontiers in immunology*. 2013;4:342. Epub 2013/10/24.
14. Kirino Y, Bertsias G, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E, et al. Genome-wide association analysis identifies new susceptibility loci for Behcet's disease and epistasis between HLA-B\*51 and ERAP1. *Nature genetics*. 2013;45(2):202-7. Epub 2013/01/08.
15. Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. *Lancet*. 1990;335(8697):1078-80. Epub 1990/05/05.
16. Zhou O, LR, Pelletier M., Ramaswamy M., Wang H-Y., Chin D., Gul A., Sibley C., Barat-Houari M., Siegel R., Kastner D.L., Aksentijevich I. xone sequencing in monogenetic Behcet-like disease. 2013.





# 4

## Cytokines in Beçhet's disease





# Cytokine profiles in tissue

*Based on*

**Do synovial biopsies help to support evidence for involvement of the innate immunity in the immunopathology of Behçet's disease?**

Jan A.M. van Laar, Jasper H. Kappen, Paul.L.A. van Daele, P. Martin van Hagen  
*Arthritis Res Ther.* 2009;11(2):109.

**Cytokines in the colon of a patient with Behçet's disease.**

Jasper H Kappen, Willem A Dik, Gemma M Dingjan, Paul LA van Daele, Herbert Hooijkaas, P Martin van Hagen, Jan AM van Laar  
*Arthritis Res Ther.* 2009;11(4):412.



The etiology of BD is obscure, but considered a complex systemic vasculitis, caused by Th1-cytokine skewed neutrophilic and lymphohistiocytic inflammation. The innate immune response is held responsible for the inflammatory symptoms occurring in patients with BD. Activation of BD can be triggered by exogenous factors such as skin damage, introduction of bacterial components, viruses or stress resulting in inflammation[1-3].

The association of HLA-B51 with BD and hyperactive neutrophils adds to assumption that BD is an "innate disease"[4]. Other factors supporting this assumption include; prevalence of symptoms at places in close contact with the outside environment (skin, mucosa, gut), hypersensitive T-cells, TLR expression in affected cells, hyperactive neutrophilic and CD8+T-cell responses to heat shock proteins or bacterial cell wall fragments[1, 3]. A normal inflammatory innate response is rapid, non-specific and self-limiting. It contains a carefully balanced reaction between activated inflammatory cells and an exogenous trigger. In inflammatory disorders such as BD this response is disbalanced and causes excessive tissue damage.

Cytokines involved in BD are in great part pro-inflammatory (IL-1 $\beta$ , IL-8, IL-10, TNF- $\alpha$  and IFN- $\gamma$ ) and also associated with innate immunological patterns. Peripheral T-cells in BD patients express a predominant Th1-type cytokine pattern[5]. The rarity of BD and the lack of adequate *in vitro* or animal study models challenge to investigate immunopathological innate inflammatory patterns on the cytokine level *in vivo*. Therefore a model of easily reachable inflammatory material in BD patients with active disease is sparse.

Canete et al. describe a model of studying the immunopathology of BD by analyzing inflammatory cells, tissue and cytokines of inflamed joints from BD patients [6].

How does the study of Canete et al. add to biomechanistic studies already done in BD? First, in contrast to most of these studies analysis are performed in untreated patients. In an uncommon disease as BD, few studies in naïve patients are published. In RA for example, early and aggressive treatment is considered mandatory for optimal therapeutic outcome. It will therefore be of great therapeutic importance to appreciate possible initiating factors in BD too by testing therapy-naïve patients. This is especially important for irreversible ophthalmic disease. Second, it is of importance that representative tissue is studied. In BD most mechanistic studies are published on blood samples, and predominantly circulating cytokines or *in vitro* testing of PBMC's is done. Th1 cytokines are involved, hyperactive neutrophils and hyper reactive T-cells are held responsible for the symptoms observed[7].

But BD is an inflammatory disorder with involving tissues such as skin, joints, eyes, gut, brain, oral and genital mucosa[1, 3]. It is therefore mandatory to know that observa-

tions in the blood are comparable with bio-mechanisms on the tissue level. Mucosal tissue is predominantly involved in BD and microorganisms from the outside can easily influence observations on inflammatory cells. On the other hand, those microorganisms are also capable of stimulating an immune response in BD. Most tissue studies on the pathophysiology of BD are performed on the skin. One of the unique and disease specific features of BD is the occurrence of a positive skin pathergy reaction (SPR) varying from 30–75% of all BD patients[1, 3]. Neutrophils and later lymphohistiocytic cells occur in sterile lesions induced by a sterile needle prick[8]. Representing endothelial injury and functioning as leukocyte trafficking factors, cell adhesion molecules (ICAM-1, VCAM-1) and endothelial growth factor markers such as E-selectin, P-selectin and endoglin are linked with SPR[9]. Infiltrating cells are mainly of the HLADR+/ CD3+/CD4+/CD45RO+ type[10]. Other observations include mature dendritic cells, monocytes, (regulatory) T-cells, elevated IFN- $\gamma$ , IL-12-p40 and IL-15, MIP3- $\alpha$ , IP-10, Mig, and iTac, and adhesion molecules[11]. Studies of ocular BD show elevated Vgamma9Vdelta2 (CD4-/CD8-) and CD8brightCD56+ T-cells that are probably different than those found infiltrating the SPR[12]. Cytokines found elevated in ocular fluid of BD patients with active uveitis are IFN-gamma, TNF- $\alpha$ , IL-15[13]. It must be stressed however that aqueous humour is seldomly studied, difficult approachable and is only studied in intensively and long treated BD patients [14].


In contrast to most of the inflamed organs in BD, the joint is a sterile and often involved in BD patients [1, 3]. Canete et al. use this easily accessible model that has not been studied too often in BD. Previous, more than 30 year old, studies on BD arthropathy predominantly show neutrophilic infiltration depending on the stage and treatment of the disease. A more recent study in synovial fluid (SF) of BD patients show increased chemokines (CXCL-9 and CXCL-10) related with Th1-directed inflammation[15]). The group of Canete has studied SF extensively in various other arthropathies such as SpA, RA and comparisons might be made with historical data. SF of RA, juvenile SpA, juvenile polyarthritis, and juvenile oligoarthritis compared with SpA showed merely similar CD3, 4 and 8 positive cells in all groups[16]. In the study presented it is concluded that PsA clinically resembles BD and probably also because in SF of PsA patients neutrophils are present. By showing increased intraarticular CD15+ neutrophils, CD3+ T-cells, and perforin in SF of active BD patients as compared to PsA it can be emphasized that also in early BD the innate immunity is involved and interacts with the adaptive immunity reflected by perforin presumably secreted by CD3+Tcells. It might therefore be of interest to further study on these naïve T-cells and cytokines in sterile SF in order to relate these observations with immunological patterns already described in a-sterile tissues that are exposed to exogenous factors, or more intensively treated BD patients. These results can then be compared with various other inflammatory diseases in order to ob-

tain more insight in the immuno-etiology of BD and to develop more specific, molecular based immuno-therapy. Examples may include targeting cytokines (IL-1, IL-10, or IL6) and lymphocyte action interfering agents.

Cañete *et al* described cytokine patterns of inflamed joints from BD patients (BD)[6], we add to this an observation showing a similar cytokine profile in the colon of a BD patient with active disease, despite TNF-blocking treatment.

A 37-year old BD patient with severe colitis failed to traditional immunosuppressive treatment. Steroids were contraindicated because of a previous retinal serosal ablation, probably induced by prednisone. TNF-blockage initially successfully reduced the severity of the colitis, but relapses occurred. Variation of different TNF-blockers (etanercept, infliximab and adalimumab) could not permanently resolve the intestinal complaints. Antibodies against infliximab or adalimumab were not detected. Eventually, high dose infliximab (10mg/kg) and intravenous immunoglobulins (IVIG's) led to disease regression facilitating a hemi-colectomy. Hereafter the patient's condition improved significantly and IVIG's were terminated whilst continuing TNF-blockage.

Cytokines were evaluated in the resected colon by analyzing mRNA expression levels of cytokine genes as previously described[17]. Because of the extensive prior treatment apparently healthy colon tissue of the patient served as internal control. Intestinal inflammation was patchy and the observed difference between healthy and diseased tissue was confirmed microscopically. The mRNA expression of cytokines in diseased colon is presented relative to those of healthy colon and can be seen as a reflection of intramural cytokines (Figure 1). Comparable to Cañete *et al*, we observed a Th1 and Th17-skewed pattern (elevated IFN- $\gamma$  and TNF- $\alpha$ , and IL-17A, respectively). We could not demonstrate elevation of IL-10, possibly because our patient was intensively treated, and colon environment is not sterile.



**Figure 1.** mRNA expression of cytokine genes in diseased relative healthy tissue.

Hence, understanding how cells and cytokines are functioning in inflamed tissues can be of great importance for therapeutic interventions[1]. In this light, one of the century's most eye-seeing examples is that by blocking TNF- $\alpha$ , a key cytokine in BD, disease symptoms can be effectively and rapidly blocked too[2]. Most new treatment modalities will focus on blocking cytokines in specific pathways that play a key role in immunopathophysiology of BD.

BD's immunopathology remains fascinating and highly relevant for the development of future, immune directed, therapy. Since the successful introduction of TNF-blockers it became apparent that Th1-cytokines might be key players in the immunopathology of BD, emphasizing the importance of cytokine studies[2, 3]. Our data add to Cañete *et al* that also in colonic tissue of a BD patient, IFN-gamma, TNF-alpha and IL-17A appear key cytokines, even in a treated patient. Maybe tissue cytokines reflect disease activity better than serum cytokine profiles.



## REFERENCES

1. Sakane T, Takeno M, Suzuki N, Inaba G: Behçet's disease. *N Engl J Med*. 1999, 341:1284-91.
2. van Laar JA, Missotten T, van Daele PL, Jamnitski A, Baarsma GS, van Hagen PM: Adalimumab: a new modality for Behçet's disease? *Ann Rheum Dis*. 2007, 66:565-6. Epub 2006 Nov 23.
3. Yazici H, Fresko I, Yurdakul S: Behçet's syndrome: disease manifestations, management, and advances in treatment. *Nat Clin Pract Rheumatol*. 2007, 3:148-55.
4. Takeno M, Kariyone A, Yamashita N, Takiguchi M, Mizushima Y, Kaneoka H, Sakane T: Excessive function of peripheral blood neutrophils from patients with Behçet's disease and from HLA-B51 transgenic mice. *Arthritis Rheum*. 1995, 38:426-33.
5. Suzuki N, Nara K, Suzuki T: Skewed Th1 responses caused by excessive expression of Txx, a member of the Tec family of tyrosine kinases, in patients with Behçet's disease. *Clin Med Res*. 2006, 4: 147-51.
6. Cañete JD, Celis R, Noordenbos T, Moll C, Gómez-Puerta JA, Pizcueta P, Palacin A, Tak PP, Sanmartí R, Baeten D: Distinct synovial immunopathology in Behçet disease and psoriatic arthritis. *Arthritis Res Ther*. 2009, 11:R17. [Epub ahead of print]
7. Accardo-Palumbo A, Triolo G, Carbone MC, Ferrante A, Ciccia F, Giardina E, Triolo G: Polymorphonuclear leukocyte myeloperoxidase levels in patients with Behçet's disease. *Clin Exp Rheumatol*. 2000, 18:495-8.
8. Ergun T, Gürbüz O, Harvell J, Jorizzo J, White W: The histopathology of pathergy: a chronologic study of skin hyperreactivity in Behçet's disease. *Int J Dermatol*. 1998, 37:929-33.
9. Inaloz HS, Evereklioglu C, Unal B, Kirtak N, Eralp A, Inaloz SS: The significance of immunohistochemistry in the skin pathergy reaction of patients with Behçet's syndrome. *J Eur Acad Dermatol Venereol*. 2004, 18:56-61.
10. Gül A, Esin S, Dilsen N, Koniçe M, Wigzell H, Biberfeld P: Immunohistology of skin pathergy reaction in Behçet's disease. *Br J Dermatol*. 1995, 132:901-7.
11. Melikoglu M, Uysal S, Krueger JG, Kaplan G, Gogus F, Yazici H, Oliver S: Characterization of the divergent wound-healing responses occurring in the pathergy reaction and normal healthy volunteers. *J Immunol*. 2006, 177:6415-21.
12. Verjans GM, van Hagen PM, van der Kooi A, Osterhaus AD, Baarsma GS: Vgamma9Vdelta2 T cells recovered from eyes of patients with Behçet's disease recognize non-peptide prenyl pyrophosphate antigens. *J Neuroimmunol*. 2002, 130:46-54.
13. Ahn JK, Yu HG, Chung H, Park YG: Intraocular cytokine environment in active Behçet uveitis. *Am J Ophthalmol*. 2006, 142:429-34.
14. Vernon-Roberts B, Barnes CG, Revell A: Synovial pathology in Behçet's syndrome. *Ann Rheum Dis*. 1978;37:139-145.
15. Erdem H, Pay S, Musabak U, Simsek I, Dinc A, Pekel A, Sengul A: Synovial angiostatic non-ELR CXC chemokines in inflammatory arthritides: does CXCL4 designate chronicity of synovitis? *Rheumatol Int*. 2007, 27:969-73. Epub 2007 Jan 31.
16. Kruithof E, Van den Bossche V, De Rycke L, Vandooren B, Joos R, Cañete JD, Tak PP, Boots AM, Veys EM, Baeten D: Distinct synovial immunopathologic characteristics of juvenile-onset spondylarthritis and other forms of juvenile idiopathic arthritis. *Arthritis Rheum*. 2006, 54:2594-604.
17. Dik WA, Nadel B, Przybylski GK, Asnafi V, Grabarczyk P, Navarro JM, Verhaaf B, Schmidt CA, Macintyre EA, van Dongen JJ, Langerak AW: Different chromosomal breakpoints impact the level of LMO2 expression in T-ALL. *Blood*. 2007;110:388-92. Epub 2007 Mar 14.



# Detection of intestinal Behçet's disease by double balloon enteroscopy combined to serum cytokine profiles; improved diagnostic yield?

J.H. Kappen, P.B.F. Mensink, W.A. Dik, H. Hooijkaas, S. Lachman, P.L.A. van Daele, P.M. van Hagen, J.A.M. van Laar

*Submitted*

**ABSTRACT**

*Background:* Gastrointestinal symptoms are often present in patients with Behçet's disease (BD), but detection of gastrointestinal inflammation remains challenging. Double balloon enteroscopy (DBE) enhances the yield of gastrointestinal investigations by combining visualization of the entire small bowel (SB) with tissue sampling, but has not been introduced in BD patients so far. In addition, inflammatory parameters can improve the decision-making strategy to intensify diagnostic approach. We evaluated the value of DBE and serum cytokines in BD patients with abdominal complaints.

*Methods:* 10 BD patients with recurrent abdominal complaints were evaluated with DBE, serum cytokine profiles and lymphocyte subsets.

*Results:* DBE demonstrated SB inflammation in four (40%) patients, leading to treatment intensification in two. No complications occurred during the DBE procedures. Interferon- $\gamma$  (IFN- $\gamma$ ) levels correlated with SB inflammation.

*Conclusions:* DBE is a valuable and safe tool to evaluate involvement of the entire gastrointestinal tract in BD patients and might lead to a change in therapy. The clinical relevance of the observed elevated IFN- $\gamma$  levels warrants further evaluation in the decision-making strategy in BD patients with abdominal complaints.

## INTRODUCTION

Behçet's disease (BD) is an idiopathic systemic vasculitis in which pathological involvement of Th1 and Th17 cytokines is suggested [1, 2]. It is characterized by oral and genital aphthous ulcers, skin lesions and ocular inflammation. Aphthous ulcers, erosions or ulcers also occur in the lower gastrointestinal tract, most frequently the terminal ileum and right-sided colon [3-6]. Mucosal lesions in other parts of the small bowel (SB) however, are seldomly shown. BD patients often present various gastrointestinal symptoms, but proof of intestinal inflammation remains disappointingly low, 3 – 25% depending on geography [5-9]. A reliable algorithm to decide for improvement to detect intestinal BD in symptomatic patients, for example expanded with inflammatory parameters or cytokine patterns, does not exist. Amongst patients and BD treating physicians there is substantial need to find a cause for the often aspecific abdominal complaints.

Visualization of the small bowel using regular endoscopic techniques is limited to the terminal ileum. No data is available on CT or MRI enterography in BD. This might cause underestimation of gastrointestinal involvement in BD. Double balloon enteroscopy (DBE) is a relatively new technique, but has not been applied in BD patients so far [10,11]. By combining endoscopic visualization to tissue sampling, DBE can be considered to be the gold standard for SB evaluation [12-14]. It therefore can enhance the diagnostic evaluation of abdominal complaints from BD patients.

The prognosis and clinical outcome of intestinal BD is comparable with Crohn's disease (CD) [15]. BD patients with gastrointestinal involvement may require relatively aggressive treatment compared to patients without intestinal disease [8]. This includes combined systemic anti-inflammatory or immunosuppressive therapy [4,8,16,17]. The introduction of biological agents such as anti-tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) and IFN- $\alpha$  improves the therapeutic arsenal in (intestinal) BD [3-5,18-21].

The aim of this study is to evaluate the yield of extending diagnostic procedures by DBE and serum cytokines profiles in BD patients with abdominal complaints, in order to develop a clinically applicable algorithm for those patients.

## MATERIALS AND METHODS

### Study design

In this case series, 10 patients with known BD and recurrent abdominal complaints such as diarrhea or abdominal pain, were selected and evaluated by serum inflammatory parameters and DBE. Before this, upper endoscopy and ileocolonoscopy was indicated, but had not revealed the cause of the complaints in all but one patient. Additional SB visualization was judged of pivotal diagnostic and therapeutic importance. All patients

met the criteria for BD according to the “International Study Group for Behçet's Disease” [22].

### **DBE procedure**

All patients had bowel preparation using 4 Liters of a polyethylene glycol solution. On an outpatient basis patients underwent the DBE using conscious sedation, consisting of intravenous administration of midazolam and fentanyl, or in selected cases general anesthesia with propofol sedation. The enteroscopes used were the Fujinon EN-450P5 or EN-450T5 (Fujinon Inc., Saitama, Japan). In all patients visualization of the entire SB was attempted: starting with a transoral approach combined with a transanal procedure if the distal ileum was not reached by the transoral route. Biopsies were made according to the decision of the performing physician.

### **Definition of small bowel BD lesions**

The small bowel segments proximal to the Treitz ligament and the distal 50 cm of the (neo-) terminal ileum were defined as within reach of conventional endoscopy. The small bowel ‘in between’ was divided into four segments: 1) proximal jejunum: from Treitz ligament to 150 cm distally, 2) distal jejunum: 150 – 300 cm from Treitz, 3) proximal ileum: 300 – 450 cm from Treitz, and 4) distal ileum: up to 150 cm proximal from the (neo-) terminal ileum. In the absence of a validated enteroscopic small bowel BD severity scale exists currently we introduced a subjective scale. Small bowel lesions were defined as 0) absent, 1) minor: erythematous and/or edematous mucosa and/or small ulcerative lesions < 0.5 mm within normal mucosa, 2) moderate: larger ulcerative lesions  $\geq$  0.5 mm and < 20 mm, or 3) severe: ulcerative lesions  $\geq$  20 mm and/or not significant stenotic lesions, 4) stenotic: significant stenotic lesions, with or without inflammation.

### **Cytokine measurement**

The cytokines interleukin (IL)-1 $\beta$ , IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, TNF- $\alpha$ , and IFN- $\gamma$  were measured in serum using commercially available cytometric bead arrays (CBA Human Inflammation Kit, BD Biosciences™ (New Jersey, USA) and CBA Human Th1/Th2 Cytokine Kit, BD Biosciences™) according to the manufacturers protocol. Measurements were performed on a FACS Calibur (BD Biosciences™) and analysis of the data was performed using FCAP Array™ Software (BD Biosciences™). The assay sensitivity was 5 pg/mL for all cytokines. Chi-square tests were used to analyse significant ( $P < 0.05$ ) detectable cytokine levels.

## RESULTS

In total 10 patients were included in the present study. For patient 4 with known active BD in the terminal ileum and colon, DBE was considered of a step-up towards intensifying immunosuppressive -or initiating surgical therapy. Patient characteristics, including therapy and organ involvement, are presented in table 1A. Patients on COX-2 antagonists also had proton pump inhibitors to prevent potential gastroduodenal toxicity.

### DBE results

A combined DBE procedure, transoral and –anal was performed in all patients. Complete SB visualization was achieved in eight (80%) patients. Of the remaining patients we visualized half of the SB. SB lesions were identified in four (40 %) patients: one showed grade 1 and three patients had grade 2 lesions, compatible with BD activity (Table 1b). The SB lesions were located in the distal ileum in three, and distal jejunum and terminal ileum in one patient. In patient number 4, also grade 3 lesions were found in the proximal colon. SB lesions were out of reach for conventional upper endoscopy or ileocolonoscopy in all patients. No complications occurred during or after the DBE procedure. No correlation was found between the presence and severity of the SB lesions and the severity of the abdominal complaints.

### Laboratory results

In two (50%) of the patients with SB lesions serum CRP was elevated (patient 3: 29 mg/l, patient 4: 24 mg/l). Only one (17%) patient without SB lesions presented with elevated CRP (18 mg/l) (table 2). Serum IFN- $\gamma$ , IL-6 and IL-10 were significantly ( $p < 0.01$ ) higher in patients with SB lesions than those without. In general, total numbers of different lymphocyte subsets (shown at the bottom of table 2) were within the normal range.

### Follow-up

The severity of SB lesions in patient 2 impelled intensification of treatment by use of local steroids (budesonide) eventually relieving abdominal complaints. The grade 3 lesions in the distal colon of patient 4 prompted the need for an extensive right-sided colectomie after intravenous immunoglobulines and high doses of infliximab. Abdominal complaints of patient 1 and patient 3 were relieved without intensification of immunosuppressive treatment.

**Table 1;** Baseline characteristics and results of DBE in BD patients (n=10) with therapy refractory abdominal complaints.

A) Patient data	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7	Patient 8	Patient 9	Patient 10
Sex	M	F	M	M	F	M	M	M	M	M
Abdominal pain (# weeks/month)	1	4	1	3	2	2	1	1	2	1
Diarrhoea (# weeks/month)	0	2	1	3	1	2	0	1	2	0
Other symptoms	Oral ulcers, pustules	Oral ulcers, pustules, arthralgia	Oral ulcers	Oral ulcers	Oral ulcers, pustules, arthralgia, eye activity	Arthralgia	Oral ulcers, genital ulcers, arthralgia	Oral ulcers, genital ulcers, pustules, arthralgia	Oral ulcers, genital ulcers, Cyclosporine	Arthralgia
Medication	Infliximab	Etoricoxib, Colchicine, Hydroxychloroquine	Mycofenolic acid, Azathioprine, Prednisolon	Infliximab, Cyclosporine	Prednisolon, Methotrexate, Adalimumab	None	Celecoxib, Cyclosporine	Cyclosporine, Sulfasalazine	Celecoxib, Cyclosporine, Colchicine	Prednisolon, Azathioprine
<b>B) DBE Results</b>	50%	Complete	Complete	Complete	Complete	Complete	50%	Complete	Complete	Complete
SB visualization	50%	Complete	Complete	Complete	Complete	Complete	50%	Complete	Complete	Complete
Inflammation Grade	Grade 2; Moderate	Grade 2; two aphthous lesions distal ileum	Grade 2; Moderate activity distal ileum, coecum and colon ascens dens	Grade 1; Superficial inflammation distal jejunum and terminal ileum. Grade 3; Multiple severe ulcers in distal colon	None	None	None	None	None	None
1 - 3 †	active small ulcerations distal ileum	lesions distal ileum	coecum and colon ascens dens	severe ulcers in distal colon						

† The grading of inflammatory lesions ranges from minor to severe (grade 1-3).  
 Abbreviations: DBE = double balloon enteroscopy BD = Behçet's Disease; M = male; F = female; BDCAF = BD Current Activity Form; SB = small bowel



**Table 2;** Inflammatory parameters in BD patients (n=10) with therapy refractory abdominal complaints evaluated by DBE.

Lab results	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7	Patient 8	Patient 9	Patient 10
CRP (<10 mg/l)*	1	6	29	24	<1	3	6	17	1	3
<b>Cytokine [pg/ml]</b>										
IFN-γ (<10)	22	14	5	30	<5	<5	<5	<5	18	<5
TNF-α (<10)	<5	32	<5	<5	<5	<5	<5	<5	<5	<5
IL-10 (<10)	6	10	<5	5	<5	<5	<5	<5	<5	<5
IL-5 (<10)	<5	<5	<5	1	<5	<5	<5	<5	<5	<5
IL-4 (<10)	5	<5	<5	<5	<5	<5	<5	<5	<5	<5
IL-2 (<10)	7	<5	<5	<5	<5	<5	<5	<5	<5	<5
IL-12 p70 (<10)	<5	5	<5	<5	<5	<5	<5	<5	<5	<5
IL-6 (<10)	7	<5	5	9	<5	<5	<5	<5	<5	<5
IL-1β (<10)	<5	33	<5	3	<5	<5	<5	<5	<5	<5
<b>Celltype [10e9/L]</b>										
Lymphocytes (1.1-2.5)	2,14	1,77	1,05	1,93	3,96	1,18	1,22	2,5	1,22	1,48
B-cells (0.1-0.4)	0,22	0,18	0,11	0,04	0,44	0,16	0,14	0,32	0,12	0,07
T-cells (0.7-1.9)	1,55	1,4	0,91	1,69	3,07	0,96	0,92	1,86	1,05	1,22
CD4+ (0.4-1.3)	0,85	0,84	0,57	0,5	1,69	0,57	0,37	0,85	0,44	0,88
CD8+ (0.2-0.7)	0,63	0,66	0,31	0,97	1,43	0,36	0,46	0,88	0,47	0,35
HLA-DR+ (<0.2)	0,03	0,06	0,08	0,49	0,24	0,03	0,02	0,07	0,07	0,05
NK-cells (0.1-0.5)	0,37	0,19	0,03	0,18	0,45	0,06	0,16	0,32	0,05	0,19

## DISCUSSION

To our knowledge, this is the first case-series of BD patients evaluated by DBE. Although symptomatic, BD patients seldomly present with elevated inflammatory markers such as BSE or CRP. Therefore, the cytokine patterns of BD patients with SB lesions in the presented study might facilitate the decision to extend gastrointestinal evaluations by DBE in BD patients with abdominal complaints.

Gastrointestinal inflammation occurs infrequently in BD, but patients often mention abdominal complaints[1-4]. DBE enhances the extent in which the bowel can be investigated. Our study demonstrates that with DBE, SB lesions can be identified and proven by pathologic evaluation where conventional methods would have missed these lesions. Demonstration of SB involvement remains an important topic in BD. The SB might be a more frequent location than reported up till now and the introduction of DBE might add to this hypothesis. So far no data have been published on DBE in BD patients, but SB evaluation by video capsule enteroscopy (VCE) showed high incidence of SB involvement in two small studies[23,24]. Hamdulay et al demonstrate in 10 out of 11 BD patients suspected for intestinal BD lesions in the ileum, although three of them had known intestinal involvement identified by traditional endoscopic methods[23]. The Brazilian study demonstrates SB inflammation by VCE in all 10 patients studied of whom 5 with clinical inactive BD[24]. In our study population we encounter lesions in 40% of the patients. Explanations for these differences might be false positive results of VCE, geographical variation of intestinal BD, different methods in patient selection and the relative small groups studied [25-29]. It seems however, that SB involvement in BD occurs unexpectedly less infrequent than presumed, and can be at least encountered in 40 – 100% of the patients, depending on selection criteria.

One of the major advantages of DBE over VCE is that interventions and diagnostic biopsies can be performed during the procedure. Microscopic SB biopsy analysis can be especially helpful to differentiate between CD and BD. Histological examination also enables to determine the degree of inflammation, which is relevant for therapeutic considerations. In our study biopsies are taken in patients 3 and 4 to differentiate between grade 2 and grade 1 type inflammation. Another advantage of DBE as compared to VCE is that the colon is visualized in the same session. In patient 4 DBE shows therapy resistant enterocolitis eventually leading to a right-sided colectomy to resolve the abdominal complaints successfully. VCE is less invasive and better tolerated than DBE, but capsule retention, reported in up to 7%, might be a disadvantage [30-35]. Since little is known of small bowel evaluation by CT and MRI enterography it is difficult to discuss the position of radiographic techniques in BD. Recent studies show that radiologic diagnosis becoming more and more accurate and even comparable to endoscopic techniques [12,14,36,37]. Therefore in the future the approach of a BD patient with unexplained gastrointestinal

complaint can start with CT or MRI enterography. If no diagnosis is obtained or when histological evaluation is needed DBE can be the next step. Similar approaches are proposed other inflammatory bowel disease[14]. Therefore the observations of the presented study are important and may establish DBE as an important diagnostic tool for the evaluation of BD patients with gastro-intestinal complaints.

Studies on cytokines in BD patients often show a Th1 skewed cytokine profile with elevated IFN- $\gamma$ , TNF- $\alpha$ , and IL-2 [1-2, 38-39]. Although we could detect levels of inflammatory cytokines in some of our patients, this did not reflect a typical Th1 nor Th17 cytokine profile. Elevated IL-10 could be part of the pathogenesis of intestinal BD as well as a normal response on inflammation. Immune modulating treatment might have influenced these cytokines as well as the composition of the blood lymphocyte compartment in our study[40-43]. Since our study population is limited in size with different types of treatment between patients it remains difficult to draw any firm conclusions on the clinical use of cytokines and lymphocyte subsets, but IFN- $\gamma$  levels might be of importance.

In conclusion, this study provides additional clinical tools in the management of BD patients with gastrointestinal complaints. It shows that DBE is a valuable and safe tool to evaluate the involvement of the entire gastrointestinal tract in BD patients possibly leading to a change in therapy and that IFN- $\gamma$ , IL-6 and IL-10 levels can help in determining patients with SB lesions and intestinal BD. Our findings warrant further evaluation to compare these cytokines in relation to DBE and VCE in both BD patients with and without intestinal complaints.

## REFERENCES

1. van Laar JA, Kappen JH, van Daele PL, et al. Do synovial biopsies help to support evidence for involvement of innate immunity in the immunopathology of Behçet's disease? *Arthritis Res Ther.* 2009;11:R17
2. Kappen JH, Dik WA, Dingjan GM, et al. Cytokines in the colon of a patient with Behçet's disease. *Arthritis Res Ther.* 2009;11:412.
3. Evereklioglu C, Current concepts in the etiology and treatment of Behçet disease. *Surv Ophthalmol.* 2005;50:297-350.
4. Yazici H, Fresko I, Yurdakul S. Behçet's syndrome: disease manifestations, management, and advances in treatment. *Nat Clin Pract Rheumatol.* 2007;3:148-55
5. Sakane T, Takeno M, Suzuki N, et al. Behçet's disease. *N Engl J Med.* 1999;341:1284-91.
6. Lee, Chung Ryul; Kim, Won Ho; Cho, Yong Suk; et al. Colonoscopic Findings in Intestinal Behçet's Disease. *Inflam Bowel Dis.* 2001;7(3):243-249
7. Kasahara Y, Tanaka S, Nihino M, et al. Intestinal involvement in Behçet's disease: Review of 136 surgical cases in the Japanese literature. *Dis Colon Rectum* 1981;24:103-106,
8. Yurdakul S, Tuzuner N, Yarakul I, et al. Gastrointestinal involvement in Behçet's syndrome; a controlled study. *Ann Rheum dis,* 1996, 55:208-210
9. Bayraktar Y, Özaslan E, Van Thiel DH. Gastrointestinal manifestations of Behçet's disease. *J Clin Gastroenterol* 2000;30:144-54.
10. Yamamoto H, Sekine Y, Sato Y, et al. Total enteroscopy with a nonsurgical steerable double-balloon method. *Gastrointest Endosc* 2001;53:216-20.
11. Yamamoto H, Yano T, Kita H, et al. New system of double-balloon enteroscopy for diagnosis and treatment of small intestinal disorders. *Gastroenterology* 2003;125:1556.
12. Wiarda, B.M., et al., Small bowel Crohn's disease: MR enteroclysis and capsule endoscopy compared to balloon-assisted enteroscopy. *Abdom Imaging,* 2012. 37(3): p. 397-403.
13. Tong, J.L., et al., Computed tomography enterography versus balloon-assisted enteroscopy for evaluation of small bowel lesions in Crohn's disease. *J Gastroenterol Hepatol,* 2013. 28(7): p. 1180-6.
14. Dye, C.E., et al., Endoscopic and radiographic evaluation of the small bowel in 2012. *Am J Med,* 2012. 125(12): p. 1228 e1-1228 e12.
15. Jung, Yoon Suk; Cheon, Jae Hee; Park, Soo Jung; et al. Long-term Clinical Outcomes of Crohn's Disease and Intestinal Behcet's Disease. *Inflam Bowel Dis.* 2013;19(1):99-105
16. Matsumura, Kayoko; Nakase, Hiroshi; Chiba, Tsutomu. Efficacy of oral tacrolimus on intestinal Behcet's disease. *Inflam Bowel Dis.* 2010;16(2):188-189
17. Ariyachaipanich, Aekarach; Berkelhammer, Charles; Nicola, Haidy. Intestinal Behçet's disease: Maintenance of remission with adalimumab monotherapy. *Inflam Bowel Dis.* 2009;15(12):1769-1771
18. Naganuma, Makoto; Sakuraba, Atsushi; Hisamatsu, Tadakazu; et al. Hibi, Toshifumi. Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease. *Inflam Bowel Dis.* 2008. 14(9):1259-1264
19. van Laar JA, Missotten T, van Daele PL, et al. Adalimumab: a new modality for Behçet's disease? *Ann Rheum Dis.* 2007;66:565-6
20. Travis SP, Czajkowski M, McGovern DP, et al. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody. *Gut.* 2001;49:725-8

21. Kappen JH, Mensink PB, Lesterhuis W, et al. Mycophenolate sodium: effective treatment for therapy-refractory intestinal Behçet's disease, evaluated with enteroscopy. *Am J Gastroenterol.* 2008;103:3213-4.
22. Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. *Lancet* 1990;335:1078-80.
23. Neves FS, Fylyk SN, Lage LV, et al. Behçet's disease: clinical value of the video capsule endoscopy for small intestine examination. *Rheumatol Int.* 2009;29:601-3.
24. Hamdulay SS, Cheent K, Ghosh C, et al. Wireless capsule endoscopy in the investigation of intestinal Behçet's syndrome. *Rheumatology.* 2008 ;47:1231-4.
25. Mehdizadeh S, Han NJ, Cheng DW, et al. Success rate of retrograde double-balloon enteroscopy. *Gastrointest Endosc.* 2007;65:633-9.
26. Matsumoto T, Esaki M, Moriyama T, et al. Comparison of capsule endoscopy and enteroscopy with the double-balloon method in patients with obscure bleeding and polyposis. *Endoscopy* 2005; 37:827-32.
27. Hadithi M, Heine GD, Jacobs MA, et al. A prospective study comparing video capsule endoscopy with double-balloon enteroscopy in patients with obscuregastrointestinal bleeding. *Am J Gastroenterol* 2006;101:52-7.
28. Kameda N, Higuchi K, Shiba M, et al. A prospective, single-blind trial comparing wireless capsule endoscopy and double-balloon enteroscopy in patients with obscure gastrointestinal bleeding. *J Gastroenterol.* 2008;43:434-40.
29. Arakawa D, Ohmiya N, Nakamura M, et al. Outcome after enteroscopy for patients with obscure GI bleeding: diagnostic comparison between double-balloon endoscopy and videocapsule endoscopy. *Gastrointest Endosc.* 2009;69:866-74.
30. Costamagna G, Shah SK, Riccioni ME, et al. A prospective trial comparing small bowel radiographs and video capsule endoscopy for suspected small bowel disease. *Gastroenterology.* 2002;1234: 999-1005.
31. Scapa E, Jacob H, Lewkowicz S, et al. Initial experience of wireless-capsule endoscopy for evaluating occult gastrointestinal bleeding and suspected small bowel pathology. *Am J Gastroenterol.* 2002;97:2776-2779.
32. Ell C, Remke S, May A, et al. The first prospective controlled trial comparing wireless capsule endoscopy with push enteroscopy in chronic gastrointestinal bleeding. *Endoscopy.* 2002;34: 685-689.
33. Chong AK, Taylor A, Miller A, Hennessy O, et al. Capsule endoscopy vs. push enteroscopy and enteroclysis in suspect small-bowel Crohn's disease. *Gastrointest Endosc.* 2005;61:255-261.
34. Van Tuyl SA, van Noorden JT, Kuipers EJ, et al. Results of videocapsule endoscopy in 250 patients with suspected small bowel pathology. *Dig Dis Sci.* 2006;51:900-905.
35. Mensink PBF, Groenen MJ, van Buuren HR, et al. Double-balloon enteroscopy in Crohn's disease patients suspected of small bowel activity: findings and clinical impact. *Gastroenterol* 2009;44: 271-6
36. Honda, W., et al., Enteroscopic and radiologic diagnoses, treatment, and prognoses of small-bowel tumors. *Gastrointest Endosc,* 2012. 76(2): p. 344-54.
37. Park, M.J. and J.S. Lim, Computed tomography enterography for evaluation of inflammatory bowel disease. *Clin Endosc,* 2013. 46(4): p. 327-66.
38. Frassanito MA, Dammacco R, Cafforio P, et al. Th1 polarization of the immune response in Behçet's disease: a putative pathogenetic role of interleukin-12. *Arthritis Rheum.* 1999 ;42:1967-74.

39. Ben Ahmed M, Houman H, Miled M, et al. Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behçet's disease. *Arthritis Rheum.* 2004;50:2291-5.
40. Misumi M, Hagiwara E, Takeno M, et al. Cytokine production profile in patients with Behçet's disease treated with infliximab. *Cytokine.* 2003;24:210-218.
41. Takayama E, Koike Y, Ohkawa T, et al. Functional and Vbeta repertoire characterization of human CD8+ T-cell subsets with natural kill cell markers, CD56+CD57- T cells, CD56+CD57+ T cells and CD56- CD57+ T cells. *Immunology.* 2003;108:211-219.
42. Snyder MR, Weyand CM, Goronzy JJ. The double life of NK receptors: stimulation or co-stimulation? *Trend Immunol.* 2004; 25:25-32.
43. Yu J, Oh FS, Chung H, et al. Down-regulation of IFN-gamma-producing CD56+ T cells after combined low-dose cyclosporine/prednisone treatment in patients with Behçet's uveitis. *Invest Ophthalmol Vis Sci.* 2005 Jul;46(7):2458-64.

# 5

## New treatment modalities







# **Mycophenolate sodium: effective treatment for therapy refractory intestinal Behçet's disease, evaluated with enteroscopy**

J.H. Kappen, P.B.F. Mensink, W. Lesterhuis, S. Lachman, M.A. den Bakker, P.L.A. van Daele, P.M. van Hagen, J.A.M. van Laar.

*Am J Gastroenterol.* 2008 Dec;103(12):3213-4.

**ABSTRACT**

A 59-year old man with Behçet's disease (BD) was referred with complaints of continuous non-bloody diarrhea and abdominal pain since April 2006. On colonoscopy multiple aphthous lesions encompassed the entire colon showing a chronic merely neutrophilic infiltrate and oedema. Treatment with 30 mg prednisone and 200 mg azathioprine (AZA) was started. Attempts to lower the dose of prednisone led instantaneously to a relapse. In February 2007 symptoms worsened and mycophenolate sodium (MPS) was added, whilst tapering prednisone and AZA, yielding an immediate and sustained effect. Evaluation with a double balloon scopy four months later showed that the colonic lesions had healed. In the terminal ileum that had not been reached in the first colonoscopy, some minor ulcerative lesions could be detected. Eleven months after initiation with MPS the patient remains in good clinical condition and improved symptoms with a reduced steroid and AZA dose.

*Conclusions:* This case shows that MPS might be a good therapy before using biologicals or chemotherapeutics in therapy-refractory BD patients with severe ileo-colitis. The involvement of the entire gastrointestinal tract in BD and the response to the therapy can be visualized using the double balloon endoscopy.

## INTRODUCTION

Although abdominal complaints may be regularly mentioned, gastrointestinal inflammation occurs infrequently (1-5 %) in the Western population of patients with Behçet's disease (BD), an idiopathic systemic vasculitis with oral and genital aphthous ulcers, skin lesions and ocular inflammation [1, 2, 3].

If present, aphthous lesions, erosions or ulcers, are most often reported in the terminal ileum and right sided colon, leading to anorexia, vomiting, diarrhoea and abdominal pain [3, 4, 5]. Mucosal lesions in other parts of the small bowel and colon are rarely reported.

Although the etiology of BD remains unknown, it is generally considered an excessive, T-cell mediated inflammatory response, possibly triggered by an (infectious) antigen in a genetically susceptible host. The inflammatory cells in the lesions are of lymphocytic and monocytic origin. Neutrophilic infiltration is present in early lesions and might indicate innate immunity involvement in the pathophysiology of BD [6]. This suggestion might be supported by recent findings of SNP's associated with a defective innate immunity in Crohn's disease (CD), a disease clinically similar to BD [2, 7].


Most patients with BD only need symptomatic treatment. However, patients with gastrointestinal involvement may require more aggressive treatment [5]. This includes, often combined systemic anti-inflammatory or immunosuppressive drugs such as corticosteroids, azathioprine (AZA), cyclosporine and sporadically other immunosuppressives [2, 5]. The introduction of biological agents such as anti-TNF- $\alpha$  and interferon  $\alpha$  has improved the therapeutic potential, also in intestinal Behçet [1, 2, 3, 8, 9]. In patients with therapy-refractory intestinal BD surgery might be the final therapeutic option [4].

Investigational drugs in BD are the mycophenolates, which are widely used in transplantation medicine and increasingly in autoimmune diseases such as CD, SLE and autoimmune rheumatic disease (ARD) [10, 11, 12]. Mycophenolate sodium (MPS) and mycophenolate mofetil (MMF) are prodrugs of mycophenolic acid (MPA), a strong inhibitor of the key enzyme monophosphate dehydrogenase (IMPDH). It suppresses both B- and T-cell proliferation, but also affects endothelial cells, including inhibition of TNF- $\alpha$  and neutrophil attachment [13].


We present the case of a patient with steroid and AZA refractory BD involving both colon and small bowel, treated with MPS and evaluated by double balloon endoscopy.

## CASE

A 59-year old Caucasian man was referred from another hospital in December 2006. He complained of continuous non-bloody diarrhoea and abdominal pain since April.



**Figure 1.** A: Significant colitis with aphthous lesions in the distal colon in an untreated 59 year old patient with BD. B: Distal colon of the same patient 4 months after treatment with mycophenolate sodium and low doses of azathioprine and prednisone.




**Graph 1:** Prednisone dose (triangles) in relation to the Behçet’s disease current activity (BDCAF, squares) score in a patient with BD and gastrointestinal involvement treated with mycophenolate sodium and azathioprine (tapered swiftly from 200 mg to 50mg).

On colonoscopy multiple aphthous lesions encompassed the entire colon (Figure 1a). Biopsies showed a chronic predominantly neutrophilic infiltrate and oedema. Other symptoms were papulopustular skin lesions, orogenital ulcers and arthralgia. BD was diagnosed. Treatment with mesalazine and later 30mg prednisone combined with 200mg azathioprine (AZA) only briefly relieved the complaints of diarrhoea, abdominal pain and arthralgia. Patient was referred to our hospital. Attempts to taper the prednisone below 30 mg instantaneously led to a relapse. In February 2007 symptoms worsened and 1440 mg MPS per day was added.

The effect was immediate, both AZA and prednisone could be tapered to 25 and 2.5mg, within 2 weeks and 4 months, respectively (Figure 2).

Although some minor abdominal complaints were noted, orogenital ulcers, skin lesions and arthralgia disappeared. Four months later both colon and the entire small



**Figure 3:** Limited eosinophilic and neutrophilic infiltrates in the lamina propria of the terminal ileum after successful treatment with MPS in a patient with BD and gastrointestinal involvement.

bowel were evaluated by double balloon scopy. The colonic lesions observed previously in the entire colon had totally disappeared (Figure 1b). Some minor ulcerative lesions were detected in the terminal ileum which had not been reached at the first colonoscopy. Biopsy showed a small amount of eosinophilic and neutrophilic infiltrates in the lamina propria surrounded by normal intestinal tissue (Figure 3). Eleven months after the therapy-switch the patient remains in good clinical condition (Figure 2).

## DISCUSSION

This case of effective additive treatment with MPS might support a basis for the use of a new class of therapy in BD patients. The double balloon endoscopy proves a valuable tool for evaluation of the entire intestinal tract.

A variety of immunosuppressive therapy is used in BD. In our patient TNF-blocking agents were considered, but preserved for a more severe or life threatening situation [8, 9, 10]. Mycophenolates are increasingly used in the treatment of autoimmune diseases including uveitis and CD [12, 14]. Experience in BD is limited and to our knowledge there are no reports of its use in patients with gastrointestinal involvement. Adler et al. describes thirty patients with mucocutaneous BD quickly relapsing after initial response to MMF [15]. These relapses might be explained by the cessation of prednisone quickly after start of the MMF treatment. In our case tapering the other immunosuppressive therapy was monitored by the clinical condition and laboratory parameters. We therefore felt confident with the initiation of MPS in our BD patient. Up till now response lasts almost one year.

BD patients can have gastrointestinal complaints. Endoscopic evaluation was until recently restricted to the proximal and distal part of the small bowel and colon. Recent introduction of new endoscopic methods such as double balloon -or capsule endoscopy

enables to visualize the entire gastrointestinal tract. Our case shows that the small intestine can be involved even in a BD patient with minor abdominal complaints. The additional value of these techniques might be helpful in diagnosing mucosal lesions in the small bowel of BD patients with abdominal symptoms and even may change the frequency of intestinal involvement. We therefore recently have initiated a prospective case study to observe intestinal involvement in BD patients with abdominal complaints.

In conclusion, this case shows that MPS might be used up front biologicals or chemotherapeutics in BD patients with ileo-colitis, refractory to corticosteroid- or AZA-therapy. Tapering of instituted immunosuppressive medication may prevent an early relapse. The involvement of the entire gastrointestinal tract in BD and the response to the therapy can be visualised by double balloon endoscopy.

## REFERENCES

1. Evereklioglu C, Current concepts in the etiology and treatment of Behçet disease. *Surv Ophthalmol.* 2005;50(4):297-350.
2. Yazici H, Fresko I, Yurdakul S. Behçet's syndrome: disease manifestations, management, and advances in treatment. *Nat Clin Pract Rheumatol.* 2007;3(3):148-55
3. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet's disease. *N Engl J Med.* 1999;341(17):1284-91.
4. Kasahara Y, Tanaka S, Nihino M, Umemura H, Shiraha S, Kuyama T: Intestinal involvement in Behçet's disease: Review of 136 surgical cases in the Japanese literature. *Dis Colon Rectum* 1981,24: 103–106,
5. Yurdakul S, Tuzuner N, Yarakul I, Hamuryudan V, Yazici H. Gastrointestinal involvement in Behçet's syndrome; a controlled study. *Ann Rheum dis,* 1996, 55:208-210
6. Direskeneli H. Behçet's disease: Infectious aetiology, new autoantigens, and HLA-B51. *Ann Rheum Dis.* 2001;60(11):996-1002.
7. Strober W, Murray PJ, Kitani A, Watanabe T. Signalling pathways and molecular interactions of NOD1 and NOD2. *Nat Rev Immunol.* 2006;6(1):9-20
8. van Laar JA, Missotten T, van Daele PL, Jamnitski A, Baarsma GS, van Hagen PM. Adalimumab: a new modality for Behçet's disease? *Ann Rheum Dis.* 2007;66(4):565-6
9. Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody. *Gut.* 2001;49(5):725-8
10. Legendre C, Cohen D, Zeier M, Rostaing L, Budde K. Efficacy and safety of enteric-coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12-month multicenter, open-label, prospective studies. *Transplant Proc.* 2007 39(5):1386-91.
11. Iaccarino L, Rampudda M, Canova M, Della Libera S, Sarzi-Puttinic P, Doria A. Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases? *Autoimmun Rev.* 2007;6(3):190-5.
12. Wenzl HH, Hinterleitner TA, Aichbichler BW, Fickert P, Petritsch W. Mycophenolate mofetil for Crohn's disease: short-term efficacy and long-term outcome. *Aliment Pharmacol Ther.* 2004;19(4): 427-34.
13. Huang Y, Liu Z, Huang H, Liu H, Li L. Effects of mycophenolic acid on endothelial cells. *Int Immunopharmacol.* 2005;5(6):1029-39
14. Siepmann K, Huber M, Stübiger N, Deuter C, Zierhut M. Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis : a retrospective analysis of 106 patients. *Graefes Arch Clin Exp Ophthalmol.* 2006;244(7):788-94
15. Adler YD, Mansmann U, Zouboulis CC. Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Behçet's disease. *Dermatology.* 2001;203(4):322-4.





# Successful long-term triple disease control by ustekinumab in a patient with Behçet's disease, psoriasis, and hidradenitis suppurativa

Ewout M. Baerveldt, Jasper H. Kappen, H. Bing Thio, Jan A.M. van Laar, Martin van Hagen, and Errol P. Prens

*Ann Rheum Dis.* 2013 Apr;72(4):626-7



## INTRODUCTION

Behçet's disease (BD) is an auto-inflammatory disorder, characterized by recurrent oral aphthosis, genital ulcers, uveitis and pustular skin lesions.[1] Associated cutaneous diseases include Sweet's syndrome,[2] erythema nodosum and pyoderma gangrenosum. [3] Next to BD, both psoriasis and hidradenitis suppurativa (HS) are clear neutrophilic and IL-17-based diseases, suggesting a pathomechanistic overlap.[4-8] However, these diseases rarely co-occur.[4] Ustekinumab (anti-p40 mAb), an effective biologic treatment for psoriasis, might be effective in BD by interfering with the IL-17 signalling via IL-23 blockage. We present a 39-year-old Caucasian woman, in which the combination of BD, psoriasis and HS, was successfully treated with ustekinumab.

## CASE

At the age of 5, patient developed guttate psoriasis followed by psoriasis vulgaris with severe acne vulgaris since puberty. She started smoking at the age of 13 and periodically developed inflamed and tender boils in both axilla and groins during puberty. At 35, she was diagnosed with BD according to the guidelines of the international study group on BD based on oro-genital ulcers and uveitis anterior [4]. Inquiry learned that she repeatedly developed ulcers at injection sites, highly suggestive of a pathergy reaction. This was complicated by bilateral arthritis of the distal interphalangeal joints and weight loss due to multiple intestinal ulcers at the terminal ileum. Dermatological examination revealed vulvar and multiple circumscribed punched-out vaginal scars and ulcers, and fibrotic and rope-like scarring in the groins, together with HS, Hurley stage 2. The BD-related symptoms prompted immunosuppressive treatment with diclofenac/misoprostol, ocular steroids, colchicine, intra-articular triamcinolone injection and cyclosporin, unfortunately all without with only temporarily effect. In the course of the disease she experienced an exacerbation of her psoriasis that was treated with subcutaneous injections of 45 mg ustekinumab at weeks 0, 4 and every 12 weeks thereafter. Fifty percent clinical improvement, as measured by the Psoriasis Activity and Severity Index (PASI 50), was achieved within 4 weeks, followed by PASI 75 within 3 months. Subsequently, both BD and HS skin complaints gradually decreased, and remained in complete remission for at least 36 months without adjunctive immunosuppressive treatment.

Before and 4 weeks after first injection of ustekinumab, serum was analysed using a semi-quantitative multiplex protein array to monitor changes in circulating cytokines, chemokines, and growth factors [5]. Before treatment, 64 out of 507 proteins, showed an increased,  $\geq 2$ -fold expression compared to healthy control serum, including IL-23 and IL-12p70 (Table 1). Four weeks following the first injection of ustekinumab, 18 proteins

**Table 1.** Serum proteins compared to healthy controls and change induced by ustekinumab

Protein	Fold change to healthy controls (n=2)	Fold change by ustekinumab	General function
IL-23	21,60	-2,18	Th17
Ciliary neurotrophic factor (CNTF)	12,08	-1,82	Il-6 family member
Osteoprotegerin	12,05	-1,68	Serum biomarker of arthritis
IL-12 p70	7,71	-1,93	Th1
CCL27	7,37	-1,63	Th1/Th17
Glut2	5,56	-2,34	Glucose metabolism
VEGF	4,03	3,33	Angiogenesis
Kininostatin	3,70	-1,61	Angiogenic inhibitor
CCL3 (MIP1 $\alpha$ )	3,45	-1,50	Th1/Th17
TRAIL R4 (TNFRSF10D)	2,82	1,62	Marker of inflammatory DCs
IGFBP-3	2,65	1,85	Growth factor
BMP-8	2,57	1,98	Growth factor
TGF-beta 2	2,29	2,06	Growth factor
FGF Basic	2,29	1,53	Growth factor
IGFBP-6	2,24	3,27	Growth factor
Inhibin B	2,14	2,51	Endocrine function
Neurturin	2,13	2,06	Neurotrophic factor
IL-24	2,04	2,85	Th17

showed a change of more than 1.5 fold (Table 1), among which the Th1 and Th17-associated proteins IL-12p70 and IL-23 were downregulated. These findings support an important role of Th1/Th17 pathways in BD [6].

There are only two other cases describing combined occurrence of BD and HS [7]. This case is the first in which these three diseases were simultaneously present. In addition, our case is the first BD patient reported that was effectively treated with ustekinumab. The successful treatment with ustekinumab provides a valuable addition to the current therapeutic armamentarium.

## REFERENCES

1. Sakane T, Takeno M, Suzuki N, et al. Behçet's disease. *N Engl J Med* 1999;341:1284-91.
2. Hassikou H, Tabache F, Baaj M, et al. Sweet's syndrome in Behçet's disease. *Joint Bone Spine* 2007;74:495-6.
3. Chun SI, Su WP, Lee S, et al. Erythema nodosum-like lesions in Behçet's syndrome: a histopathologic study of 30 cases. *J Cutan Pathol* 1989;16:259-65.
4. Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. *Lancet* 1990;335:1078-80.
5. Lin Y, Huang R, Chen LP, et al. Profiling of cytokine expression by biotin-labeled-based protein arrays. *Proteomics* 2003;3:1750-7.
6. Shimizu J, Takai K, Fujiwara N, et al. Excessive CD4+ T cells co-expressing interleukin-17 and interferon-gamma in patients with Behçet's disease. *Clin Exp Immunol* 2012;168:68-74.
7. Sahin MT, Ozturkcan S, Turel-Ermertcan A, et al. Behçet's disease associated with hidradenitis suppurativa. *J Eur Acad Dermatol Venereol* 2007;21:428-9.



# **Adalimumab treatment in refractory mucocutaneous Behçet's Disease: An observational case series**

Diana M. Verboom, Jasper H. Kappen, Willem A. Dik, Marianne W. van der Ent, Paul L.A. van Daele, P. Martin van Hagen, Jan A.M. van Laar

*Submitted*

## ABSTRACT

*Introduction:* Retrospective studies indicate that the TNF-blocker adalimumab can be effective in Behçet's disease (BD), a multisystem auto-inflammatory ulcerative disorder. We examined the efficacy of adalimumab in refractory BD.

*Methods:* The effect of bi-weekly 40mg adalimumab in nine patients with therapy refractory, non-ocular or organ threatening BD was studied during six months. Primary endpoint was decreased in BD activity as measured by the BD Current Activity Form (BDCAF). Secondary endpoints include serum cytokines and Endothelin-1 (ET-1) levels. Normally distributed data were analyzed with repeated measures ANOVA and the paired t-test, other data were analyzed with the Wilcoxon signed-rank test.

*Results:* BDCAF improved significantly in all patients from 5.4 (SD = 1.4) to 2.4 (SD = 1.4) ( $p = 0.007$ ) within one month and improvement lasted the entire observation period so that eight patients could either taper or stop concomitant therapy. Symptoms of mucocutaneous lesions, erythema nodosum and joint involvement decreased or completely disappeared. Initially, serum TNF-alpha levels were elevated in five patients and decreased ( $p = 0.017$ ) in line with BDCAF improvement. Serum ET-1 and other laboratory results did not show any significant change. No adverse effects were reported and all patients continued treatment (mean 3.1, range 1.6-4.1 years).

*Conclusion:* We present a case series on patients with refractory BD treated with adalimumab and provides a basis for its use in refractory mucocutaneous BD. These findings show that adalimumab can safely be administered yielding sustainable clinical effects in refractory BD patients.



## INTRODUCTION

Behçet's disease (BD) is widely considered to be an auto-inflammatory vasculitis of variable vessels. Most prevalent oral aphthous lesions can be accompanied by mucocutaneous manifestations at various sites, neurological or ocular complaints. The symptoms interfere with the quality of daily life at every level and require systemic treatment depending on the presence of potential irreversible organ damage [1, 2].

BD is thought to be a disease of multifactorial origin. Genetic predisposition and a combination of environmental factors lead to an aberrant immunological reaction possibly resulting from molecular mimicry associated with infection and defects in T-cells [3]. Several human studies demonstrate increased pro-inflammatory cytokine production by increased and activated T helper 1 (Th1) lymphocytes in BD [4-6]. In this inflammatory process tumor necrosis factor alpha (TNF- $\alpha$ ) is regarded a key player.[7-10] Genetic studies on SNP's related to the TNF gene underscore this assumption [11, 12]. TNF- $\alpha$  stimulates production of other cytokines in the immune cascade and exerts direct cell killing, thus explaining the inflammatory symptoms. The important role of TNF- $\alpha$  in the pathogenesis of BD suggests that TNF-inhibition may interrupt the inflammatory process [10, 13].

Treatment of patients with BD is directed by the presence of organ involvement, or vision –or life-threatening situations as stated in the EULAR recommendations [1, 14] . In short, when refractory disease systemic steroids are effective, and step-up and tailored treatment includes various disease modifying anti- rheumatic drugs as well as biologicals such as TNF-blockers [1, 14]. In the new millennium TNF-blockers are increasingly used and described in refractory BD, particularly in patients with uveitis or colitis [13, 15-19]. Evidence on the efficacy of the TNF-blockers infliximab and adalimumab is emerging, however, no prospective data with adalimumab in BD have been published so far.

The aim of this study was to confirm the existing positive retrospective data of the effective use of adalimumab in BD. Furthermore we measured various cytokines potentially involved in the disease process to study potential clinical correlations.

## METHODS

### Inclusion of patients

In this case series 9 BD patients with treatment refractory active oral, skin, genital or joint symptoms (Table 1 and 2) who, were selected for TNF blocking therapy based on the EULAR recommendations. All patients were treated at the Erasmus University MC

**Table 1.** Patient characteristics before treatment.

	Before treatment
<b>Number of patients (n)</b>	9
<b>Male/Female</b>	6/3
<b>Mean age (years)</b>	42.7 (30-64)
<b>Ethnic background</b>	
<b>Caucasian</b>	2
<b>Turkish</b>	6
<b>Moroccan</b>	1
<b>Clinical manifestation (n /total n)</b>	
<b>Oral ulceration</b>	7/9
<b>Genital ulceration</b>	6/9
<b>Skin lesions</b>	9/9
<b>Arthralgia</b>	8/9
<b>Arthritis</b>	3/9
<b>Mean BCDAF at start ± SD</b>	5.4 ± 1.4

The characteristics of 9 pretreated patients with Behçet's disease before starting adalimumab. *n*= number, SD= Standard deviation.

outpatient clinic from July 2010 until December 2011 and fulfilled the BD criteria of the International Study Group of Behçet's Disease [20]. Adalimumab was started on a patient care basis after (latent) tuberculosis was ruled out (chest X-ray, and a IGRA test (Quantiferon GOLD)). Patients were subsequently followed for six months after initiation of therapy. Hereafter, therapy could either be continued or terminated depending on disease activity.

**Table 2.** Medication use of included patients.

Patient	1	2	3	4	5	6	7	8	9
<b>Prior therapy</b>	Cut, D	Col, IFX	Cyc, Myc	Cut, P	P, SZP, Col, Cut, NSAID	Col, NSAID, P, Cut	Col, HcqI, MTX, Pe	Cyc, P	D, SZP
<b>At start</b>	Col, SZP, Th,	Cyc, Cut, NSAID, SZP	Col, Myc, NSAID, P, SZP, Th,	P, col, NSAID, Opat	Col, Cut, NSAID	Col, Cut, NSAID	Col, Cyc, NSAID, Th	Col, Cut, D, HcqI, NSAID, P	Col, Cut, HcqI, NSAID
<b>Tapering or stopped</b>	Th, Cut, <SZP	none	<Myc, P	NSAID, P	NSAID, Col <	NSAID, Col	Cyc, Th	<Col, <NSAID	HcqI, NSAID

Prior, concomitant and tapered treatment in 9 patients with Behçet's disease, studied on the clinical effects of 40mg adalimumab subcutaneously every 2 weeks.

< , dosage decreased; *Cut*, Cutaneous Corticosteroids (including diprolene creme, triamcinolon paste and fluticasone creme); *D*, dapsone; *Col*, colchicine; *SZP*, sulfasalazine; *Th*, thalidomide; *IFX*, infliximab; *Cyc*, cyclosporine; *NSAID*, Non Steroid Anti-Inflammatory Drugs (including diclofenac, celecoxib, etoricoxib, indometacin and arthrotec); *P*, prednisone; *Myc*, mycophenolic acid; *Opat*, opatanol eyedrops; *HcqI*, hydroxychloroquine; *MTX*, methotrexate.

### **Administration of Adalimumab (Humira®)**

Every two weeks patients received subcutaneously 40 mg/0.8 mL adalimumab (provided by Abbott BV, The Netherlands). When symptoms recurred within those two weeks, dose frequency could be increased up to once weekly.

### **Clinical effect**

Primary endpoint of the study was > 30% decrease in disease activity as measured by the Behçet's Disease Current Activity Form (BDCAF) 2006 published by the International Society of Behçet's Disease [21, 22]. It is a clinical tool to rate disease activity and remission of disease symptoms and was the most commonly used outcome measure in clinical trials for Behçet syndrome [23]. It scores presence of symptoms over a monthly period. Time points included last clinical visit before inclusion (hereafter named "before treatment", eg BT; > 21 days; mean of 2.8 months; range 0.7-5.6 months), day 0, 30, 90 and 180. Clinical symptoms were rated in weeks of duration according to previous studies [21, 24]. The form was filled out by the same clinician during the follow up. Liver enzymes and infection parameters were monitored on determined time points. Development of double stranded DNA antibodies was analyzed at the routine medical immunology laboratory of Erasmus MC. Adverse effects were registered, therapy was adjusted if applicable. Concomitant (immunosuppressive therapy) was tapered according to the opinion of the treating physician. Non-specific inflammatory parameters included C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR).

### **Serum cytokine measurement**

Sera were collected from the patients before initiation of treatment, and one and six months after start of treatment. The cytokines GM-CSF, IFN- $\gamma$ , IL-10, IL-12(p70), IL-13, IL-1 $\beta$ , IL-2, IL-4, IL-5, IL-6, IL-7, IL-8 and TNF- $\alpha$  were measured using a standard 13-plex Luminex kit (Millipore, Bedford, MA, USA). Cytokine levels above 10 picogram per milliliter (pg/ml) were considered elevated. Additionally, IFN-1 signatures were evaluated as described previously [25].

### **Serum Endothelin-1 (ET-1) measurement**

Serum ET-1 levels were measured in all patients before treatment, after one month and after six months at the routine clinical chemistry laboratory of Erasmus MC. ET-1 levels of more than 2,48 pg/ml were considered increased.

### **Statistics**

Statistical analyses were performed using SPSS 20.0 (SPSS Inc., Chicago, IL, United States). Data that were normally distributed were analyzed with repeated measures ANOVA and the paired t-test. Data that were not normally distributed were analyzed

with the Wilcoxon signed-rank sum test. A p-value of  $< 0.05$  was considered significant. To ensure that the observed clinical effects after initiation of adalimumab are not caused by a placebo-effect, study bias or normal BD activity fluctuations, all BDCAF scores after therapy were not only compared with day 0, but also compared with the last BDCAF at time point BT.

## RESULTS

### Patient characteristics

In this open-label series, nine immunosuppressive therapy refractory BD patients were screened. All patients could be included. Most were from Turkish descent and had high activity scores (Table 1). There was no ocular, major vessels or nervous system involvement in those patients within 3 months before, during or 3 months after the follow up period.

### Administration of Adalimumab (Humira®) and tapering of concomitant medication

After one or two outpatient clinic instructions, patients could inject adalimumab. In one patient dose frequency of adalimumab injections was increased to once per ten days after four months because of persistent erythema nodosum. Eight patients could taper or stop concomitant medication (Table 2).

### Clinical effects

Most patients demonstrated increasing BDCAF scores before initiating adalimumab, whilst significantly decreasing after treatment initiation, both as compared to BT as to day 0 (Table 3, Figure 2). Within one month after starting adalimumab all patients reached the primary endpoint that lasted up to six months in eight (80%) of nine patients ( $p = 0.007$ , Table 3). Presence of mucocutaneous lesions and arthralgia decreased significantly in duration. If present, erythema nodosum and arthritis disappeared completely within six months. Additionally, seven of nine patients rated their own condition as improved ( $p < 0.05$ ). No worsening of clinical symptoms occurred in the studied period of 6 months. There was no decrease in experienced headache (Table 3).

Clinical manifestations of patients with Behçet's disease treated with adalimumab at various time points before and after initiation. Clinical symptoms are scored according to those described in a former version of the BDCAF.[24]  $P < 0.05$  is considered significant.

*BT*, before treatment ( $> 21$  days; mean of 2.8 months; range 0.7-5.6 months); *BDCAF*, Behçet's Disease Current Activity Form; *SD*, Standard deviation.

**Table 3.** Effect of adalimumab on BDCAF score and symptoms in Behçet's disease

		<b>BT</b>	<b>Day 0</b>	<b>After 1 month</b>	<b>After 3 months</b>	<b>After 6 months</b>
<b>Disease activity</b> <b>(range 0-12)</b>	Mean ± SD	4.4 ± 1.4	5.4 ± 1.4	2.4 ± 1.4	2.6 ± 1.6	2.4 ± 1.5
	Range	3-7	3-8	0-4	1-6	0-5
	P*	0.023	-	0.007	0.007	0.007
<b>Oral ulcers</b>	Patients (n/total n)	8/8 <sup>#</sup>	7/9	2/9	3/9	5/9
	Mean ± SD	3.6 ± 0.5	3.1 ± 1.8	0.6 ± 1.3	0.7 ± 1.1	1.0 ± 1.3
	P	1.00	-	0.020	0.016	0.026
<b>Genital ulcers</b>	Patients	3/8	6/9	0/9	2/9	1/9
	Mean ± SD	1.0 ± 1.6	1.7 ± 1.6	0 ± 0	0.6 ± 1.1	0.3 ± 1.0
	P	0.334	-	0.026	0.023	0.026
<b>Headache</b>	Patients	7/8	7/9	7/9	6/9	6/9
	Mean ± SD	2.8 ± 1.4	2.6 ± 1.6	1.7 ± 1.4	1.0 ± 1.2	2.0 ± 1.7
	P	0.731	-	0.066	0.034	0.416
<b>Erythema</b>	Patients	2/8	4/9	0/9	3/9	0/9
	Mean ± SD	0.8 ± 1.5	1.6 ± 1.9	0 ± 0	0.7 ± 1.1	0 ± 0
	P	0.102	-	0.059	0.176	0.059
<b>Nodosum</b>	Patients	5/8	7/9	6/9	3/9	4/9
	Mean ± SD	2 ± 1.9	2.9 ± 1.8	1.0 ± 0.9	0.8 ± 1.4	1.3 ± 1.7
	P	0.083	-	0.017	0.025	0.068
<b>Arthralgia</b>	Patients	5/8	8/9	5/9	5/9	4/9
	Mean ± SD	1.5 ± 1.5	2.7 ± 1.5	1.3 ± 1.7	1.1 ± 1.4	1.4 ± 1.9
	P	0.066	-	0.496	0.023	0.041
<b>Arthritis</b>	Patients	0/8	3/9	0/9	0/9	0/9
	Mean ± SD	0 ± 0	0.9 ± 1.5	0 ± 0	0 ± 0	0 ± 0
	P	0.102	-	0.102	0.102	0.102
<b>Abdominal Symptoms</b>	Patients	4/8	4/9	2/9	2/9	1/9
	Mean ± SD	1.0 ± 1.4	0.8 ± 1.0	0.6 ± 1.3	0.3 ± 0.7	0.1 ± 0.3
	P	0.581	-	0.496	0.334	0.098
<b>Diarrhea</b>	Patients	1/8	3/9	0/9	0/9	1/9
	Mean ± SD	0.1 ± 0.3	0.8 ± 1.4	0 ± 0	0 ± 0	0.1 ± 0.3
	P	0.197	-	0.109	0.109	0.197
<b>Self-rating</b>	Mean ± SD	3.4 ± 1.3	4.1 ± 1.1	2.7 ± 0.5	2.7 ± 0.7	2.4 ± 1.4
	P	0.059	-	0.010	0.006	0.031

\*All P-values are based on the mean score at the different time points compared to day 0

# One patient was left out of the analysis of clinical symptoms because these were registered than 8 months BT, BDCAF, however could be determined closer to BT.

### Adverse effects

No severe adverse effects occurred. Five patients developed slightly elevated liver enzymes ( $< 3$  times the normal values), without the need to stop or adapt the dose or frequency of adalimumab. One patient had a lower respiratory, probably bacterial, infection, swiftly responding to oral antibiotics. After one month one patient had transient abdominal pain and diarrhea, without a need to stop adalimumab. No other patients noted these complaints. Two patients developed anti-dsDNA antibodies after six months. Up till now neither developed autoimmune disease or failure of therapy during follow-up


### Non-specific inflammatory parameters

C-reactive protein (CRP) was elevated (mean  $16.7 \text{ mg/l} \pm 20.3$ , range  $1\text{-}61 \text{ mg/l}$ ) in four of the nine patients (above  $>10 \text{ mg/l}$ ) and normalized after six months. Only three patients showed elevated erythrocyte sedimentation rate (ESR), which decreased to  $<23 \text{ mm/hr}$  during treatment. White blood cell count (data not shown) was normal in most patients.


### Serum cytokine levels

TNF- $\alpha$  serum levels were elevated ( $>10 \text{ pg/ml}$ ) in five (55.6%) patients before start of treatment. These levels decreased significantly up to normal values ( $<10 \text{ pg/ml}$ ) in the first month following treatment ( $p = 0.002$ ) and remained within the normal range during the remainder of the study period (Figure 1).

TNF- $\alpha$  levels were not correlated with BDCAF score at start, but BDCAF score and serum TNF- $\alpha$  levels both decreased most in the first month and remained significantly



**Figure 1.** TNF- $\alpha$  in patients with elevated levels at start. Threshold for normal levels is  $10 \text{ pg/ml}$ .



**Figure 2. Relative BDCAF score and TNF- $\alpha$  in all patients.** BDCAF = Behçet's Disease Current Activity Form. BT = Before treatment (> 21 days; mean of 2.8 months; range 0.7-5.6 months), P-values represent the comparison of the BDCAF's between the depicted time points as indicated by the horizontal line.

lower compared to baseline during follow-up ( $p = 0.007$  and  $p = 0.017$ , respectively; Figure 2).

TNF- $\alpha$  serum levels did not correlate with CRP levels (only two overlapping patients). In fact, TNF levels were normal in the patient with the highest CRP level. All other cytokines remained stable and within the normal range (<10 pg/ml) in all nine patients at all time-points (with the exception of the 6 month sample in one patient) (data not shown).

IFN type I gene expression remained stable and normal in all 5 patients measured (data not shown).

### Serum Endothelin-1

ET-1 serum levels were within the normal range throughout the whole study period in all patients.

## DISCUSSION

All nine therapy refractory BD patients treated with adalimumab demonstrated a significant and sustained response starting within one month. These data provide evidence for the widely accepted opinion that patients with BD respond well to TNF-blockers in general and adalimumab in particular.

We here report a significant positive therapeutic efficacy of adalimumab in a studied case series of refractory BD patients. Previously we retrospectively have demonstrated improvement of clinical symptoms in BD patients treated with adalimumab as have others thereafter [19, 26]. Case-series with adalimumab progressively report major responses of BD-related symptoms [13, 18]. Significant prospective studies encompassing > 5, mainly ocular, BD patients treated with infliximab involve in total 174 patients in 16 publications, however, no prospective data with Adalimumab in BD is available[13]. The high clinical therapeutic efficacy of adalimumab in refractory BD patients in the presented study are comparable with over 90% of patients improving in previous prospective BD studies with the alternative TNF-blocker, infliximab[13, 27]. Our results are also in line with data of etanercept in mucocutaneous refractory BD [28].

Limitations of our study are the relatively small patient cohort, the short follow-up period and absence of a placebo treated control group might hamper the clinical impact. However, we consider the observed 100% response rate, the disappearance of oral ulcers and erythema nodosum, and the fact that treatment with other anti-inflammatory drugs could be tapered when treated with adalimumab indicative for a substantial clinical response to therapy. This is further supported by the observed normalization of serum CRP and TNF- $\alpha$  levels. Expansion to larger controlled studies might therefore not essentially alter the described improved therapeutic efficacy or conclusions. Resistant mucocutaneous lesions as present in our case series might also be treated with azathioprine [1, 14]. A comparative study of azathioprine and Adalimumab would help treating physicians in choosing the optimal therapy for each individual patient.

One can argue that it could take longer than 6 months to develop adverse effects or therapy resistance. Although our follow up was limited, we could maintain adalimumab treatment for more than 4 years up till now ( $3.1 \pm 0.8$  years, range 1.6-4.1; data not shown). During this period adalimumab remained therapeutically effective. One patient was lost to follow up because of remigration to Turkey and one patient discontinued adalimumab because of transient hepatitis after 1.6 year of effective treatment. This termination however, did not necessitate initiation of new immunosuppressive medication. We therefore feel confident that our data are of clinical significance. Also these long-term observations are in line with other long term follow-up retrospective BD studies with adalimumab and the long term effects of this TNF-blocker in other inflammatory diseases [18, 19, 29, 30]. The exact duration of TNF-blocking therapy required to control BD is unknown and is subject of debate. Considering the effectiveness of TNF-blocking therapy in BD future studies that address this topic are required. Furthermore, adalimumab appears safe immunosuppressive therapy consistent with other reports of TNF-blockers in BD [13, 14, 27] [13, 14, 27]. The low number of relatively minor adverse effects and its clinical activity implicate that adalimumab is as potent as its intravenous alternative, infliximab.



Pro-inflammatory cytokines, including TNF- $\alpha$  and IFN- $\gamma$ , can induce ET-1 release by endothelium [31, 32]. Because BD can affect all types of vessels serum ET-1 might levels might reflect endothelial distress and disease activity and response to therapy. Indeed some studies demonstrated a correlation between serum ET-1 with BD activity, but this finding is not consistent as evidenced by others and our current study [33-36].

Non-specific inflammatory parameters such as CRP and ESR are infrequently elevated in our data, hence limiting its clinical application in BD [37, 38]. A substantial proportion of our patients initially expressed elevated TNF- $\alpha$  serum levels, normalizing from the first month following treatment, in line with previously described case-reports [10, 39]. However, our data also indicate that normal serum TNF- $\alpha$  levels in BD do not exclude a beneficial response to adalimumab, indicating that serum cytokine levels not always accurately reflect the local inflammatory situation within affected tissues. Serum TNF- $\alpha$  may thus be a poor biomarker to predict the response to adalimumab treatment in BD, but when initially elevated can be used to monitor treatment efficacy.

We present data on of Adalimumab treatment in BD patients including both clinical and laboratory parameters. The positive clinical results provide a strong signal for the use of adalimumab in refractory BD. Larger prospective studies in BD patients with intestinal disease or uveitis, are currently ongoing elsewhere, and may add to the development of a treatment strategy involving adalimumab in BD. Furthermore, the exact timing and duration of TNF-blockers will remain an important issue and a challenging subject for future treatment protocols in BD. In conclusion, adalimumab can safely and effectively be used in refractory mucocutaneous BD patients.

## COMPETING INTERESTS

The authors declare that they have no competing interests.

## ACKNOWLEDGEMENTS

The study has been made in the course of the authors' employment. We thank Abbott BV, the Netherlands for providing Humira®. There were no external sources of financial funding. The authors would like to acknowledge the following people who contributed to the study: Marjan Versnel coordinated the IFN signature analysis, Corinne van der Helden-Meeuwssen, Laboratory Analyst (processed samples and did sequencing work) and Edith Uitterlinden-Frie sema, Lab coordinator (coordinated ET-1 analysis).

## REFERENCES



1. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman MH, Kotter I, Olivieri I, Salvarani C *et al*: EULAR recommendations for the management of Behcet disease. *Annals of the rheumatic diseases* 2008, 67(12):1656-1662.
2. Moses Alder N, Fisher M, Yazici Y: Behcet's syndrome patients have high levels of functional disability, fatigue and pain as measured by a Multi-dimensional Health Assessment Questionnaire (MDHAQ). *Clin Exp Rheumatol* 2008, 26(4 Suppl 50):S110-113.
3. Evereklioglu C: Current concepts in the etiology and treatment of Behcet disease. *Surv Ophthalmol* 2005, 50(4):297-350.
4. Boyd SR, Young S, Lightman S: Immunopathology of the noninfectious posterior and intermediate uveitides. *Surv Ophthalmol* 2001, 46(3):209-233.
5. Frassanito MA, Dammacco R, Cafforio P, Dammacco F: Th1 polarization of the immune response in Behcet's disease: a putative pathogenetic role of interleukin-12. *Arthritis and rheumatism* 1999, 42(9):1967-1974.
6. Sugi-Ikai N, Nakazawa M, Nakamura S, Ohno S, Minami M: Increased frequencies of interleukin-2- and interferon-gamma-producing T cells in patients with active Behcet's disease. *Invest Ophthalmol Vis Sci* 1998, 39(6):996-1004.
7. Oztas MO, Onder M, Gurer MA, Bukan N, Sancak B: Serum interleukin 18 and tumour necrosis factor-alpha levels are increased in Behcet's disease. *Clin Exp Dermatol* 2005, 30(1):61-63.
8. Sayinalp N, Ozcebe OI, Ozdemir O, Haznedaroglu IC, Dundar S, Kirazli S: Cytokines in Behcet's disease. *Journal of Rheumatology* 1996, 23(2):321-322.
9. Evereklioglu C, Er H, Turkoz Y, Cekmen M: Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behcet's disease. *Mediators of inflammation* 2002, 11(2):87-93.
10. Misumi M, Hagiwara E, Takeno M, Takeda Y, Inoue Y, Tsuji T, Ueda A, Nakamura S, Ohno S, Ishigatsubo Y: Cytokine production profile in patients with Behcet's disease treated with infliximab. *Cytokine* 2003, 24(5):210-218.
11. Radouane A, Oudghiri M, Chakib A, Bennani S, Touitou I, Barat-Houari M: SNPs in the TNF-alpha gene promoter associated with Behcet's disease in Moroccan patients. *Rheumatology (Oxford)* 2012, 51(9):1595-1599.
12. Zhang M, Xu WD, Wen PF, Liang Y, Liu J, Pan HF, Ye DQ: Polymorphisms in the tumor necrosis factor gene and susceptibility to Behcet's disease: an updated meta-analysis. *Molecular vision* 2013, 19: 1913-1924.
13. Arida A, Fragiadaki K, Giavri E, Sfikakis PP: Anti-TNF agents for Behcet's disease: analysis of published data on 369 patients. *Seminars in arthritis and rheumatism* 2011, 41(1):61-70.
14. Sfikakis PP, Markomichelakis N, Alpsoy E, Assaad-Khalil S, Bodaghi B, Gul A, Ohno S, Pipitone N, Schirmer M, Stanford M *et al*: Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations. *Rheumatology (Oxford)* 2007, 46(5):736-741.
15. Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL: Treatment of intestinal Behcet's syndrome with chimeric tumour necrosis factor alpha antibody. *Gut* 2001, 49(5):725-728.
16. Hassard PV, Binder SW, Nelson V, Vasiliauskas EA: Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: a case report. *Gastroenterology* 2001, 120(4): 995-999.
17. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN: Effect of infliximab on sight-threatening panuveitis in Behcet's disease. *Lancet* 2001, 358(9278):295-296.

18. Calvo Catala J, Campos Fernandez C, Rueda Cid A, Gonzalez-Cruz Cervellera MI, Baixauli Rubio A, Pastor Cubillo MD: [Efficacy of adalimumab in Behcet's disease. Description of 6 cases] Eficacia del adalimumab en la enfermedad de Behcet: descripción de 6 casos. *Reumatol Clin* 2011, 7(4): 258-261.
19. Perra D, Alba MA, Callejas JL, Mesquida M, Rios-Fernandez R, Adan A, Ortego N, Cervera R, Espinosa G: Adalimumab for the treatment of Behcet's disease: experience in 19 patients. *Rheumatology (Oxford)* 2012, 51(10):1825-1831.
20. Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. *Lancet* 1990, 335(8697):1078-1080.
21. Lawton G, Bhakta BB, Chamberlain MA, Tennant A: The Behcet's disease activity index. *Rheumatology (Oxford)* 2004, 43(1):73-78.
22. International Society of Behçet's Disease: Behçet's Disease Current Activity Form 2006. In.: University of Leeds UK.
23. Hatemi G, Merkel PA, Hamuryudan V, Boers M, Direskeneli H, Aydin SZ, Yazici H: Outcome measures used in clinical trials for Behcet syndrome: a systematic review. *The Journal of rheumatology* 2014, 41(3):599-612.
24. Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ: Behcet's disease: evaluation of a new instrument to measure clinical activity. *Rheumatology (Oxford)* 1999, 38(8):728-733.
25. Wildenberg ME, van Helden-Meeuwsen CG, van de Merwe JP, Drexhage HA, Versnel MA: Systemic increase in type I interferon activity in Sjogren's syndrome: a putative role for plasmacytoid dendritic cells. *Eur J Immunol* 2008, 38(7):2024-2033.
26. van Laar J, Misotten T, van Daele P: Adalimumab: a new modality for Behcet's disease? . *Annals of the rheumatic diseases* 2007(66):565-566.
27. Handa T, Tsunekawa H, Yoneda M, Watanabe D, Mukai T, Yamamura M, Iwaki M, Zako M: Long-term remission of ocular and extraocular manifestations in Behcet's disease using infliximab. *Clin Exp Rheumatol* 2011, 29(4 Suppl 67):S58-63.
28. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP: Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. *Annals of the rheumatic diseases* 2013, 72(4):517-524.
29. Behm BW, Bickston SJ: Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. *The Cochrane database of systematic reviews* 2008(1):CD006893.
30. Kanse SM, Takahashi K, Lam HC, Rees A, Warren JB, Porta M, Molinatti P, Ghatei M, Bloom SR: Cytokine stimulated endothelin release from endothelial cells. *Life sciences* 1991, 48(14):1379-1384.
31. Woods M, Mitchell JA, Wood EG, Barker S, Walcot NR, Rees GM, Warner TD: Endothelin-1 is induced by cytokines in human vascular smooth muscle cells: evidence for intracellular endothelin-converting enzyme. *Molecular pharmacology* 1999, 55(5):902-909.
32. Er H, Evreklioglu C, Cumurcu T, Turkoz Y, Ozerol E, Sahin K, Doganay S: Serum homocysteine level is increased and correlated with endothelin-1 and nitric oxide in Behcet's disease. *The British journal of ophthalmology* 2002, 86(6):653-657.
33. Uslu T, Erem C, Tosun M, Deger O: Plasma endothelin-1 levels in Behcet's disease. *Clin Rheumatol* 1997, 16(1):59-61.
34. Ural AU, Yalcin A, Beyan C, Isimer A, Bayhan H: Plasma endothelin-1 concentrations in patients with Behcet's disease. *Scandinavian journal of rheumatology* 1994, 23(6):322-325.

35. Hamzaoui A, Hamzaoui K, Chabbou A, Ayed K: Endothelin-1 expression in serum and bronchoalveolar lavage from patients with active Behcet's disease. *British journal of rheumatology* 1996, 35(4):357-358.
36. Liu S, Ren J, Xia Q, Wu X, Han G, Ren H, Yan D, Wang G, Gu G, Li J: Preliminary case-control study to evaluate diagnostic values of C-reactive protein and erythrocyte sedimentation rate in differentiating active Crohn's disease from intestinal lymphoma, intestinal tuberculosis and Behcet's syndrome. *The American journal of the medical sciences* 2013, 346(6):467-472.
37. Ozuguz P, Karabulut AA, Tulmac M, Kisa U, Kocak M, Gunduz O: Markers of Endothelial Dysfunction and Evaluation of Vascular Reactivity Tests in Behcet Disease. *Angiology* 2013.
38. Fujikawa K, Aratake K, Kawakami A, Aramaki T, Iwanaga N, Izumi Y, Arima K, Kamachi M, Tamai M, Huang M *et al*: Successful treatment of refractory neuro-Behcet's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile. *Annals of the rheumatic diseases* 2007, 66(1):136-137.

# 6

## Discussion





## GENERAL DISCUSSION

Behçet's disease (BD) is a fascinating disorder. The epidemiology and pathophysiology of BD are widely debated, however, still need to be unravelled. This thesis encompasses translational studies to improve the insight in the demographic characteristics, genetical background, immunopathophysiology and treatment modalities of BD. Each chapter elaborates on specific segments of these subjects. In Chapter 2 it is argued that the prevalence of BD, contrary to a general assumption, doesn't decrease after migration. Also we correlate specific disease features to ethnical background. In Chapter 3 we demonstrate that some genetic variations are protective and others are associated with a higher risk on BD. We also demonstrate that it is possible to run a GWAS in a rare condition like BD in a cohort of multi-ethnic background. In Chapter 4 we show that cytokine profiles in affected tissue seem to be more relevant than serum cytokine profiles. Finally in Chapter 5 we present new treatment modalities such as TNF- $\alpha$  blockers, that successfully can be applied in BD patients. In this final Chapter we will discuss the results and implications of all initiated studies as well as the and suggestions for further research.


### Pathophysiology

In Chapter 1 an overview on the pathophysiology of BD is presented, indicating that BD is a multifactorial auto-inflammatory vasculitis occurring in virtually all types of blood vessels, with a certain genetic predisposition, in combination with various environmental factors, leading to inflammation [1-4] (Figure 1).

The inflammation is characterized by a Th-1 and probably also Th-17 mediated immune response(4, 5). In the early phase of inflammation granulocytes and gamma-delta T-cells ( $T\gamma\delta$ ) are identified in the affected tissues(6). These are believed to be activated by environmental "triggers" [7]. Several cytokines are involved in the event mechanisms. Starting with IL6, produced by antigen presenting cells, which promotes the differentiation towards Th1 cells and IL23, produced by  $T\gamma\delta$  cells that promotes the Th17 differentiation P40 [8, 9]. The central cytokine in the inflammatory process is tumor necrosis factor (TNF) - $\alpha$ , which is produced by virtually all the cells involved. TNF- $\alpha$  subsequently activates the production of other cytokines including IL-6, IL-8, IL-10 and IL-17.

### Epidemiology


BD is a disease that is traditionally associated with countries along the former Silk Road, an ancient route of commerce from the Mediterranean Sea to the Far East (China). In Turkey occurs the highest prevalence: 20-420 cases per 100,000. In Asian countries, such as Japan, Korea, China, Iran and Saudi Arabia, prevalences vary from 13.5 to 20 cases per 100,000. In Western- European countries prevalences ranging from 1-7.5 per 100,000 are reported (figure 2) [10-12].



**Figure 1;** Immunopathophysiology of Behçet's disease

It is assumed that stimulation by pathogens of granulocytes, T $\gamma\delta$  and DCs, in a genetically predisposed host a cascade of inflammatory cytokines eventually lead to vascular damage and vasculitis.

Abbreviations: IL; interleukin, TNF; tumor necrosis factor, T $\gamma\delta$ ; T $\gamma\delta$  subset T cells, Th; CD4 + cells Thelper, DC; dendritic cells



No. of cases per 100.000 inhabitants

**Figure 2:** Prevalences of BD in different countries. Printed with permission from prof. dr. A. Mahr [12]



A remarkable phenomenon often referred to, is a decreasing prevalence of BD after migration. *Zouboulis et al.* presented that the prevalence of BD in a Turkish population decreased after migrating to Germany [13]. The data, however, could not be reproduced by the same group in another study in that was published later in 2012 [14]. A similar observation was presented in 1976 amongst Japanese immigrants on Hawaii. The prevalence of BD in Japan is 7-13.5 per 100,000 whereas the prevalence amongst the Japanese population on Hawaii is reported 0 [15]. However in 1976, about 800,000 inhabitants lived on Hawaii with 13% Japanese immigrants. It can be assumed that at least 13 BD patients of Japanese origin must be living on Hawaii. Such low numbers however, can easily be missed in epidemiological studies. We addressed these issues by identifying all BD patients treated in the Rotterdam postal area. In Chapter 2 we show that the prevalence of BD in the Rotterdam area in three ethnic groups, Dutch, Turkish and Moroccan, is 1, 72 and 35 per 100,000 respectively. This is completely in line with comparable epidemiological studies in other cohorts with similar ethnic background and also with the prevalences of BD in the aforementioned countries. For example, BD amongst the Turkish population in Germany is found to be 72 per 100,000, which is similar to the reported prevalence in the European part of Turkey(14). Additionally, the fact that substantial numbers of our Turkish (up to 20%) and Moroccan patients is born in the Netherlands underlines that environmental circumstances are not decisively dictate the ability to develop BD and does not appear to be involved in the pathogenesis of BD.

The average age in our BD cohort is about forty years and does not differ amongst various ethnicities, while male/ female ratio is lower in Dutch-Caucasians as compared to Moroccans and Turks (Chapter 2) [16, 17]. These variations in male/ female ratios in different ethnic groups are comparable with observations in other cohorts [18, 19]. *Saylan et al* reported female predominance in the United States, the United Kingdom, Korea and China, whereas a male predominance was found for almost all Middle Eastern countries [20]. The cause of the female preference in Western and Asian countries remains unknown. But it is known that low male/ female ratio is often seen in auto-immune diseases. BD, however, is considered be an auto-inflammatory disease which is not associated with female predominance(21, 22). Secondly, underdiagnosing of BD in women in Middle Eastern countries can arguably be explained by the suggestion that women might visit less frequent their physician than men in these regions. Possibly female preference is present all regions, new reliable data is needed to clear this debate.

Relevant differences between ethnic groups in disease features is limited. Surprisingly we encountered a significantly higher percentage skin involvement in our cohort as compared with Germany and Morocco (Chapter 2). We expected to see more skin involvement in countries with high disease prevalence since environmental factors are considered of


great importance. Our data indicates that other factors, such as genetic susceptibility might be of more relevance than environmental factors which is supported by the observations of stable prevalences after migration as described in the first part of Chapter 2.

We also observed a significantly higher prevalence of uveitis in our Western cohort (which consists of Caucasians, Turks and Moroccans) as compared to Turkish and Moroccan cohorts (Chapter 2). Considering the rarity of BD in the Netherlands it can be argued that BD is easily missed in patients presenting with oral ulcers. A relative underdiagnosis of the less severe cases of BD might lead to relatively higher prevalence of severe case with uveitis. Additional education on BD might minimize this effect. This thesis can be used as a starting point for educational purposes in the future, possibly facilitated by the patients associations. An additive reason for the high percentage of uveitis found in the Erasmus MC cohort is the close cooperation between our hospital and the Rotterdam Eye Hospital hence referral of selected patients. Future research can focus on collecting a substantial amount of patient data to elucidate migrational effects on the occurrence and morbidity of BD more robustly.

### Genetics

Over the years it has been widely accepted that there is a genetic component in the etiology of BD. In patients of Turkish origin there is positive family history in 12% of the cases with a sibling risk ratio between 11–52 [4, 14]. The discovery of the association with HLA-B51 has been the first breakthrough, explaining about 20% of the heritability of BD [4, 14]. Over the years numerous single nucleotide polymorphisms (SNP) have been found associated with BD [2, 23–25]. The initial approach of candidate gene selection has been based on clinical similarities with other diseases. The candidate disease for this matter might be CD, both disorders share many symptoms (figure 3).

In this light, specific similar symptoms such as uveitis, arthritis, erythema nodosum and colitis with ileocecal mucosal inflammation and punched-out fissuring ulcers suggest




**Figure 3:** Symptoms of CD and BD

a possible genetic overlap between BD and CD [3, 26]. Since CD has been associated with variations in NOD2 innate immunity, the NOD2/ CARD15 gene, we hypothesized that BD, considering its association with innate immune malfunctioning, might be associated with the same variants [27, 28].

Surprisingly and contrarily at first, we determined a protective association between BD and the NOD2 variants (Chapter 3). In a protective association the variants are significantly less present in the patients as compared to the control group. Previous reports showed no association nor a protective association. A low prevalence of NOD2 variants in Turkish individuals however, was presented previously [29, 30]. Possibly the cohort sizes of the other studies were too limited to detect the protective association. Our observation was confirmed in 2013 by *Kirino et al.* in a targeted resequencing study in Turkish and Japanese individuals [31]. Their study confirmed our results and hypotheses by demonstrating NOD2 variants are associated with a higher risk in CD, but a lower risk on BD. The exact mechanisms of this finding are unclear and have not functionally been tested. In CD both gain of function and loss of function mechanisms are proposed to explain the involvement of NOD2 variants. A loss of function might possibly lead to decreased NF- $\kappa$ B activation and thus reduced defensin production resulting in an increased bacterial load in the gut of CD patients and subsequently an inflammatory response with tissue damage (figure 4b) [32-34]. On top of that, NOD2 activation inhibits stimulation of Toll-like receptors by pathogen products, and as NOD2 function is impaired, TLR signaling is enhanced and generates an exaggerated inflammatory response inducing tissue damage [32, 33].

Another hypothesis is based on the observations in a second model. Here transgenic expression of the Leu1007fs variant show a gain of function, with a direct increase in NF- $\kappa$ B, pro-inflammatory cytokines and tissue damage (figure 4a and 4c) [32]. A potential connection between these paradoxical results lays in the kinetics of the NOD2 response. Normally, acute stimulation of human blood-derived macrophages with the NOD2 agonist, muramyl dipeptide (MDP) induces a pro-inflammatory cytokine response. By comparison, persistent treatment of cells with MDP prior to activation through TLR2 or TLR4 ligands decreases cytokine responses (tolerance), possibly through induction of IRAK-M, in support of control of TLR signaling. However, this tolerance is lost in cells from patients homozygous for the mentioned Leu1007fs homozygous patients leading to higher cytokine levels and more inflammation [35]. As gut epithelial cells, dendritic cells and macrophages are in constant contact with bacterial products of the normal gut flora it is proposed that such tolerance is a protective mechanism, losing this tolerance leads to a failure to control responses and eventually leads to tissue damage as seen in CD [36].

The observation in this thesis that NOD2 variants decrease the risk on developing BD suggest that under continuous or repetitive exogenous stimulation, NOD2 variants in BD



Copyright © 2005 Nature Publishing Group  
Nature Reviews | Immunology

**Figure 4:** Possible mechanisms of Crohn's disease in patients with mutations in CARD15 [32]. *Printed with permission Strober W, Murray PJ, Kitani A, Watanabe T. Signaling pathways and molecular interactions of NOD1 and NOD2. Nature reviews Immunology. 2006;6(1):9-20.*

patients lead in some cases with a decreased production of inflammatory cytokines. Thus patients without this mutation would not be able to control their inflammatory response. This loss of function model is supported by the observation that NOD2 gene-deficient mice show reduced joint inflammation and are protected against early cartilage damage after intra-articular injection of MDP through *Streptococcus pyogenes* cell wall fragments [37].


After some reluctance it is now widely accepted that NOD2 plays a role in the pathophysiology of BD, since the complex role of NOD2 in response to bacterial challenges in different cell types more functional analyses.

As compared to the targeted candidate gene approach, Genome Wide Association Study (GWAS) involve the other spectrum of genetic evaluations in the search for disease modifying variants. In GWAS one assay compares multiple variations (up to 600.000) between patients and controls. Since GWAS results can be confounded by ancestry differences between cases and controls, potentially leading to spurious associations, novel statistical methodology such as Genomic Principal Components (GPC) and Linear Mixed Models (LMM) to correct for these for ancestry differences have been applied. These correct also for family structure and cryptic relationships [38]. In order to gain enough power in these statistical analyses, large cohorts are used to identify possible

associations. In 2010 the first genome-wide association study (GWAS) in BD cohorts of Turkish and Japanese origin demonstrated association of various variants in the known HLA-B51 domain, and two new association signals, mapping to the interleukin-10 (*IL10*), and the IL-23 receptor–IL-12 receptor Beta2 (*IL23R–IL12RB2*) locus [39, 40]. These associations have later been confirmed in an Iranian cohort [41]. Yet another study in Algerian individuals only replicated the associations from the *IL10* variants [42]. GWAS in Chinese and Korean individuals reported associations of SNPs mapping to two other loci, with regions containing the signal transducer and activator of transcription 4 (*STAT4*) and GTPase of immune associated protein *GIMAP* genes, respectively. Polymorphisms in *IL10* and *IL23R–IL12RB2* are not found to be significantly associated with BD in neither of those studies [43, 44]. More recently, associations with *CCR1*, *STAT4* and *KLRC4* were identified by means of imputation and GWAS meta-analysis [45]. This study also identified the *IL12A* region as suggestively associated with BD, but genome wide significance (GWS) was not reached. Discrepant association results, as those observed for variants mapping to the *GIMAP* locus, might be explained by the different ethnic origin of the cohorts studied (46, 47). Therefore, studying cohorts of diverse ethnic background may be useful to understand the origin of these differences. Moreover, the inclusion of multiple ethnicities results in larger datasets (representing higher power) crucial for these analyses given the typically small effects of common genetic variants discovered by the GWAS approach [48]. Enabled by innovative novel methodology as GPC and LMM we could run a GWAS in a rare condition like BD within a unique case collection of multiethnic background (Chapter 3). We identified variants associated with BD mapping to the well-established MICA-HLA-B locus and to two regions on chromosome 6 in the *SLC22A* gene region and on chromosome 18 in an uncharacterized region. Nevertheless, all variants had relatively low MAF (2-3%) and thus their significance must be interpreted with caution. We could not find evidence for replication of the associations in an independent yet underpowered case/control set. Considering the low MAF and the very limited power of the replication further scrutiny in an expanded dataset is required to confirm these variants as real or spurious associations. Yet another GWS association with rs17810546 in the *IL12A* locus was identified by meta-analyses of our results with those reported previously in the literature, Kirino *et al.*, previously labelled this locus as suggestive for association with BD. In that study the variants did not reach GWS in the combined analysis likely due to the variant being monomorphic in the samples of Japanese origin included in the study. Variants in *CCR1–CCR3*, *STAT4* and *KLRC4* which were polymorphic in both Turkish and Japanese populations surpassed GWS thresholds, suggesting that the lower power likely contributed to the non-significant findings in the *IL12A* locus. All together, the common variants across this four loci identified in our study explained up to 32% of the variance in BD risk.

The role of IL12A in the pathophysiology of BD might be explained by its function. IL12 is a heterodimer composed of two chains, IL12A, also commonly known as the P35, and IL12B (or P40) [8, 9]. IL12A (P35) shares homology with other cytokines such as IL6, while IL12B (P40) is one of the chains of another heterodimer, IL23. An important function of IL12 is the promotion of the differentiation of naïve T-cells to Th1 subsets and subsequently the production of IFN- $\gamma$ . BD is considered to be an Th1-cell mediated disease. IL12A variants in a gain of function manner can lead to an overexpression of Th1-cells. Differentiation to Th17 subsets is initiated by IL6 and IL23. IL6 shares homology with IL12A (P35) while one of the dimers of IL23 is IL12B (P40). Possibly IL12A (P35) variants together with yet unidentified variants in IL12A (P35) and IL12B (P40) lead to observed elevated Th17 subsets in BD(49). Moreover, involvement of the IL12 and IL23 pathway is also supported by the identification of variants in the *IL23R-IL12RB2* region in the first GWAS presented in BD [39, 40].

Some variant that have been identified in the last years are involved sensing of pathogens and other variants are more involved in the regulation of the immune system (figure 5) [50]. Potential implications of this hypotheses are that in an early phase of the pathophysiological events a defect in pathogen sensing, mainly the innate immune system must be involved. As a result the immune response is out of balance and the regulation is lost. In this phase several organs can get involved in the disease, even when the initial stimulants is already gone. The pathogenomic pathergy skin prick test would be a reflection of the early phase.



**Figure 5:** Genetic variants involved in the pathogenesis of BD, adapted from Gul A. *Genetics of Behcet's disease: lessons learned from genome-wide association studies*. *Current opinion in rheumatology*. 2014;26(1):56-63. [50]

The next step to unravel the pathogenetics of BD would be a whole genome sequence study in which a complete genome is scanned for variants related to the disease. By analyzing subjects and controls from one family covariants can be filtered out. Our sequence study unfortunately had a low yield in DNA isolation in 3 of the 5 subjects (Chapter 3). The result was a list of 340 genes that possibly are involved in BD. This number is too high for further processing. Future research should therefore focus on whole genome sequencing in families to identify genes that so far could not be linked to BD. Subsequently mechanistic studies are needed to understand the exact effects of the variants such as IL12A and NOD2 and the inflammatory implications in the cytokine cascade in the disease mechanisms. In the next chapter we address the value of measuring these cytokines in BD patients.

### **Cytokines profiles in Behçet's disease**

Apart from the genetic studies in order to identify pathways and target cytokines involved in the pathophysiology of BD we also looked for clues in cytokine levels in BD patients. In the past several cytokines have been linked to the pathophysiology of BD, such as IL12 and IFN- $\gamma$  as traditional Th1 cytokines and more recently IL23 and IL17 [5, 51-53]. Also elevated serum levels of the Th2 cytokine IL10, that normally inhibits the Th1 response, are found in BD patients [54]. Last, but not least, TNF- $\alpha$  that appears to play a central role in many auto-immune and auto-inflammatory disease and also in BD. TNF- $\alpha$  is produced by virtually all cells involved and subsequently activates the production of other cytokines such as IL-1 $\beta$ , IL-6, IL-8, IL-10 and IL-17. Other inflammatory cells are attracted to the inflammation site and contribute to an inflammatory infiltrate.

Most studies in the pathophysiology of BD focussing on cytokine levels concentrate on serum profiles. In Chapter 4 we relate elevated IFN- $\gamma$ , IL-6 and IL-10 levels with active small bowel (SB) involvement in BD. These cytokine profiles however, are not typically Th1 nor Th17 patterns as we would have expected based on the current opinion of the involvement of the Th1 and Th17 axes in the pathophysiology of BD. The increased IL-10 levels could be either part of the pathogenesis of intestinal BD as well as a physiological response on inflammation in these patients. In addition to this, although in both SB-positive and negative BD patients cytokine profiles were measured, immune modulating treatment of the B-positive group might have been more profound and therefore influenced these observations as well as the composition of the blood lymphocyte compartment in our study [55-57]. Since this study population has been limited in size with different types of immunosuppressive treatment between patients it remains difficult to draw any firm conclusions on the clinical use of cytokines and lymphocyte subsets, but IFN- $\gamma$  levels might be of importance.

More interesting are the cytokine levels in affected tissue. Also in Chapter 4 we demonstrate high mRNA expressions of IFN-gamma, TNF- $\alpha$  and IL-17A in affected tissue

of intensively treated patients. As previously mentioned all are key cytokines in BD. In this perspective of the few data available, also in synovial fluids of naïve BD patients a similar Th1 skewed pattern has been demonstrated, it didn't report on IL17A [58]. We know that serum cytokine profiles not always seem to correlate with disease activity and suspect that serum cytokine profiles not always reflect the inflammation on tissue level. We therefore conclude that more data in cytokine profiles on tissue levels in comparison with serum levels is needed. These measurements might have implications on the development and possibly monitoring of targeted therapy in BD.

### New treatment modalities

BD is a disease in which symptoms usually respond well to a wide variety of immunosuppressive therapy. Depending on the severity of the disease and involvement of vital organs immunosuppressives are titrated (table 1).

**Table 1:** Current immunosuppressant treatment used for Behçet's disease

Medication	Dose	Main indications
Prednisone	Local	Uveitis
	Systemic: 0.5 – 1 mg/kg	Mucocutaneous involvement Induction treatment uveitis Neurological involvement Refractory arthritis Gastro-intestinal ulceration
	High apoptotic dose iv: 1g/day, 1-3 times iv	Life-threatening disease, or severe neurological involvement
Colchicine	0.5 - 1.5 mg / day	Skin involvement Arthritis
Dapsone	100 - 200 mg / day	Mucocutaneous involvement Arthritis
Azathioprine	2 - 3 mg / kg / day	Uveitis
Pentoxifylline	1200 mg /day	Mucocutaneous involvement
Sulfasalazine	1- 3 g / day	Mucocutaneous involvement arthritis
Thalidomide	50 - 200 mg / day	Refractory mucocutaneous involvement
Cyclosporine	2 dd 3 - 5 mg/kg / day	Uveitis Mucocutaneous involvement
Methotrexate	7.5 - 15 mg / week	Arthritis Uveitis (rarely)
Cyclophosphamide	750 mg / m <sup>2</sup> /mo IV	Life threatening involvement (vasculitis, neurological)
IFN-α-2a	9 million units /week for 3 months followed by a low maintenance dose of 3 million units /week)	Uveitis
TNF- blockers	Various doses	Uveitis Arthritis Gastro-intestinal ulceration



In Chapter 5 we also present data of a patient that was successfully treated by Myfortic (mycophenolate sodium (MPS)), we feel that MPS can be added to this list, at least for patients with intestinal BD.

Every immunosuppressant has its own, unique, point of action in the pathophysiological events in the inflammatory process in BD. New insights in this pathophysiology with the identification of novel cytokines and pathways by either genetic studies or cytokine studies can therefore be used for the development of new treatment modalities using biological agents (or biologicals). Most biologicals are exerting their effect by blocking, such as for example a key cytokine such as TNF- $\alpha$  [59, 60]. TNF- $\alpha$  blockers are increasingly used and described in refractory BD, particularly in patients with uveitis or colitis [61-66]. Evidence for efficacy of the TNF-blockers infliximab and adalimumab in BD is emerging. We add to this data of for adalimumab in refractory BD patients presented in Chapter 5. Some retrospectively studies already have demonstrated the improvement of clinical symptoms in BD patients treated with adalimumab [66, 67]. Also case-series with adalimumab report major responses of BD-related symptoms [64, 65]. Although studies with BD patients treated with infliximab involve in total 174 patients in 16 publications, limited data with adalimumab is available [64]. Therefore we followed 9 patients with therapy refractory BD that were treated with abalimumab. We observed a 100% response rate, the disappearance of oral ulcers and erythema nodosum, and the possibility to taper or terminate other anti-inflammatory drugs. Our observations are in line with other long term follow-up retrospective BD studies with adalimumab and the long term effects of this TNF- $\alpha$  blocker in other inflammatory diseases [65, 66, 68, 69]. Furthermore, adalimumab appears safe immunosuppressive therapy consistent with other reports of TNF-blockers in BD [60, 64, 70]. The low number of relatively minor adverse effects and its clinical activity implicate that adalimumab is as potent as its intravenous alternative, infliximab. Consensus on the indications for the use of TNF- $\alpha$  blockers, for example using a phenotypic approach; e.g. intestinal BD, ocular BD, as well as data when to stop the therapy is still needed. Future research might focus on these aspects helping treating physicians in the choice and the duration of TNF- $\alpha$  blocking therapy.


By blocking TNF- $\alpha$  a multi-functional cytokine is blocked, while ustekinumab (anti-P40) blocks a more specific pathway, IL23 and IL12. In our GWAS we identified IL12A variants related to BD, furthermore we observed elevated levels of IL17 on tissue level in one of our BD patients. We therefore postulated that blocking P40 might lead to better disease control. We used anti-P40 in a patient with a combination of BD and HS. It proved to be an effective treatment in this case. We feel that cytokines and pathways involved in BD as well as the result in this case support the need for exploration of the effect of anti-P40 in BD.

Only anecdotal data is present on other biologicals such as anti-IL1 (anakinra) or anti-IL6 (tocilizumab), however genetic data and cytokine data suggest a possible positive

effect by blocking the targets of these agents, namely either IL-1 or IL-6. . In the ideal world it would be most efficient if various mechanistic pathways could be blocked simultaneously, however this has so far not been exerted.

### In conclusion

The pathophysiology of BD is complex, both genetic as environmental factors might play a role. In this thesis we have challenged the assumption that the prevalence of BD decreases after migration. Combined with specific apparent ethnical related disease symptoms this might accentuate the importance of the genetic compound in the pathogenesis in BD. We added proof to these increasing insights with the determination of variants of NOD2 and IL12A in patients with BD. Malfunctioning of these genes might be reflected by the cytokine patterns involved in the inflammatory cascade known in BD. The elevated levels of Th1 -as well as Th17 cytokines in in both tissue and serum of patients with active BD, described in Chapter 4 fit in this pattern and suggest that BD is more than a Th1 mediated disease. These findings can help us in the development of new treatment modalities and our understanding of the immunopathophysiology of BD. The key-cytokine in the inflammatory process of BD, TNF- $\alpha$  seems to play a central role (figure 6). Blocking TNF- $\alpha$  as described in Chapter 5 effectively down regulates the



**Figure 6:** Pathophysiology of BD, white boxes show variants or cytokines identified in this thesis related to BD. Blocking P-40 will block Th1 promotion as well as Th17 promotion. Blocking TNF- $\alpha$  will lead to a broader down regulation of the inflammatory response.

inflammatory response. In case of therapy failure or intolerance to TNF-blockers new agents, such as ustekinumab (anti-P40) can secure or even enhance therapeutic efficacy via another inflammatory pathway by blocking the promotion of Th1 production by IL12 as well as blocking the promotion of IL17 production by IL23. Translational research is and will be the cornerstone in the development of new molecular designed drugs, single or combination therapies of monoclonal antibodies that might more effectively block different inflammatory pathways in order to overcome escaping mechanisms.

## REFERENCES

1. Direskeneli H. Autoimmunity vs autoinflammation in Behcet's disease: do we oversimplify a complex disorder? *Rheumatology*. 2006;45(12):1461-5. Epub 2006/09/26.
2. Kappen JH, Wallace GR, Stolk L, Rivadeneira F, Uitterlinden AG, van Daele PL, et al. Low prevalence of NOD2 SNPs in Behcet's disease suggests protective association in Caucasians. *Rheumatology*. 2009;48(11):1375-7. Epub 2009/09/15.
3. Sakane T, Takeno M, Suzuki N, Inaba G. Behcet's disease. *The New England journal of medicine*. 1999;341(17):1284-91. Epub 1999/10/21.
4. Yazici H, Fresko I, Yurdakul S. Behcet's syndrome: disease manifestations, management, and advances in treatment. *Nature clinical practice Rheumatology*. 2007;3(3):148-55. Epub 2007/03/06.
5. Hamzaoui K. Th17 cells in Behcet's disease: a new immunoregulatory axis. *Clinical and experimental rheumatology*. 2011;29(4 Suppl 67):S71-6. Epub 2011/11/02.
6. Neves FS, Spiller F. Possible mechanisms of neutrophil activation in Behcet's disease. *International immunopharmacology*. 2013;17(4):1206-10. Epub 2013/08/27.
7. Verjans GM, van Hagen PM, van der Kooi A, Osterhaus AD, Baarsma GS. Vgamma9Vdelta2 T cells recovered from eyes of patients with Behcet's disease recognize non-peptide prenyl pyrophosphate antigens. *Journal of neuroimmunology*. 2002;130(1-2):46-54. Epub 2002/09/13.
8. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. *Immunity*. 2003;19(5):641-4. Epub 2003/11/15.
9. Watford WT, Hissong BD, Bream JH, Kanno Y, Muul L, O'Shea JJ. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. *Immunological reviews*. 2004;202:139-56. Epub 2004/11/18.
10. DL. K. Intermittent and periodic arthritic syndromes. Baltimore: Williams & Wilkins. 1997.
11. Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behcet's Disease. *Seminars in arthritis and rheumatism*. 1998;27(4):197-217. Epub 1998/03/26.
12. prof. A. Mahr M, PhD. Epidemiology of Behcet's Disease. 16th International conference on Behcet's Disease. 2014;Paris, France.
13. Zouboulis CC, Kotter I, Djawari D, Kirch W, Kohl PK, Ochsendorf FR, et al. Epidemiological features of Adamantiades-Behcet's disease in Germany and in Europe. *Yonsei medical journal*. 1997;38(6):411-22. Epub 1998/03/24.
14. Altenburg A, Mahr A, Maldini C, Kneifel CE, Krause L, Kotter I, et al. [Epidemiology and clinical aspects of Adamantiades-Behcet disease in Gemany. Current data]. *Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft*. 2012;109(6):531-41. Epub 2012/06/16. Epidemiologie und Klinik des Morbus Adamantiades-Behcet in Deutschland. Aktuelle Daten.
15. Hirohata T, Kuratsune M, Nomura A, Jimi S. Prevalence of Behcet's syndrome in Hawaii. With particular reference to the comparison of the Japanese in Hawaii and Japan. *Hawaii medical journal*. 1975;34(7):244-6. Epub 1975/07/01.
16. Önder M GM. The multiple faces of Behçet's disease and its aetiological factors. *J Eur Acad Dermatol Venereol*. 2000;15:126-36.
17. Fauci/Braunwald/Kasper/Hauser. *Harrison's Internal Medicine*. 17 ed: McGraw-Hill Education - Europe; 2008.
18. Seaman G PR. Behcet's Disease manifestation in a population drawn from the UK Behcet's Syndrome Society. Hamza M (ed) *Behcet's Disease*. 1997:196-9.
19. Benamour S NT, Echchilali K. Study of 1034 cases of Behcet's Disease. *Clin Exp Rheumatol*. 2006;24:S13.

20. Saylan T MC, Fresko I, Melikoglu M. Behçet's Disease in the Middle East. *Clin in Dermatol.* 1999;17: 209-23.
21. Geraint James D. Silk Route disease. *Postgraduate Medical Journal.* 1986;62:151-3.
22. Gul A. Behcet's disease as an autoinflammatory disorder. *Current drug targets Inflammation and allergy.* 2005;4(1):81-3. Epub 2005/02/22.
23. Baranathan V, Stanford MR, Vaughan RW, Kondeatis E, Graham E, Fortune F, et al. The association of the PTPN22 620W polymorphism with Behcet's disease. *Annals of the rheumatic diseases.* 2007;66(11):1531-3. Epub 2007/07/31.
24. Touma Z, Farra C, Hamdan A, Shamseddeen W, Uthman I, Hourani H, et al. TNF polymorphisms in patients with Behcet disease: a meta-analysis. *Archives of medical research.* 2010;41(2):142-6. Epub 2010/05/18.
25. Hu K, Yang P, Jiang Z, Hou S, Du L, Li F. STAT4 polymorphism in a Chinese Han population with Vogt-Koyanagi-Harada syndrome and Behcet's disease. *Human immunology.* 2010;71(7):723-6. Epub 2010/05/05.
26. Marshall SE. Behcet's disease. *Best practice & research Clinical rheumatology.* 2004;18(3):291-311. Epub 2004/05/26.
27. Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. *The Journal of biological chemistry.* 2003;278(8):5509-12. Epub 2003/01/07.
28. Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. *The Journal of biological chemistry.* 2003;278(11):8869-72. Epub 2003/01/16.
29. Ahmad T, Zhang L, Gogus F, Verity D, Wallace G, Madanat W, et al. CARD15 polymorphisms in Behcet's disease. *Scandinavian journal of rheumatology.* 2005;34(3):233-7. Epub 2005/09/02.
30. Uyar FA, Saruhan-Direskeneli G, Gul A. Common Crohn's disease-predisposing variants of the CARD15/NOD2 gene are not associated with Behcet's disease in Turkey. *Clinical and experimental rheumatology.* 2004;22(4 Suppl 34):S50-2. Epub 2004/11/02.
31. Kirino Y, Zhou Q, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E, et al. Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 in Behcet disease. *Proceedings of the National Academy of Sciences of the United States of America.* 2013;110(20):8134-9. Epub 2013/05/02.
32. Strober W, Murray PJ, Kitani A, Watanabe T. Signalling pathways and molecular interactions of NOD1 and NOD2. *Nature reviews Immunology.* 2006;6(1):9-20. Epub 2006/02/24.
33. Chamaillard M, Philpott D, Girardin SE, Zouali H, Lesage S, Chareyre F, et al. Gene-environment interaction modulated by allelic heterogeneity in inflammatory diseases. *Proceedings of the National Academy of Sciences of the United States of America.* 2003;100(6):3455-60. Epub 2003/03/11.
34. Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nunez G, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. *Science.* 2005;307(5710):731-4. Epub 2005/02/05.
35. Hedl M, Li J, Cho JH, Abraham C. Chronic stimulation of Nod2 mediates tolerance to bacterial products. *Proceedings of the National Academy of Sciences of the United States of America.* 2007; 104(49):19440-5. Epub 2007/11/23.
36. Abreu MT, Fukata M, Arditi M. TLR signaling in the gut in health and disease. *Journal of immunology.* 2005;174(8):4453-60. Epub 2005/04/09.

37. Joosten LA, Heinhuis B, Abdollahi-Roodsaz S, Ferwerda G, Lebourhis L, Philpott DJ, et al. Differential function of the NACHT-LRR (NLR) members Nod1 and Nod2 in arthritis. *Proceedings of the National Academy of Sciences of the United States of America*. 2008;105(26):9017-22. Epub 2008/06/25.
38. Price AL, Zaitlen NA, Reich D, Patterson N. New approaches to population stratification in genome-wide association studies. *Nature reviews Genetics*. 2010;11(7):459-63. Epub 2010/06/16.
39. Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet's disease. *Nature genetics*. 2010;42(8):698-702. Epub 2010/07/14.
40. Mizuki N, Meguro A, Ota M, Ohno S, Shiota T, Kawagoe T, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet's disease susceptibility loci. *Nature genetics*. 2010;42(8):703-6. Epub 2010/07/14.
41. Xavier JM, Shahram F, Davatchi F, Rosa A, Crespo J, Abdollahi BS, et al. Association study of IL10 and IL23R-IL12RB2 in Iranian patients with Behcet's disease. *Arthritis and rheumatism*. 2012;64(8):2761-72. Epub 2012/03/02.
42. Khaib Dit Naib O, Aribi M, Idder A, Chiali A, Sairi H, Toutitou I, et al. Association Analysis of IL10, TNF-alpha, and IL23R-IL12RB2 SNPs with Behcet's Disease Risk in Western Algeria. *Frontiers in immunology*. 2013;4:342. Epub 2013/10/24.
43. Hou S, Yang Z, Du L, Jiang Z, Shu Q, Chen Y, et al. Identification of a susceptibility locus in STAT4 for Behcet's disease in Han Chinese in a genome-wide association study. *Arthritis and rheumatism*. 2012;64(12):4104-13. Epub 2012/09/25.
44. Lee YJ, Horie Y, Wallace GR, Choi YS, Park JA, Song R, et al. Genome-wide association study identifies GIMAP as a novel susceptibility locus for Behcet's disease. *Annals of the rheumatic diseases*. 2012. Epub 2012/10/09.
45. Kirino Y, Bertsias G, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E, et al. Genome-wide association analysis identifies new susceptibility loci for Behcet's disease and epistasis between HLA-B\*51 and ERAP1. *Nature genetics*. 2013;45(2):202-7. Epub 2013/01/08.
46. Lee YJ, Horie Y, Wallace GR, Choi YS, Park JA, Choi JY, et al. Genome-wide association study identifies GIMAP as a novel susceptibility locus for Behcet's disease. *Annals of the rheumatic diseases*. 2013;72(9):1510-6. Epub 2012/10/09.
47. Ortiz-Fernandez L, Conde-Jaldon M, Garcia-Lozano JR, Montes-Cano MA, Ortego-Centeno N, Castillo-Palma MJ, et al. GIMAP and Behcet disease: no association in the European population. *Annals of the rheumatic diseases*. 2014. Epub 2014/03/15.
48. McCarthy MI, Hirschhorn JN. Genome-wide association studies: potential next steps on a genetic journey. *Human molecular genetics*. 2008;17(R2):R156-65. Epub 2008/10/15.
49. Rich RR. *Clinical immunology : principles and practice*. St. Louis, Mo.: Mosby-Year Book; 1996.
50. Gul A. Genetics of Behcet's disease: lessons learned from genomewide association studies. *Current opinion in rheumatology*. 2014;26(1):56-63. Epub 2013/11/22.
51. Zhou ZY, Chen SL, Shen N, Lu Y. Cytokines and Behcet's disease. *Autoimmunity reviews*. 2012;11(10):699-704. Epub 2011/12/27.
52. Guenane H, Hartani D, Chachoua L, Lahlou-Boukoffa OS, Mazari F, Touil-Boukoffa C. [Production of Th1/Th2 cytokines and nitric oxide in Behcet's uveitis and idiopathic uveitis]. *Journal francais d'ophtalmologie*. 2006;29(2):146-52. Epub 2006/03/09. Production des cytokines Th1/Th2 et du monoxyde d'azote au cours de l'uveite "Behcet" et de l'uveite "idiopathique".
53. Belguendouz H, Messaoudene D, Hartani D, Chachoua L, Ahmedi ML, Lahmar-Belguendouz K, et al. [Effect of corticotherapy on interleukin-8 and -12 and nitric oxide production during Behcet

- and idiopathic uveitis]. *Journal francais d'ophtalmologie*. 2008;31(4):387-95. Epub 2008/06/20. Effet de la corticothérapie sur la production des interleukines 8, 12 et du monoxyde d'azote au cours des uveites Behcet et idiopathique.
54. Ben Ahmed M, Houman H, Miled M, Dellagi K, Louzir H. Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behcet's disease. *Arthritis and rheumatism*. 2004;50(7):2291-5. Epub 2004/07/13.
  55. Misumi M, Hagiwara E, Takeno M, Takeda Y, Inoue Y, Tsuji T, et al. Cytokine production profile in patients with Behcet's disease treated with infliximab. *Cytokine*. 2003;24(5):210-8. Epub 2003/11/05.
  56. Snyder MR, Weyand CM, Goronzy JJ. The double life of NK receptors: stimulation or co-stimulation? *Trends in immunology*. 2004;25(1):25-32. Epub 2003/12/31.
  57. Ahn JK, Seo JM, Yu J, Oh FS, Chung H, Yu HG. Down-regulation of IFN-gamma-producing CD56+ T cells after combined low-dose cyclosporine/prednisone treatment in patients with Behcet's uveitis. *Investigative ophthalmology & visual science*. 2005;46(7):2458-64. Epub 2005/06/28.
  58. Canete JD, Celis R, Noordenbos T, Moll C, Gomez-Puerta JA, Pizcueta P, et al. Distinct synovial immunopathology in Behcet disease and psoriatic arthritis. *Arthritis research & therapy*. 2009; 11(1):R17. Epub 2009/02/07.
  59. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. EULAR recommendations for the management of Behcet disease. *Annals of the rheumatic diseases*. 2008;67(12):1656-62. Epub 2008/02/05.
  60. Sfikakis PP, Markomichelakis N, Alpsoy E, Assaad-Khalil S, Bodaghi B, Gul A, et al. Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations. *Rheumatology*. 2007;46(5):736-41. Epub 2007/04/04.
  61. Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behcet's syndrome with chimeric tumour necrosis factor alpha antibody. *Gut*. 2001;49(5):725-8. Epub 2001/10/16.
  62. Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: a case report. *Gastroenterology*. 2001;120(4):995-9. Epub 2001/03/07.
  63. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. *Lancet*. 2001;358(9278):295-6. Epub 2001/08/11.
  64. Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behcet's disease: analysis of published data on 369 patients. *Seminars in arthritis and rheumatism*. 2011;41(1):61-70.
  65. Calvo Catala J, Campos Fernandez C, Rueda Cid A, Gonzalez-Cruz Cervellera MI, Baixauli Rubio A, Pastor Cubillo MD. [Efficacy of adalimumab in Behcet's disease. Description of 6 cases] Eficacia del adalimumab en la enfermedad de Behcet: descripcion de 6 casos. *Reumatol Clin*. 2011;7(4): 258-61. Epub 2011/07/29.
  66. Perra D, Alba MA, Callejas JL, Mesquida M, Rios-Fernandez R, Adan A, et al. Adalimumab for the treatment of Behcet's disease: experience in 19 patients. *Rheumatology (Oxford)*. 2012;51(10): 1825-31. Epub 2012/06/23.
  67. van Laar J, Misotten T, van Daele P. Adalimumab: a new modality for Behcet's disease? . *Annals of the rheumatic diseases*. 2007(66):565-6.
  68. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. *Annals of the rheumatic diseases*. 2013;72(4):517-24. Epub 2012/05/09.

69. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. The Cochrane database of systematic reviews. 2008(1):CD006893. Epub 2008/02/07.
70. Handa T, Tsunekawa H, Yoneda M, Watanabe D, Mukai T, Yamamura M, et al. Long-term remission of ocular and extraocular manifestations in Behcet's disease using infliximab. Clin Exp Rheumatol. 2011;29(4 Suppl 67):S58-63. Epub 2011/11/02.



# 7

## Appendix



## SUMMARY

Behçet's disease (BD) is an multifactorial auto-inflammatory vasculitis characterized by recurrent oral -and genital ulcers, uveitis, and skin lesions. The first series of patients with BD was already published in 1937 as a triad of these symptoms. Less frequently, involvement of the gastrointestinal tract, central nervous system and large vessels may occur. As in other immune mediated disorders BD is characterized by attacks rather than by a persistent inflammatory symptoms. Cases of BD cluster along the ancient Silk Road, which extends from eastern Asia to the Mediterranean basin. The reported prevalence in Turkey varies between 70 and 420 per 100.000. In Northern European countries however, the prevalence is probably less than 1 per 100.000 in Caucasians. It is believed that both genetic and environmental factors contribute to the development of the disease. Men might be more frequently and severely affected than women Susceptibility to BD is strongly associated with the presence of the HLA-B51 allele and its presence is also strongly associated with a more aggressive course. The cause of BD, however, is still unknown. Triggers such as infections, both viral and bacterial, trauma, and other stress factors may play a role in the inflammatory process.

Although the exact pathophysiology of BD remains to be elucidated, it is clear that neutrophils interacting with T-cells play an important role. Activated T-cells produce TNF- $\alpha$ , leading to production of other proinflammatory cytokines like IL1 and IL6. These proinflammatory cytokines stimulate migration and activation of leucocytes, thereby causing a local inflammatory response. In this thesis translational aspects of BD on areas of epidemiology, genetics, cytokines and new treatment modalities will be linked with these immuno-pathophysiological features.

In **Chapter 2** it is argued that the prevalence of BD, contrary to the general assumption, doesn't decrease after migration. Also we correlate specific disease features to ethnical background. Prevalences of BD in the Rotterdam area differed per ethnicity; 1, 71 and 39 per 100.000 for Dutch-Caucasians, Turks, and Moroccans, respectively. These figures are similar to other cohorts in countries where BD prevails. The first epidemiologic study of BD in the Netherlands initiated by the Erasmus MC demonstrates, in 110 patients no significant differences in morbidity between ethnic groups. However, uveitis and pustules were significantly more present in the EMC cohort as compared to UK, German, Turkish and Moroccan cohorts.

The heritability of BD has been estimated to range between 20 to 60%, with the strongest genetic association embracing variants in HLA-B51, explaining about 20% of the disease heritability. The combination of epidemiological and genetic data suggest causal involvement of both genetic and environmental factors. In **Chapter 3** we demonstrate that some genetic variations are protective and others are associated with a higher risk on BD. We also demonstrate that it is possible to run a GWAS in a rare condition like BD in

a cohort of multi-ethnic background. In patients of Turkish origin there is positive family history in 12% of the cases with a sibling risk ratio between 11–52 .

Over the years numerous single nucleotide polymorphisms (SNPs) have been found associated with BD. We are the first to identify a protective association with NOD2 variants. In 2010 the first genome-wide association study (GWAS) in BD cohorts of Turkish and Japanese origin demonstrated association of various variants in the known HLA-B51 domain, and two new association signals, mapping to the interleukin-10 (IL10), and the IL-23 receptor–IL-12 receptor Beta2 (IL23R–IL12RB2) locus. Other associations identified in GWAS are signal transducer and activator of transcription 4 (STAT4), GTPase of immune associated protein GIMAP genes, CCR1, STAT4 and KLRC4.

We ran a GWAS on 336 BD cases and 5,843 controls. The cases consisted of Western Europeans, Middle Eastern and Turkish individuals. Participants from the Generation R study, a multiethnic birth cohort in Rotterdam, The Netherlands were used as controls. Linear regression models were corrected for population stratification using Genomic Principal Components and Linear Mixed Modelling. Meta-analysis was performed on selected results previously published. We identified SNPs associated at genome-wide significant (GWS) level mapping to the 6p21.33 (HLA) region. In addition to this known signal two potential novel associations on chromosomes 6 and 18 were identified, yet with low minor allele frequencies. Extended meta-analysis reveal a GWS association with the IL12A variant rs17810546 on chromosome 3.

In **Chapter 4** we show that cytokine profiles in affected tissue seem to be more relevant than serum cytokine profiles. The central cytokine in the inflammatory process in BD is tumor necrosis factor (TNF)  $\alpha$ , which is produced by virtually all the cells involved. TNF- $\alpha$  subsequently activates the production of other cytokines such as interleukin (IL)  $1\beta$ , IL-6, IL-8, IL-10 and IL-17. Other inflammatory cells are attracted to the inflammation site and contribute to an inflammatory infiltrate.

We demonstrate that in patients with small bowel (SB) BD IFN- $\gamma$ , IL-6 and IL-10 were significantly higher in patients with SB lesions than those without. It does not reflect a typical Th1 nor Th17 cytokine profile. Elevated IL-10 could be part of the pathogenesis of intestinal BD as well as a normal response on inflammation. More interestingly are the cytokine levels in affected tissue. We present a case of an intensively treated patient with high mRNA expression of IFN-gamma, TNF-alpha and IL-17A, that appear to be key cytokines in BD. To therapeutically target such key-enzymes can be achieved by novel (molecular designed) drugs.

Finally in **Chapter 5** we present the results of such innovative treatment modalities. We start with the successful use of mycophenolate sodium up front biologicals in a BD patient with ileo-colitis, refractory to corticosteroid- or AZA-therapy. Secondly we describe a patient with the combination of BD, psoriasis and hydradenitis suppurativa. This case is the first in which these three diseases were simultaneously present. In addition,

our case is the first BD patient reported that was effectively treated with ustekinumab. These reports add to few available data about the use of mycophenolates sodium and ustekinumab and supply evidence to boost the armamentarium in BD.

Finally, we present data of a study of TNF- $\alpha$  blockage (Adalimumab). The effect of bi-weekly 40mg adalimumab in 9 patients with therapy refractory BD was studied during 6 months. The disease activity scored by the BD Current Activity Form (BDCAF) improved significantly in all patients from 5.4 to 2.4 ( $p = 0.007$ ) within 1 month and improvement lasted the entire observation period so that 8 patients could either taper or stop concomitant therapy. Symptoms of mucocutaneous lesions, erythema nodosum and joint involvement decreased or completely disappeared. These data on patients with refractory BD treated with adalimumab provide a basis for its use in refractory mucocutaneous BD.

In **chapter 6** we discuss the implications of our results and give our view on future research. We conclude that the pathophysiology of BD is complex, both genetic as environmental factors might play a role and that translational research is the fundament in the development of new molecular designed drugs, single or combination therapies of monoclonal antibodies that might more effectively block different inflammatory pathways in order to overcome escaping mechanisms.

## NEDERLANDSE SAMENVATTING

De ziekte van Behçet (BD) is een multi-factoriele (auto)inflammatoire vasculitis die vooral voorkomt bij mensen uit landen van de Middellandse Zee gebied en langs de voormalige zijderoute naar het Verre Oosten. De symptomen bestaan uit spontane fluctuerende orale en genitale afteuze laesies, uveïtis en diverse huidaandoeningen. Bijkomende inflammatoire manifestaties kunnen zich uiten in colitis, urethritis, steriele meningitis en vaso-occlusie. In de vijfde eeuw voor Christus werden symptomen al door Hippocrates beschreven, maar pas in 1937 werd de ziekte vernoemd naar de Turkse dermatoloog Hulusi Behçet. In Turkije is ook de hoogste prevalentie: 70 tot 420 patiënten per 100.000 inwoners. In Noord- Europese landen is de prevalentie rond de 1 per 100.000 inwoners en neemt de laatste jaren toe door de veranderende bevolkingsamenstelling. De associatie met HLA-B51 positiviteit suggereert een genetische component in de etiologie. BD wordt het meest gediagnosticeerd in de derde levensdecade en de ziekte lijkt vaker voor te komen bij mannen dan bij vrouwen.

De exacte pathofysiologie van BD moet nog worden opgehelderd, de interactie tussen neutrofielen en T-cellen lijkt in ieder geval een belangrijke rol te spelen. Geactiveerde T-cellen produceren TNF- $\alpha$ , wat leidt tot de productie van andere pro-inflammatoire cytokines zoals IL1 en IL6. Deze pro-inflammatoire cytokines stimuleren migratie en activatie van leukocyten, waardoor een lokale ontstekingsreactie wordt veroorzaakt.

In dit proefschrift worden translationele aspecten van BD gepresenteerd op het gebied van epidemiologie, genetica, cytokines en nieuwe behandelmodaliteiten.

In **hoofdstuk 2** wordt de veronderstelling dat de prevalentie van BD afneemt na migratie ter discussie gesteld. Verder wordt de ziekte presentatie van BD in een cohort in Rotterdam beschreven. Prevalentie van BD in de regio Rotterdam verschilt per etniciteit; 1, 71 en 39 per 100.000 voor Nederlanders, Turken en Marokkanen, respectievelijk. Deze cijfers zijn gelijk aan andere cohorten uit West-Turkije en Marokko. Binnen het Erasmus MC cohort van 110 patiënten zijn geen significante verschillen in morbiditeit tussen de etnische groepen gevonden. Maar uveïtis en pustels zijn significant meer aanwezig in het EMC-cohort in vergelijking met Britse, Duitse, Turkse en Marokkaanse cohorten.

Bij patiënten van Turkse afkomst is er een positieve familiegeschiedenis in 12% en een "sibbling risk ratio" van 11-52. De erfelijkheid van BD is naar schatting tussen 20 tot 60%, met als sterkste genetische associatie met HLA-B51. In **hoofdstuk 3** laten we zien dat sommige genetische varianten beschermend en andere een risico voor de ontwikkeling van BD kunnen zijn. In de loop der jaren zijn tal van single nucleotide polymorfismen (SNP's) geassocieerd met BD. Als eerste presenteerden wij dat er ook een beschermende associatie bij BD was, namelijk met NOD2 varianten. De eerste Genome Wide Association Study (GWAS) in Turkse en Japanse BD cohorten in 2010 lieten de bekende varianten in het HLA-B51 domein zien. Daarnaast ware er twee nieuwe signalen, de eerste in inter-

leukine-10 (IL-10), en de tweede in IL-23 receptor IL-12 receptor beta2 (IL23R-IL12RB2) locus. Later zijn in GWAS studies ook relaties tussen BD en andere varianten gevonden; signal transducer and activator of transcription 4 (STAT4), GTPase of immune associated protein (GIMAP), CCR1, STAT4 en KLRC4. Wij presenteren een GWAS met 336 BD patiënten en 5843 controles. De patiënten groep bestond uit West-Europeanen, Midden-Oosten en de Turken. Het Generation R cohort, een multi-etnische geboortecohort in Rotterdam, werd gebruikt als controle groep. Genomic Principal Components en Linear Mixed Modelling zijn gebruikt voor dataverwerking. Meta-analyse werd uitgevoerd op geselecteerde resultaten eerder gepubliceerd. We identificeerden SNPs in het bekende 6p21.33 (HLA) regio, daarnaast worden twee potentiële nieuwe associaties op chromosomen 6 en 18 werden geïdentificeerd, maar met lage minor allel frequenties. Een meta-analyse laat een significante associatie met de IL12A variant rs17810546 op chromosoom 3 zien.

In **hoofdstuk 4** stellen we dat cytokines in weefsel meer relevant zijn dan cytokines in serum. Tumornecrosefactor (TNF) - $\alpha$  speelt een centrale rol in het ontstekingsproces in BD, het wordt door vrijwel alle betrokken cellen geproduceerd. TNF- $\alpha$  activeert vervolgens de productie van andere cytokinen zoals interleukine (IL) -1 $\beta$ , IL-6, IL-8, IL-10 en IL-17. Andere inflammatoire cellen worden aangetrokken naar het ontstoken weefsel en vormen een ontstekingsinfiltraat.

We laten zien dat bij patiënten met dunne darm betrokkenheid IFN- $\gamma$ , IL-6 en IL-10 significant zijn verhoogd. Het zijn echter niet typische Th1 of Th17 profielen. Het verhoogde IL-10 kan onderdeel zijn van de pathogenese van intestinale BD maar het kan ook een normale reactie op ontsteking zijn. Aangezien het aantal patiënten in de studie beperkt is, blijft het moeilijk om definitieve conclusies te trekken over de betrokken en het klinisch gebruik van cytokines.

Relevanter lijken de cytokine niveaus in aangetast weefsel. We presenteren een casus van een intensief behandelde patiënt met hoge mRNA expressie van IFN-gamma, TNF- $\alpha$  en IL-17A.

In **hoofdstuk 5** presenteren we mogelijk nieuwe behandelingen. We laten zien dat mycophenolate sodium een toevoeging is aan de immuunsuppressiva die bij BD gebruikt kunnen worden, met name bij intestinale BD. Verder hebben wij een casus van een patiënt met BD in combinatie met psoriasis en hydradenitis suppurativa. Het is voor het eerst dat deze drie ziekten gelijktijdig worden beschreven in een patiënt. Daarnaast is het de eerste BD patiënt die effectief werd behandeld met ustekinumab (anti P40).

Tot slot, presenteren we een serie patiënten die TNF- $\alpha$  blokkade (Adalimumab) hebben gehad. Het effect van tweewekelijkse 40 mg adalimumab bij 9 patiënten met refractaire BD therapie werd gedurende 6 maanden bestudeerd. De ziekte activiteit, gemeten met de BDAF verbeterde significant bij alle patiënten van 5,4 (SD = 1,4) naar 2,4 (SD = 1,4;  $p = 0,007$ ). De verbetering was binnen 1 maand zichtbaar en was stabiel tijdens de

gehele observatieperiode. Symptomen van mucocutane laesies, erythema nodosum en gezamenlijke betrokkenheid verminderd of geheel verdwenen.

In **hoofdstuk 6** bespreken we de implicaties van onze resultaten en geven onze visie op toekomstig onderzoek. Concluderend is de pathofysiologie van BD complex, zowel genetische als omgevingsfactoren spelen een rol. Translationeel onderzoek is het fundament voor de ontwikkeling van nieuwe moleculaire geneesmiddelen, mono- of combinatietherapieën van monoklonale antilichamen die effectief verschillende inflammatoire pathways blokkeren.



## DANKWOORD

Wat is onderzoek doen ongelooflijk leuk en wat jammer dat het af is. Ik heb in de afgelopen jaren veel unieke kansen gehad om deel te nemen in het onderzoek naar de oorzaak en mechanismes van de ziekte van Behçet. Tijdens dat onderzoek heb ik veel inspirerende en motiverende mensen mogen ontmoeten. Zij hebben allemaal op hun eigen manier bijgedragen aan dit proefschrift. Iedereen wil ik bedanken maar een aantal mensen wil ik graag apart noemen.

Professor van Hagen en dr van Laar; Beste Martin en Jan, onze samenwerking begon om 10:00 op vrijdagochtend 11 november 2005 naar aanleiding van een mail die ik had gestuurd. Ik wilde wel een beetje onderzoek doen naast mijn studie, bij voorkeur klinisch maar het mocht ook wat anders zijn. Behçet werd het. Het onderzoek begon met een aftastende fase van de BDCAF, een tool die jullie nog steeds gebruiken. Vervolgens leidde mijn afstuderen tot deze promotie. Jullie onvoorwaardelijke vertrouwen en steun heeft mij een kans gegeven om het onderzoek zelf te ontplooiën in mijn eigen tempo. Ik besef hoe uniek dit is en kan jullie hier niet genoeg voor bedanken. Ik heb mogen leren van jullie enorme kennis en ervaring. Daarnaast is er ook nog die persoonlijke click, het waren mooie congressen. Ik hoop en vertrouw er op dat we elkaar nog vaak tegenkomen.

Ook in deze beginperiode van mijn onderzoek ontmoete ik Professor Laman. Beste Jon, jij hebt samen met Jan mijn afstudeeronderzoek bedacht. Ik waardeer je enorme kennis en drive. Altijd was bereid tot antwoord of feedback als ik met lange tussenposen weer eens een vraag stelde; meestal begonnen mijn mailtjes met "Beste Jon, even een korte vraag...". Ze waren natuurlijk nooit kort. Ik vind het fantastisch dat je vandaag onderdeel bent van de commissie.

Dr Graham Wallace, we met in Portugal and a couple of months later you visited the Netherlands to discuss several possibilities of collaboration. I always admire your enthusiasm and drive as well as your incredible knowledge. We met with regular intervals at conferences and it was always a pleasure. Your support of our genetic research made our candidate approach and our GWAS study possible.

Fernando, veel geleerd, altijd ben je bereid om te helpen ook al staat je agenda dat niet altijd toe. Toch mocht ik altijd even tussendoor. De GWAS paper is de kroon op dat werk. Wat een ontzettende eer dat je plaats hebt genomen in mijn commissie.

Lisette, het begon met NOD en zie waar we nu staan. Jij een aantal Nature papers later en al lang gepromoveerd. In totaal 4 kinderen verder (jullie twee, wij twee). Ik wens je alle goeds, van harte.

Carolina, it must have been frustrating for you, trying to explain these statistics to me. I wish you all the best in the finalization of your PhD.

Paul, vaste kamergenoot van Jan. We hebben elkaar de afgelopen jaren goed leren kennen. Ik bewonder je kennis en doorzettingsvermogen, nu nog even Rotterdam lopen. Ook wij gaan elkaar hopelijk nog vaak tegen komen.

Nico, vanaf 2003 zijn we gezamenlijk betrokken bij een aantal projecten in India en zitten samen in Stichting Childtuitioen. In een moeilijk fase van mijn onderzoek ben jij bereid geweest om ons te steunen. Hierdoor hebben wij als eerste in een Westers land een groot genetisch onderzoek in dit ziektebeeld kunnen uitvoeren. Ik wil je daar hartelijk voor bedanken.

Kiki en Serge, wat fantastisch dat jullie mijn paranimfen willen zijn. We wisten allemaal niet precies wat het inhield, vooral een ceremoniele functie vertelde de folder. Serge, nog uit Delft, samen gewoond, samen gelopen en samen een biertje gedronken. Ik hoop dat we dat nog lang volhouden, dat biertje dan. Kiki, samen begonnen als afwijkend in de collegezaal, samen onderzoek bij de immunologie. Jij wordt wel internist. Succes met jouw laatste loodjes.

En dan is er natuurlijk de afdeling longgeneeskunde in het SFG. Wat een fantastische plek om opgeleid te worden. Elke dag leer ik en elke dag lach ik.

Lieve papa en mama, zonder jullie was ik er natuurlijk niet geweest maar zonder jullie was ik vooral niet de persoon geworden die ik nu ben. Elk raar idee dat ik in het verleden had, hebben jullie gesteund, altijd stonden jullie klaar, en nog steeds. Ik hoop dat die onvoorwaardelijk steun ook erfelijk is en dat ik dat ook, al is het maar een beetje, heb. Eelco, Sandra, Lisa, Tijn, Lies, Frits, Nannie, Leon, Jasper, Ellen, Cathelijne en Vera, zonder het te weten hebben jullie ook bijgedragen aan dit proefschrift. Zo af en toe vragen hoe het ging, "ben je eigenlijk nog aan het promoveren?" Het stimuleerde elke keer weer.

Als laatste, Floor, Joris en Rosa, voor jullie geldt stuk voor stuk;

*"ik draag je hart met me mee (ik draag het in mijn hart)  
 ik heb het altijd bij me (waar ik ga, daar ga jij en alles wat ik doe doe ik om jou)  
 Ik vrees mijn lot niet (want jij bent mijn lot)  
 ik wil de wereld niet (want mooi ben jij, mijn wereld, mijn ware)  
 en jij bent het, jij bent wat de maan altijd heeft bedoeld  
 en wat de zon steeds weer zal zingen dat ben jij"*

E.E. Cummings

Dan wil ik eindigen met de woorden waarmee elke voordracht eindigt; More research is needed, heel graag!

## BIOGRAFIE

Jasper Henk Kappen is op 29 januari 1971 in Eindhoven geboren. Hij is opgegroeid in Uden, Noord-Brabant, waar hij in 1989 zijn VWO diploma behaalde aan het Rivendell College. Ruim 6 jaar later in 1995 studeerde hij af aan de faculteit Scheikundige Technologie van de Technische Universiteit Delft. Hierna is hij als technoloog en logistiek manager werkzaam geweest bij DSM om vervolgens een aantal jaar als vrijwilliger voor Artsen Zonder Grenzen (Afghanistan) en Maharogi Sewa Samiti (India) te werken. Eenmaal terug in Nederland is hij gestart met de studie geneeskunde aan het Erasmus MC in Rotterdam. Inmiddels is hij in het Sint Franciscus Gasthuis bezig met zijn specialisatie tot longarts.

Hij is getrouwd met Floor Grevink en samen hebben zij een zoon, Joris, en een dochter, Rosa.



## LIST OF PUBLICATIONS

Mycophenolate sodium: effective treatment for therapy-refractory intestinal Behçet's disease, evaluated with enteroscopy. **Kappen JH**, Mensink PB, Lesterhuis W, Lachman S, van Daele PL, van Hagen PM, van Laar JA.

Am J Gastroenterol. 2008 Dec;103(12):3213-4. doi: 10.1111/j.1572-0241.2008

Low prevalence of NOD2 SNPs in Behçet's disease suggests protective association in Caucasians. **Kappen JH**, Wallace GR, Stolk L, Rivadeneira F, Uitterlinden AG, van Daele PL, Laman JD, Kuijpers RW, Baarsma GS, Stanford MR, Fortune F, Madanat W, van Hagen PM, van Laar JA.

Rheumatology (Oxford). 2009 Nov;48(11):1375-7.

Managing Behçet's disease: An update on current and emerging treatment options. van Daele PL, **Kappen JH**, van Hagen PM, van Laar JA.

Ther Clin Risk Manag. 2009 Apr;5(2):385-90.

Do synovial biopsies help to support evidence for involvement of innate immunity in the immunopathology of Behçet's disease? van Laar JA, **Kappen JH**, van Daele PL, van Hagen PM.

Arthritis Res Ther. 2009;11(2):109.

Cytokines in the colon of a patient with Behçet's disease. **Kappen JH**, Dik WA, Dingjan GM, van Daele PL, Hooijkaas H, van Hagen PM, van Laar JA.

Arthritis Res Ther. 2009;11(4):412.

Successful long-term triple disease control by ustekinumab in a patient with Behçet's disease, psoriasis and hidradenitis suppurativa. Baerveldt EM, **Kappen JH**, Thio HB, van Laar JA, van Hagen PM, Prens EP.

Ann Rheum Dis. 2013 Apr;72(4):626-7

Glucocorticoid sensitivity in Behçet's disease. Quax RA, van Laar JA, van Heerebeek R, Greiner K, Ben-Chetrit E, Stanford M, Wallace GR, Fortune F, Ghabra M, Soylyu M, Hazes JM, Lamberts SW, **Kappen JH**, van Hagen PM, Koper JW, Feelders RA.

Endocr Connect. 2012 Oct 24;1(2):103-11

Genome-wide association study in an admixed case series reveals IL12A as a new candidate in Behçet disease. **Kappen JH**, Medina-Gomez C, van Hagen PM, Stolk L., Estrada K, Rivadeneira F, Uitterlinden AG, Stanford MR, Ben-Chetrit E, Wallace GR, Soylyu M, van Laar JAM

PLoS One. 2015 Mar 23;10(3):e0119085

Behçet's disease, prevalence and symptoms in the Rotterdam area. **Kappen J.H.**, van Dijk E.H.C., Baak-Dijkstra M., Lam Tse W., van Hagen P.M., van Laar J.A.M.

*Submitted*

Detection of intestinal Behçet's disease by double balloon enteroscopy combined to serum cytokine profiles; improved diagnostic yield? **J.H. Kappen**, MD, MSc, P.B.F. Mensink, MD, PhD, W.A. Dik, PhD; H. Hooijkaas, PhD; S. Lachman, MD; P.L.A. van Daele MD, PhD; P.M. van Hagen, MD, PhD; J.A.M. van Laar, MD, PhD.

*Submitted*

Adalimumab treatment in refractory mucocutaneous Behçet's Disease: An observational case series. Diana M. Verboom, **Jasper H. Kappen**, Willem A. Dik, Marianne W. van der Ent, Paul L.A. van Daele, P. Martin van Hagen, Jan A.M. van Laar

*Submitted*

Nieuwe ontwikkelingen in de Medische Immunologie 2010 Chapter 16: "Ziekte van Behçet" ISBN 978-90-73436-91-6. Jan AM van Laar, P. Martin van Hagen, **Jasper H Kappen**.

## PhD PORTFOLIO

<b>Name PhD student:</b>	Jasper Henk Kappen
<b>Erasmus MC department</b>	Internal medicine, section clinical immunology
<b>Promotor</b>	Prof. Dr. P.M. van Hagen
<b>Co-promotor</b>	Dr. J.A.M. van Laar

### Conferences and courses

- Second European Workshop on Immune-Mediated Inflammatory Diseases, 2007, Nurnberg, Germany
- Third European Workshop on Immune-Mediated Inflammatory Diseases, 2008, London, United Kingdom
- Fourth European Workshop on Immune-Mediated Inflammatory Diseases, 2009, Cascais, Portugal
- New Frontiers symposium, 2009, Radboud University, Nijmegen The Netherlands

### Conference presentations

- 12th International Conference on Behcet's Disease, 2006, Portugal, Lisbon (Poster)
- Second European Workshop on Immune-Mediated Inflammatory Diseases, 2007, Nurnberg, Germany (Poster presentation)
- Wetenschapsdagen Interne Geneeskunde EMC, 2008, (Poster presentation, second prize)
- 13th International Conference on Behcet's Disease, 2008, Poertschach/Klagenfurt, Austria. (Oral presentation)
- Third European Workshop on Immune-Mediated Inflammatory Diseases, 2008, London, United Kingdom (Poster presentation)
- Fourth European Workshop on Immune-Mediated Inflammatory Diseases, 2009, Cascais, Portugal (Poster presentation)
- Wetenschapsdagen Interne Geneeskunde EMC, 2008, (Poster presentation)
- Minder frequent voorkomende ontstekingsziekten: state of the art, 2009, Rotterdam, Netherlands (Oral presentation)
- 14th International Conference on Behcet's Disease, 2010, London, United Kingdom (Poster presentation)
- Wetenschapsdagen Interne Geneeskunde EMC, 2011, (Poster presentation)
- 15th International Conference on Behcet's Disease, 2012, Yokohama, Japan (Oral presentation)
- 16th International Conference on Behcet's Disease, 2014, Paris, United Kingdom (Poster presentation)

**Grants and funds**

- 2008 and 2010 Stichting Trustfonds: funding of research
- 2008 Travel Grant Abbot
- 2009 Actelion: funding of research
- 2008 Travel Grant Baxter
- 2009 Travel Grant Baxter
- 2010 Stichting Janivo: funding of research
- 2010 Stichting Mitalto: funding of research
- 2010 dr N. Nobel: funding of research
- 2010 Travel Grant Abbot
- 2013 Travel Grant Abbvie

**Teaching**

- Several post-graduate lectures on Behçet's Disease
- Minor in immunology ErasmusMC, 2009 (teacher)
- Master in immunology ErasmusMC, 2010 (teacher)
- Clinical lesson Eye Hospital Rotterdam, 2009, 2010, 2011 (speaker)
- Master Student project ErasmusMC, 2011- 2012: Behcet's disease and vascular parameters (supervision)
- Student project ErasmusMC, 2011 - 2012: Aortic stiffness in patients with Behçet's disease (supervision)
- Master Student project ErasmusMC, 2012: B-cells in Behcet's disease (supervision)

**Other**

- Council Member - International Society for Behçet's Disease, 2014